Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Pressure regulated basis for gene transcription by delta-cell micro-compliance modeled in silico: Biphenyl, bisphenol and small molecule ligand models of cell contraction-expansion

  • Hemant Sarin

    Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing

    hsmd74@hotmail.com

    Affiliation Freelance Investigator in Translational Science and Medicine, Charleston, West Virginia, United States of America

Retraction

After this article [1] was published, the corresponding author contacted PLOS ONE to request corrections. The author advised that he did not intend for [1] to be published in its current online form, and that the article should be retracted in the event that the requested revisions could not be incorporated into the published version of the article.

The requested changes involve substantial revisions to the rationale, methodology, results and conclusions reported in the article text, as well as changes to Tables 3, 6, 7, 8, 10, 11, 12, and Figs 2 and 3. The PLOS ONE Editors determined that the requested revisions go beyond what is suitable for a Correction per the journal’s editorial standards and would instead necessitate a full re-review of an updated manuscript.

In reviewing the correction request, the PLOS ONE Editors identified additional concerns with the article, including:

  • A specific scientific rationale for the selection of representative small molecules and genes was not provided, raising questions about whether the results presented are applicable beyond the compounds studied.
  • The methods were not described in sufficient detail to clearly relay the study design and enable other researchers to interpret the results or reproduce the analyses.
  • The article did not report adequate validation of the in silico model to support the reported claims about gene transcription regulation.

In light of these additional issues, the PLOS ONE Editors determined that the published article does not meet the journal’s publication criteria and there are concerns about the validity of the reported results and conclusions.

Based on the outcome of the editorial assessment and in line with the author’s request, the PLOS ONE Editors retract this article. We regret that the concerns about this work were not addressed prior to the article’s publication.

In response to the retraction decision, HS expressed an intention to address the above issues in a future submission of this work.

25 Mar 2021: The PLOS ONE Editors (2021) Retraction: Pressure regulated basis for gene transcription by delta-cell micro-compliance modeled in silico: Biphenyl, bisphenol and small molecule ligand models of cell contraction-expansion. PLOS ONE 16(3): e0249385. https://doi.org/10.1371/journal.pone.0249385 View retraction

Abstract

Molecular diameter, lipophilicity and hydrophilicity exclusion affinity limits exist for small molecule carrier-mediated diffusion or transport through channel pores or interaction with the cell surface glycocalyx. The molecular structure lipophilicity limit for non-specific carrier-mediated transmembrane diffusion through polarity-selective transport channels of the cell membrane is Lexternal structure ∙ Hpolar group-1 of ≥ 1.07. The cell membrane channel pore size is > 0.752 and < 0.758 nm based on a 3-D ellipsoid model (biphenyl), and within the molecular diameter size range 0.744 and 0.762 nm based on a 2-D elliptical model (alkanol). The adjusted van der Waals diameter (vdWD, adj; nm) for the subset of halogenated vapors is predictive of the required MAC for anesthetic potency at an initial (-) Δ Cmicro effect. The molecular structure L ∙ Hpolar group-1 for Neu5Ac is 0.080, and the L ∙ Hpolar group-1 interval range for the cell surface glycocalyx hydrophilicity barrier interaction is 0.101 (Saxitoxin, Stx; Linternal structure ∙ Hpolar group-1) - 0.092 (m-xylenediamine, Lexternal structure · Hpolar group). Differential predictive effective pressure mapping of gene activation or repression reveals that p-dioxin exposure results in activation of AhR-Erβ (Arnt)/Nrf-2, Pparδ, Errγ (LxRα), Dio3 (Dio2) and Trα limbs, and due to high affinity Dio2 and Dio3 (OH-TriCDD, Lext · H-1: 1.91–4.31) exothermy-antagonism (Δ contraction) with high affinity T4/rT3-TRα-mediated agonism (Δ expansion). co-planar PCB metabolite exposure (Lext · H-1: 1.95–3.91) results in activation of AhR (Erα/β)/Nrf2, Rev-Erbβ, Errα, Dio3 (Dio2) and Trα limbs with a Δ Cmicro contraction of 0.89 and Δ Cmicro expansion of 1.05 as compared to p-dioxin. co-, ortho-planar PCB metabolite exposure results in activation of Car/PxR, Pparα (Srebf1,—Lxrβ), Arnt (AhR-Erβ), AR, Dio1 (Dio2) and Trβ limbs with a Δ Cmicro contraction of 0.73 and Δ Cmicro expansion of 1.18 (as compared to p-dioxin). Bisphenol A exposure (Lext struct ∙ H-1: 1.08–1.12, BPA–BPE, Errγ; BPAF, Lext struct ∙ H-1: 1.23, CM Erα, β) results in increased duration at Peff for Timm8b (Peff 0.247) transcription and in indirect activation of the AhR/Nrf-2 hybrid pathway with decreased duration at Peff 0.200 (Nrf1) and increased duration at Peff 0.257 (Dffa). The Bpa/Bpaf convergent pathway Cmicro contraction-expansion response increase in the lower Peff interval is 0.040; in comparison, small molecule hormone Δ Cmicro contraction-expansion response increases in the lower Peff intervals for gene expression ≤ 0.168 (Dex· GR) ≥ 0.156 (Dht · AR), with grade of duration at Peff (min·count) of 1.33x105 (Dex/Cort) and 1.8–2.53x105 (Dht/R1881) as compared to the (-) coupled (+) Δ Cmicro Peff to 0.136 (Wnt5a, Esr2) with applied DES (1.86x106). The subtype of trans-differentiated cell as a result of an applied toxin or toxicant is predictable by delta-Cmicro determined by Peff mapping. Study findings offer additional perspective on the basis for pressure regulated gene transcription by alterations in cell micro-compliance (Δ contraction-expansion, Cmicro), and are applicable for the further predictive modeling of gene to gene transcription interactions, and small molecule modulation of cell effective pressure (Peff) and its potential.

Introduction

The mechanism of detoxification in human cells is induction of the phase I aryl hydrocarbon receptor (AHR)/AhR nuclear translocator (ARNT) pathway by transcriptional activation of P450 monooxygenase system enzyme genes (CYP1A1, CYP1B1) inseries with phase II nuclear respiratory factor-2 (NRF-2, NFE2L2) activation of UDP-glucoronosyl transferases (ie UGT1A6, UGT1A7), glutathione synthesis (GCLC) and NAD(P)H-quinone acceptor oxidoreductase (NQO1), and glutathione S-transferases (ie GSTA1) [13], within which the constitutive androstane receptor pathway (CAR, NR3C1) also plays a role in phase I/II metabolism (ie CYP3A4, UGT1A1) [4]. z, x-plane alignment establishes the reading frame for transcriptional factor binding and activation or repression of genes with or without recruitment [5], which results in the differentially-increased activation of CYP1A1 and CYP1B1 genes by co-activator adapter RIP140 recruited to the AhR/ARNT binding affinity xenobiotic response element (XRE) or to the 15mer full-site estrogen response element sequences (ERE) by liganded ERα/β dimers [68], transcriptional regulation of SREBF1 by a functional CAR and LXRα or LXRβ interaction [4], or activation of the cell membrane DIO1 gene by SRC-1 co-adapter recruited to T3-liganded TRβ [9].

These pathways are activated by a spectrum of small molecule lipophiles of variable affinity either directly or indirectly, including in response to the classic high-affinity agonists, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) at 10−12 M concentration for activity in vivo [1], as compared to bisphenols such as BPA with bioavailable concentration approaching 2 ng/mL levels in blood for involvement of high- and mid-affinity binding to ERRγ and GPR30 receptors respectively for those well-characterized [1012]. Furthermore, since such exotoxicants have bioaccumulated in the ecosystem, toxicity relative potency factor (REP)-adjusted additive TEF TEQs have been developed on the basis of combinatory data of in vivo dose escalation (ie ED50) and competitive assay studies (EC50, KD) such as from kinetic in silico models as fractional measures of planar (co-, ortho-) atom structural affinity (TCDD KCALC 10−10; TEF 1) [13, 14]. With serum globulin-binding being high affinity for endogenous ligands, and OH-, MeS(O4)-PCB metabolites (Σ) present in the 0.3–30 nM to 0.07–0.7 μM range in local tissue resident adipocytes (ng/g lipid) [15, 16], it can be hypothesized that there is high-affinity pharmacokinetic non-competition at the cell membrane (CM) or subcellular membrane (SCM) enzyme/receptor, and/or nuclear receptor (AhR/ARNT) for exogenous lipophile and metabolite bioaccumulants such as OH-, MeS(O4)-PCBs, as in prior study it has been noted that dioxin-like co-planar PCB-77 alters membrane fluidity less than ortho-substituted PCB-52 [17].

Polarity-specific transmembrane channels of varying pore sizes exist for facilitated diffusion of water, electrolytes, saccharides and amino acids into eukaryotic cells [1820], though which non-polar small molecules will diffuse, both endogenous and exogenous. The permeation thresholds for small molecule hydrophile micro-molecular permeability across respiratory epithelial (macula occludens, adherens; non-pericytotic) and brain endothelial barriers (zona occludens) are lower than predictable based on molecular diameter of equivalently-sized neutral small molecules due to greater hydrophilicity for size (-Log P/vdWD, nm-1), limit interval van der Waals diameters (vdWD) for anionic, neutral and cationic small molecule hydrophiles are 0.50–0.63 nm, between 0.66–0.73/0.81 nm, and at around 0.55 nanometers, respectively [21]. With small molecule hydrophile plasma half-life and lipophile tissue biodistribution as determinants, it deserves to be considered that there exist various molecular exclusion and/or philicity affinity limits for exogenous ligands of receptors and channels (ie Saxitoxin, Tetrodotoxin, 1,2-diaminocyclohexane) and small molecule hormones of various classes (ie Cortisol, Aldosterone, E2, DHT), which include: 1, a structural hydrophilicity for interactions with the epicellular proteoglycan matrix; 2, interval range of electropolarity at channel pore entry zone for endocytic transport; 3, a transition to selective facilitated diffusion and from polarity-selective to non-specific facilitated diffusion, and 4, the limit at which molecular diameter becomes the determinant of transmembrane channel transport subcellularly.

In this study, the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), co-planar and ortho-planar PCB-activated, diethylstilbesterol (DES) and bisphenol (BPA, BPAF) gene regulation pathways are further characterized by differential effective intracellular pressure (Peff) mapping of delta-cell micro-compliance in response to exposure in silico, these being model toxicant-mediated gene activation molecular pathways, as are activation pathways of small molecule lipophiles (ie halogenate ethers), hydrophile channel substrates or receptor agonists (ie lactate, mannitol; m-xylenediamine) as compared to those of endogenous steriod axis ligands (ie Estradiol, E2; Dht). The Lexternal/internal ° Hexternal-1 quotient, isomerism-adjusted Lexternal/internal ° Hexternal-1 quotient for acyclic hydroxylates, and vdWD (nm; sub-Å) are applied as measures to model cellular interactions by affinity and molecular size; correlative differential Peff mapping of gene expression in esebssiwaagoTQ units is applied to determine the delta (Δ)-range of Peff as a measure of cell micro-compliance (Cmicro,); and the Σ min·count is determined by power regression as a measure of the pressure grade of effect for a subset of molecular size-excluded steroid axis ligands. Therefore, in this study the transcriptional regulation effects will be studied by differential predictive (pred) effective intracellular pressure (Peff) mapping of delta (Δ)-cell micro-compliance to further explore the underlying basis for cell type-specific alterations in gene transcription as it has been determined that x, z-plane alignment of intergene tropy results in gene transcription in response to applied small molecule inverse agonists over a range of molecular diameter and philicity modeled in silico.

Methods

Selection of small molecules for study and determination of molecular size exclusion and hydrophilicity affinity interaction limits

Representative classes of small molecules of increasing complexity with non-chiral carbons (2-D elliptical) and/or a chiral carbon (3-D ellipsoid) with halogen-substituted atoms (para-, ortho- and co-/meta-) or functional group charge separation (sufficiently separated in space, SS; insufficiently separated in space, IS) were sampled for the study inclusive of small molecules of sedimentary origin (C1-C13 alkanes: methane, ethane, propane, butane), biosynthetic small molecules (C2-C13 alcohols: nonalol, decanol, undecanol, dodecanol, tridecanol; saxitoxin (Stx), tetradotoxin (Ttx); trans-retinol, α-tocopherol; aldosterone (Ald), cortisol (Cort), dexamethasone (Dex), 17β-estradiol E2, dihydroxytestosterone (Dht), and thyroxine T4), and synthetic molecules (tetraethyllead, cyclononalol, acetochlor; diethylstilbestrol (DES), methyltrienolone; polybrominated diphenyl ether-209; 2,3,7,8-tetrachlorodibenzo-para-dioxin, Tcdd; co-planar polychlorinated biphenyls Pcb-77, Pcb-126; co-planar, ortho-planar Pcb-106, -153, -172, -180; ortho-planar Pcb-54, -95, -132 and metabolites; bisphenols A, C, E and AF (chiral); branched C2-C4 halogenates: halothane, desflurane, isoflurane, enflurane, sevoflurane; m-xylenediamine; phthalate (mono-, di-n-butyl)). The predicted values of Log P (unitless), molecular weight (Da), van der Waals molecular volume (Å3) and polar surface area (Å2) were applied (www.chemicalize.org) for determinations of molecular diameter (vdWD; nm), and whole or part-molecular lipophilicity or hydrophilicity per diameter (Log P/vdWD; nm-1) inclusive of functional groups as previously reported [21]. Additional parameters were determined inclusive of i) molecular exterior or interior structural lipophilicity per diameter (vdWD, 3-digit sub-Å; Lexternal (or internal); nm-1) and exterior structural hydrophilicity per diameter (Hexternal; nm-1) with determinations of ii) polar surface area (psa) Log P/vdWD (nm-1) for intervening single atoms, and iii) the intermediate values of Log P/vdWD for part-molecular structures, as:

When the isophile is an external or intervening ether, the polar part P is 0.3319 (-0.479 nm-1) for mono-oxygen and 1.8197 (0.260 nm-1) for the mono-ether adjustment; and for a 2ary amine, the polar part P is 0.2048 (-0.624 nm-1) for mono-nitrogen with no additional adjustment. The calc Lexternal/internal ° Hexternal-1 is normalized to methanol as the reference standard, 2.75 (Ch3oh nl).

Determination of molecular structure-polar group substituted lipophilicity limit for non-specific transmembrane transport

The Log Palkane/vdWD alkane (Lexternal structure)]/[Log POH/vdWDOH (Hpolar group)] ratio quotient (abs value) was determined for the subset of 1- to 4-C simple alkane hydroxylates (methanol, 1-ethanol, 1-propanol, 1,2-propanol, 1,3-propandiol, 1,2-butanediol, 1,2-ethandiol and 2,3-glycer-1-ol). The unadjusted for isomerism Log P/vdWD was applied for presence of single hydroxyl (OH) group of -1.05 nm-1 (methanol, 1-ethanol), and the adjusted for external isomerism hydrophilic moiety Log P/vdWD was applied for the presence of dual hydroxyl group isomerism, as:

i + 1 is the number of carbon bonds in-between the initial hydroxylated position and the subsequent hydroxylated position for a polar group functionalized simple aliphatic. Based on the calc nl Lexternal/internal ° Hexternal-1 limit for non-specific carrier-mediated diffusion, the interval range limits of molecular hydrophilicity for endocytosis and channel wall domain affinity interactions for the remainder of the molecules of the study sample.

Determination of the gradient of effect for duration at Peff for steroid axis ligands at cell membrane receptors

The minute-receptor counts for corticosteroid axis receptor ligands at GR and MR (Cortisol, Cort; Dexamethasone, Dex; Aldosterone, Ald), estrogen axis receptor ligands at ERα (17β-Estradiol; Diethylstilbestrol, DES), androgen axis receptor ligands (Dihydroxytestosterone, DHT; methyltrienolone, R1881) and macromolecular marker as standard (Insulin-like growth factor II) for negative Δ Cmicro shift at lower limit of Peff. The t1/2 at receptor·receptor count (min·count) was determined as a product sum of half-lives at receptor and the cell membrane receptor count, and as Σ min·count in case of co-axis receptor system expression (MR, GR). The t1/2 at receptor for DES, DHT and R1881 were determined by x, y-plotting of radiolabeled hormone disassociation constants (KD, x-axis) and known t1/2 at receptor (min, y-axis). The grade of Peff was stratified by hormone ligand and receptor subtype, positive to negative by min·count, as determined by the semi-exponential power regression, and adjusted for cell receptor count:

Selection of genes for study and effective intracellular pressure mapping of pathway genes

Representative genes were selected for effective intracellular pressure (Peff) mapping of cellular pathway regulation by small molecules of the study sample (ie acyclic C2-C4 halogenates; 2,3,7,8-tetrachlorodibenzo-para-dioxin (p-dioxin); co-planar PCB-126; co-, ortho-planar PCB-153; bisphenol A, bisphenol AF; biosynthetic, ie tetradotoxin), which includes the following genes, which fall into the following categories:

  1. Transcription factor/adapter [AHR, AR, ARNT, ARNTL, ATF3; CEBPD, DDIT3 (CHOP), CREB1, ESR1, ESR2; ESRRG, ESRRA; FOSB, FOS, FOXA1; GTF2IRD1, HNF4A, JUN; NCOR1, NCOR2; NFE2L2 (NRF-2), NR1D1 (Rev-Erbα), NRID2 (Rev-Erbβ), NR3C1 (GR), NR3C2 (MR); NR1H3 (LXRα), NR1H2 (LXRβ); NR1I2 (PXR), NR1I3 (CAR), NRF1; PPARA, PPARD, PPARG; PER1, RXRA, RXRB, RARA, RARB, RARG, SIM1, SIN3A, SREBF1, TGIF1, THRA, THRB; DBP; HOXA9, HOXA10, HOXA11, HOXA13; KLF4; WNT5A];
  2. Transcription factor co-adapter/co-adapter [PPARGC1A (PGC1α), NRIP1, NCOA1 (SRC-1), GADD45A; GADD45B, CIDEA; DFFA];
  3. Cell membrane enzymes/proteins or channels/subunits [ADAM8, EXOC7, NOS1; DIO1, DIO3; MBP; SLC9A1 (NHE-1), SLC2A4 (Glut-4)];
  4. Cell membrane antigen/receptor (CEACAM1, CEACAM5; TSPAN14; TRFC);
  5. Cell membrane receptor ligand [DLK1 (PREF-1)];
  6. Cytochrome P450 monooxygenases [CYP1A1, CYP1B1, CYP1A2, CYP2B6, CYP2E1, CYP3A5, CYP3A7, CYP5A, CYP11B1 (11-β-hydroxylase), CYP11B2 (aldosterone synthase), CYP17A1 (17, 20-lysase)];
  7. Cytosolic/nuclear enzyme, DNA or mRNA adapter (PPP1R9B, CUL2, PLEKHG4, RAPGEFL1; CCND1, CDKN1A; CIDEA; DFFA, CASP3; MEG3, MIAT, MIR132);
  8. Intracellular enzymes [ALAS1, ALAS2; ACSM2A, ALDH3A1, CAT, DAO, DUSP1; FABP4 (aP2), FABP5, FABP6; FASN, GSTM2, ME1, MT1A, NQO1, PCK1, PER1, TIPARP; SCD, SCD5; LGAL1, UGT1A_ locus (UGT1A1, UGT1A6, UGT1A7)];
  9. Mitochondrial-specific membrane-associated (COX6C, COX8C, CYCS; TIMM8B);
  10. Mitochondrial-specific protein synthesis/cell cycle regulation (TFB2M);
  11. Rough endoplasmic reticulum enzyme/receptor (DIO2, GPR30, RESP18, OLFM1); and
  12. Secretory peptides/hormones [COL1A1, TFF1 (pS2), SFTPC, PMCH, A2M].

The gene/gene loci positions of protein coding and non-coding genes/gene loci were utilized as previously reported (www.genecards.org; lncipedia.org) for determinations of the episodic sub-episode block sums split-integrated weighted average-averaged gene overexpression tropy quotient as previously reported. The sub-episode block sums and averages were determined for gene loci as categorized by episode and initial SEB structure [5, 22], 1) Episode 3 (≤ 11,864, 7 SEB); 2) Episode 2 (> 11,864 ≤ 265,005, 5 SEB); 3) Episode 4 (> 265,095 < 521,757; 9 SEB); 4) Episode 5 (≥ 521,757 < 784,883; 11 SEB); and 5) Episode 5 (≥ 784,883; 13 SEB). The upstream and downstream part anisotropic sub-episode block sum (uppasebs, dppasebs) and correlate upstream and downstream part anisotropic sub-episode block sum split integrated weighted average (uppasebssiwa, dppasebssiwa) were determined for further calculation of the weighted average upstream and downstream part mesotropic sub-episode block sum split integrated weighted average (uppmsebssiwa, dppasebssiwa) and the final esebssiwaagoTQ quotient as a measure of effective intracellular pressure (Peff). The increase (plus %; ratio Δ) or decrease (minus %; ratio Δ) in the differential Peff mapping duration response was determined for the subset of marker genes as standards, based on which the placement of additional genes of study sample was determined, as either an increase (or decrease) in duration at Peff, as: (i) (ii) (iii)

Determination of range of cell micro-compliance response by correlative differential gene expression Peff mapping

Representative gene overexpression range of cell micro-compliance Peff mapping upper and lower bounds were determined for applied TCDD, co-planar PCB (ie OH-PCB-77; OH-PCB-126), and ortho-, co-, ortho-planar (ie OH-PCB-54; OH-PCB-95; OH-PCB-153) in silico, as follows:

The Peff for activation of gene marker standards (std) in addition to predicted differential Peff gene expression of exposure-modeled cell(s) was determined on the basis of intracellular esebssiwaagoTQ pressure units (Peff). The upper and lower bounds of the expansion response were determined as subtractive residuals of the upper direction maxima from the lower direction contraction responses from the respective minima in each direction of the.PCB-95 or PCB-153 exposed normal cell modeled in silico. The contraction-expansion response range of cell micro-compliance (Cmicro) was then determined as the difference between max and min bounds of range (BoR) in Cmicro Peff range units. Pairwise delta (Δ) micro-compliance (Cmicro) comparisons between the range of the cellular contraction-expansion response to p-dioxin exposure (TCDD, std; bracket 1), and co-planar PCB-126 (bracket 2 vs 1) and co-, ortho-planar PCB-95/-153 (bracket 3 vs 1) were performed [Δ, ratio expansion; a.u.].

Results

van der Waals diameter and external structural lipophilicity per polar group hydrophilicity of small molecule hydroxylates that are polarity-specific transport channel substrates

Methane (CH4) has a Log P of 1.08, and a vdWD of 0.373 nm with a Log P/vdWD of 2.89 nm-1. Methanol (CH4O) has a calc Lexternal structure/Hpolar group ratio of 2.75 (reference, 0 or 1) (Table 1).

thumbnail
Table 1. Molecule structural hydrophilicity limit for non-specific diffusion into cells through polarity-specific transmembrane transport channels.

https://doi.org/10.1371/journal.pone.0236446.t001

Ethane (C2H6) has a Log P of 1.35, and a vdWD of 0.437 nm with a Log P/vdWD of 3.09 nm-1. Ethan-1-ol (C2H6O) has a calc Lexternal structure/Hpolar group ratio of 2.94, calc Δ Lexternal structure/Hpolar group of 0.19, and a nl calc Lexternal structure/Hpolar group quotient of 1.069. 2-ethan-1-ol (C2H6O2) has a calc Lexternal structure/Hpolar group ratio of 1.47, calc Δ Lexternal structure/Hpolar group of 1.28, and a nl calc Lexternal structure/Hpolar group quotient of 0.535 (Table 1).

Propane (C3H8) has a Log P of 1.80, and a vdWD of 0.485 nm with a Log P/vdWD of 3.71 nm-1. Propan-1-ol (C3H8O) has a calc Lexternal structure/Hpolar group ratio of 3.53, calc Δ Lexternal structure/Hpolar group of 0.78, and a nl calc ratio Lexternal structure/ Hpolar group quotient of 1.280. Propan-1,2-diol (C3H8O2) has a calc Lexternal structure/Hpolar group ratio of 2.90, calc Δ Lexternal structure/Hpolar group of 0.13, and a nl calc Lexternal structure/ Hpolar group quotient of 1.047. Propan-1,3-diol (C3H8O2) has a calc Lexternal structure/Hpolar group ratio of 3.08, calc Δ Lexternal structure/Hpolar group of 0.31, and a nl calc Lexternal/ Hpolar group quotient of 1.113. 2,3-glyercer-1-ol (C3H8O3) has a calc Lexternal structure/Hpolar group ratio of 1.18, calc Δ Lexternal structure/Hpolar group of 1.57, and a nl calc Lexternal/ Hpolar group quotient of 0.428. Mannitol (C6H14O6) has a calc Linternal structure/Hpolar group ratio of 0.838, calc Δ Linternal structure/Hpolar group of 1.91, and a nl calc Linternal/ Hpolar group quotient of 0.304 (Table 1).

Lactate (C3H5O3) has a Log P of -0.47 (Log D, -3.7), and a vdWD of 0.526 nm with a Log P/vdWD of -0.893 nm-1 (Log D/vdWD, -7.04 nm-1). Lactate (lactic acid) has a calc Lexternal structure/Hpolar group of 0.309 (0.901), calc Δ Lexternal structure/Hpolar group of 1.85 (2.44), and a nl calc Lexternal/ Hpolar group quotient of 0.112 (0.328) (Table 1).

Butane (C4H10) has a Log P of 2.24, and a vdWD of 0.526 nm with a Log P/vdWD of 4.26 nm-1. 1,2-butanediol (C4H10O2) has a calc Lexternal structure/Hpolar group of 3.54, calc Δ Lexternal structure/Hpolar group of 0.57, and a nl calc Lexternal/ Hpolar group quotient of 1.207 (Table 1).

van der Waals diameter and external structural lipophilicity per polar group hydrophilicity parameters of small molecule halogenates that are non-specific transport channel substrates

Halothane (C2HBrClF3) has a Log P of 2.12, and a vdWD of 0.554 nm with a Log P/vdWD of 3.82 nm-1 (Table 2).

thumbnail
Table 2. Small molecule halogenates with affinity interactions at inner mitochondrial membrane P450 cytochromes.

https://doi.org/10.1371/journal.pone.0236446.t002

Desflurane (C3H2F6O) has a Log P of 2.40, and a vdWD of 0.571 nm with a Log P/vdWD of 4.21 nm-1. Part-halogenate 1,1,1-trifluoro-2-fluoroethane (C2H2F4) has a Log P of 1.33, and a vdWD of 0.493 nm with a Log P/vdWD of 2.70 nm-1. Part-halogenate fluoromethane (CH3F) has a Log P of 0.370, and a vdWD of 0.394 nm with a Log P/vdWD of 0.939 nm-1. Desflurane has a calc Lexternal structure/Hpolar group ratio of 9.62, and a nl calc Lexternal structure/Hpolar group quotient of 3.50 (Table 2).

Isoflurane (C3H2ClF5O) has a Log P of 2.84, and a vdWD of 0.588 nm with a Log P/vdWD of 4.83 nm-1. Part-halogenate 1,1,1-trifluoro-2-chloroethane (C2H2ClF3) has a Log P of 1.79, and a vdWD of 0.515 nm with a Log P/vdWD of 3.48 nm-1. Part-halogenate difluoromethane (CH2F2) has a Log P of 0.677 (calc), and a vdWD of 0.413 nm with a Log P/vdWD of 1.65 nm-1. Isoflurane has a calc Lexternal structure/Hpolar group ratio of 11.25, and a nl calc Lexternal structure/Hpolar group quotient of 4.09 (Table 2).

Enflurane (C3H2ClF5O) has a Log P of 2.80, and a vdWD of 0.588 nm with a Log P/vdWD of 4.77 nm-1. Part-halogenate 1-chloro-1,2,2-trifluoroethane (C2H2ClF3) has a Log P of 1.54, and a vdWD of 0.515 nm with a Log P/vdWD of 2.99 nm-1. Part-halogenate difluoromethane (CH2F2) has a Log P of 0.677 (calc), and a vdWD of 0.413 nm with a Log P/vdWD of 1.65 nm-1. Enflurane has a calc Lexternal structure/Hpolar group ratio of 10.23, and a nl calc Lexternal structure/Hpolar group quotient of 3.72 (Table 2).

Sevoflurane (C4H3F7O) has a Log P of 2.27, and a vdWD of 0.610 nm with a Log P/vdWD of 3.72 nm-1. Part-halogenate 1,1,1,3,3,3-hexaflouropropane (C3H2F6) has a Log P of 2.13, and a vdWD of 0.553 nm with a Log P/vdWD of 3.85 nm-1. Sevoflurane has a calc Lexternal structure/Hpolar group ratio of 10.54, and a nl calc Lexternal structure/Hpolar group quotient of 3.83 (Table 2).

Gene expression effective pressure mapping for small molecule halogenates that are outer mitochondrial transmembrane channel substrates

CYP2E1 is a 2 A 2 q terminal final SEB gene at x-, y-vertical axis angulation 48.4⁰. CYP2E1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.6445E + 04, 7.3717E + 04, 2.7927E + 04 and 5.5415E + 04 intergene bases. CYP2E1 has an uppesebssiwaa and dppesebssiwaa of 2.2186E + 04 and 6.4566E + 04 intergene bases with a Peff of 0.344 esebssiwaagoTQ units (Table 3).

thumbnail
Table 3. Effective intracellular pressure mapping of gene activation by small molecule halogenates.

https://doi.org/10.1371/journal.pone.0236446.t003

CYP2B6 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation of 50.9⁰. CYP2B6 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.4887E + 04, 3.2241E + 04, 3.224E + 03, 2.3693E + 04 intergene bases. CYP2B6 has an uppesebssiwaa and dppesebssiwaa of 2.7170E + 04 and 3.1800E + 04 intergene bases with a Peff of 0.324 esebssiwaagoTQ units (Table 3).

JUN is a 3 M 5 NCA ACM final SEB gene at x-, y-vertical axis angulation 57.8⁰. JUN has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.8635E + 04, 1.32597E + 05, 1.5679E + 04 and 1.83485E + 05 intergene bases. JUN has an uppesebssiwaa and dppesebssiwaa of 4.2157E + 04 and 1.58041E + 05 intergene bases with a Peff of 0.267 esebssiwaagoTQ units (Table 3).

TFB2M is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 57.8⁰. TFB2M has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.4509E + 04, 1.64443E + 05, 6.7711E + 04 and 1.43918E + 05 intergene bases. TFB2M has an uppesebssiwaa and dppesebssiwaa of 4.110E + 03 and 1.54180E + 05 intergene bases with a Peff of 0.267 esebssiwaagoTQ units (Table 3).

SFTPC is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 59.0⁰. SFTPC has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.7644E + 04, 1.79499E + 05, 3.9387E + 04 and 8.1734E + 04 intergene bases. SFTPC has an uppesebssiwaa and dppesebssiwaa of 3.3516E + 04 and 1.30616E + 05 intergene bases with a Peff of 0.257 esebssiwaagoTQ units (Table 3).

FOSB is a 3 A 8 ACM final SEB gene at x-, y-vertical axis angulation 65.6⁰. FOSB has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.2564E + 04, 2.9210E + 04, 3.621E + 03 and 5.4102E + 04 intergene bases. FOSB has an uppesebssiwaa and dppesebssiwaa of 8.092E + 03 and 4.1656E + 04 intergene bases with a Peff of 0.194 esebssiwaagoTQ units (Table 3).

CREB1 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 71.4⁰. CREB1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.5030E + 04, 4.03885E + 05, 5.2441E + 04 and 9.8597E + 05 intergene bases. CREB1 has an uppesebssiwaa and dppesebssiwaa of 3.8736E + 04 and 2.51241E + 05 intergene bases with a Peff of 0.154 esebssiwaagoTQ units (Table 3).

HMOX1 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 71.5⁰. HMOX1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.3974E + 04, 3.8608E + 04, 4.636E + 03 and 8.2968E + 04 intergene bases. HMOX1 has an uppesebssiwaa and dppesebssiwaa of 9.305E + 03 and 6.0788E + 04 intergene bases with a Peff of 0.153 esebssiwaagoTQ units (Table 3).

van der Waals diameter and structural lipophilicity parameters of small molecules within the channel molecular size-inclusion range

Biphenyl (C12H10) has a Log P of 3.62, a vdWD of 0.655 nm and a Log P/vdWD of 5.53 nm-1 (Table 4).

thumbnail
Table 4. Small molecules with intracellular effects at inner mitochondrial membrane ETS cytochromes, rough endoplasmic reticulum deiodinase or at orphan nuclear receptors.

https://doi.org/10.1371/journal.pone.0236446.t004

Cyclononalol (C9H18O) has a Log P of 2.61, a vdWD of 0.688 nm and a Log P/vdWD of 3.91 nm-1 (Table 4).

Nonal-1-ol (C9H20O) has a Log P of 3.06, a vdWD of 0.682 nm and a Log P/vdWD of 4.48 nm-1 (Table 4).

Tetraethyllead (C8H20Pbδ+) has a Log P of 1.94, a vdWD of 0.700 nm and a Log P/vdWD of 2.77 nm-1 (Table 4).

Bisphenol E (BPE; C14H14O2) has a Log P of 3.74, a vdWD of 0.727 nm and a Log P/vdWD of 5.14 nm-1. Part-BPE 1,1-diphenylethane (C14H14) has a Log P of 4.35, a vdWD of 0.701 nm and a Log P/vdWD of 6.21 nm-1. Bisphenol E has a calc Lexternal structure/Hpolar group ratio of 2.10, and a nl calc Lexternal structure/Hpolar group quotient of 1.08 (Table 4).

Decan-1-ol (C10H22O) has a Log P of 3.47, a vdWD of 0.704 nm and a Log P/vdWD of 4.93 nm-1 (Table 4).

Bisphenol A (BPA; C15H16O2) has a Log P of 4.04, a vdWD of 0.742 nm and a Log P/vdWD of 5.44 nm-1. Part-BPA 2-phenylpropan-2-yl benzene (C15H16) has a Log P of 4.65, a vdWD of 0.722 nm and a Log P/vdWD of 6.44 nm-1. Bisphenol A has a calc Lexternal structure/Hpolar group ratio of 3.07, and a nl calc Lexternal structure/Hpolar group quotient of 1.12 (Table 4).

Undecan-1-ol (C11H24O) has a Log P of 3.92, a vdWD of 0.724 nm and a Log P/vdWD of 5.41 nm-1 (Table 4).

Mono-n-butylphthalate (BP, MBP; C12H14O4) has a Log P (D) of 2.96 (-0.55), a vdWD of 0.724 nm and a Log P (D)/vdWD of 4.09 (-0.76) nm-1(Table 4). MBP has a calc Lexternal structure/Hpolar group ratio of 0.886, and a nl calc Lexternal structure/Hpolar group quotient of 0.322.

Bisphenol C (BPC; C14H10Cl2O2) has a Log P of 4.29, a vdWD of 0.744 nm and a Log P/vdWD of 5.77 nm-1. Part-BPC 2,2-dichloro-1-phenylethenyl benzene (C14H10Cl2) has a Log P of 4.90, a vdWD of 0.727 nm and a Log P/vdWD of 6.74 nm-1. Bisphenol C has a calc Lexternal structure/Hpolar group ratio of 3.21, and a nl calc Lexternal structure/Hpolar group quotient of 1.17 (Table 4).

2,2’,6,6’-ortho-planar PCB-54 (C12H6Cl4) has a Log P of 5.84, a vdWD of 0.727 nm and a Log P/vdWD of 8.04 nm-1 (Table 4).

2,3,7,8-tetrachlorodibenzo-p, p-dioxin (C12H4Cl4O2; p-dioxin, TCDD) has a Log P of 5.42, a vdWD of 0.735 nm and a Log P/vdWD of 7.38 nm-1 (Table 4). p-dioxin has a calc Lexternal structure/Hpolar group ratio of 11.86, and a nl calc Lexternal structure/Hpolar group quotient of 4.31. 8-OH-2,3,7-TriCDD has a calc Lexternal structure/Hpolar group ratio of 5.25, and a nl calc Lexternal structure/Hpolar group quotient of 1.91 8-O-glucoronide-2,3,7-TriCDD has a calc Lexternal structure/Hpolar group ratio of 1.15, and a nl calc Lexternal structure/Hpolar group quotient of 0.419.

2,2’,5,5’,6-ortho-planar PCB-95 (C12H5Cl5) has a Log P of 6.76, a vdWD of 0.737 nm and a Log P/vdWD of 9.17 nm-1 (Table 4).

3,4,4’,5,5’-co-planar PCB-126 (C12H5Cl5) has a Log P of 6.69, a vdWD of 0.749 nm and a Log P/vdWD of 8.94 nm-1 (Table 4).

Dodecan-1-ol (C12H26O) has a Log P of 4.36, a vdWD of 0.744 nm and a Log P/vdWD of 5.86 nm-1 (Table 4).

Dodecan-1-ol (C12H26O) has a Log P of 4.36, a vdWD of 0.744 nm and a Log P/vdWD of 5.86 nm-1 (Table 4).

3,5,3’,5’-Iodothyroxine (C15H11I4NO4) has a Log P of 3.73, a vdWD of 0.745* nm and a Log P/vdWD of 5.00 nm-1* (Table 4). Iodothyroxine has a calc Lexternal structure/Hpolar group ratio of 1.625, and a nl calc Lexternal structure/Hpolar group quotient of 0.591. (4’-hydroxy-3’,5’-diiodophenoxy)-1-ethyl-3,5-diiodophenyl (non-zwitterion part T4) has a calc Lexternal structure/Hpolar group ratio of 8.92, and a nl calc Lexternal structure/Hpolar group quotient of 3.24.

4’-OH-2,3,3’,4,5-PCB-106 (C12H5Cl5O) has a Log P of 6.34, a vdWD of 0.752 nm and a Log P/vdWD of 8.43 nm-1 (Table 4).

van der Waals diameter and structural lipophilicity parameters of small molecules in the molecular size-exclusion range

2’,3,4,4’,5’,6-PCB-153 (C12H4Cl6) has a Log P of 7.24, a vdWD of 0.758 nm and a Log P/vdWD of 9.55 nm-1 (Table 5).

thumbnail
Table 5. Small molecules in the molecular size-exclusion range at the cell membrane channel pore with extracellular effects on nuclear pathways via transmembrane receptor or protein affinity interactions.

https://doi.org/10.1371/journal.pone.0236446.t005

Tridecan-1-ol (C13H28O) has a Log P of 4.81, a vdWD of 0.762 nm and a Log P/vdWD of 6.31 nm-1 (Table 5).

4’-OH-3,3’,4,5,5’,6-ortho-planar PCB-136 (C12H4Cl6O) has a Log P of 7.04, a vdWD of 0.767 nm and a Log P/vdWD of 9.18 nm-1 (Table 5).

Bisphenol AF (BFAF, C15H10F6O2) has a Log P of 4.77, a vdWD of 0.774 nm and a Log P/vdWD of 6.17 nm-1. 1,1,1,3,3,3-hexafluoro-2-phenylpropan-2-yl (C15H10F6) has a Log P of 5.38, a vdWD of 0.756 nm and a Log P/vdWD of 7.12 nm-1. Bisphenol AF has a calc Lexternal structure/Hpolar group ratio of 3.39, and a nl calc Lexternal structure/Hpolar group quotient of 1.23 (Table 5).

2,2’,4,4’,6-PBDE-100 (C12H10Br5) has a Log P of 7.32, a vdWD of 0.775 nm and a Log P/vdWD of 9.44 nm-1 (Table 5).

Acetochlor (C14H20Cl5NO2) has a Log P of 3.50, a vdWD of 0.778 nm and a Log P/vdWD of 4.50 nm-1. n-(1-chloroethyl)-n-(2-ethoxymethyl)-2-methyl-6-ethylaniline has a Log P of 4.18, a vdWD of 0.758 nm and a Log P/vdWD of 5.43 nm-1. Acetochlor has a calc Lexternal structure/Hpolar group ratio of 3.20, and a nl calc Lexternal structure/Hpolar group quotient of 1.16 (Table 5).

4’-OH-2,3,3’,4,5,5’,6’-PCB-172 (C12H3Cl7O) has a Log P of 7.55, a vdWD of 0.781 nm and a Log P/vdWD of 9.92 nm-1 (Table 5).

Di-n-butyl phthalate (DBP; C16H22O4) has a Log P of 4.63, a vdWD of 0.797 nm and a Log P/vdWD of 5.81 nm-1 (Table 5). DBP has a calc Lexternal structure/Hpolar group ratio of 4.099, and a nl calc Lexternal structure/Hpolar group quotient of 1.491.

4’-CH3-SO2-ortho-planar PCB-132 (C13H6Cl6O2S) has a Log P of 6.09, a vdWD of 0.811 nm and a Log P/vdWD of 7.51 nm-1 (Table 5).

trans-retin-1-ol (C20H30O) has a Log P of 4.69, a vdWD of 0.829 nm and a Log P/vdWD of 5.66 nm-1 (Table 5). trans-retin-1-ol has a calc Lexternal structure/Hpolar group ratio of 6.914, and a nl calc Lexternal structure/Hpolar group quotient of 2.54. trans-retinoic acid has a calc Lexternal structure/Hpolar group ratio of 0.913, and a nl calc Lexternal structure/Hpolar group quotient of 0.332.

α-tocopherol (C29H50O2) has a Log P of 10.51, a vdWD of 0.960 nm and a Log P/vdWD of 10.95 nm-1 (Table 5). α-tocopherol has a calc Lexternal structure/Hpolar group ratio of 8.018, and a nl calc Lexternal structure/Hpolar group quotient of 2.92. 13’-O-glucoronide-α-tocopherol (C16H22O4) has a calc Lexternal structure/Hpolar group ratio of 1.26, and a nl calc Lexternal structure/Hpolar group quotient of 0.459.

Gene expression effective pressure mapping for small molecule chlorinates that are cell membrane, rough endoplasmic membrane enzyme or orphan nuclear receptor substrates

2,3,7,8-tetrachlorodibenzo-p-dioxin (Tcdd). AHR is a 5 A 9 ACM final SEB gene at x-, y-vertical axis angulation 42.3⁰. AHR has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.173E + 03, 7.2908E + 04, 1.71804E + 05 and 3.79987E + 05 intergene bases. AHR has an uppesebssiwaa and dppesebssiwaa of 8.9488E + 04 and 2.26448E + 05 intergene bases with a Peff of 0.395 esebssiwaagoTQ units (Table 6).

thumbnail
Table 6. Effective intracellular pressure mapping of gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) via the AhR-Erβ (Arnt): Nrf-2:: Pparδ, Errγ (LxRα): Dio3/Dio2 (Trα) pathway.

https://doi.org/10.1371/journal.pone.0236446.t006

COX8C is a 4 M 9 initial and final SEB gene at x-, y-vertical axis angulation 44.0⁰. COX8C has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 9.8211E + 04, 1.71795E + 05, 7.786E + 03 and 1.06511E + 05 intergene bases. COX8C has an uppesebssiwaa and dppesebssiwaa of 5.2998E + 04 and 1.39153E + 05 intergene bases with a Peff of 0.381 esebssiwaagoTQ units (Table 6).

CEACAM1 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 44.2⁰ (act). CEACAM1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.3332E + 04, 1.31731E + 05, 1.4468E + 04, 7.3384E + 04 intergene bases (act). CEACAM1 has an uppesebssiwaa and dppesebssiwaa of 3.8900E + 04 and 1.02558E + 05 intergene bases with a Peff of 0.379 esebssiwaagoTQ units (act) (Table 6).

SLC2A4 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 44.6⁰. SLC2A4 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.5426E + 04, 2.7907E + 04, 917 and 1.5607E + 04 intergene bases. SLC2A4 has an uppesebssiwaa and dppesebssiwaa of 8.172E + 04 and 2.1757E + 04 intergene bases with a Peff of 0.376 esebssiwaagoTQ units (Table 6).

RXRA is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 44.8⁰. RXRA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.7754E + 04, 7.2478E + 04, 7.624E + 03 an 4.8816E + 04 intergene bases. RXRA has an uppesebssiwaa and dppesebssiwaa of 2.2689E + 04 and 6.0662E + 04 intergene bases with a Peff of 0.374 esebssiwaagoTQ units (Table 6).

NR1D1 is a 3 M 7 ext final SEB gene at x-, y-vertical axis angulation 44.9⁰. NR1D1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.2742E + 04, 6.6932E+ 04, 3.181E + 03 and 2.9279E + 04 intergene bases. NR1D1 has an uppesebssiwaa and dppesebssiwaa of 1.7961E + 04 and 4.8106E + 04 intergene bases with a Peff of 0.373 esebssiwaagoTQ units (Table 6).

DAO is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 47.9⁰. DAO has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.0186E +04, 1.15409E + 05, 440 and 6.0583E + 04 intergene bases. DAO has an uppesebssiwaa and dppesebssiwaa of 3.0313E + 04 and 8.6996E + 04 intergene bases with a Peff of 0.348 esebssiwaagoTQ units (Table 6).

PPARD is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 49.0⁰. PPARD has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.3902E + 04, 7.5097E + 04, 1.946E + 03 and 3.0504E + 04 intergene bases. PPARD has an uppesebssiwaa and dppesebssiwaa of 1.7924E + 04 and 5.2800E + 04 intergene bases with a Peff of 0.339 esebssiwaagoTQ units (Table 6).

GADD45B is a 4 M 5 stIMfa, ACM, NCA ACM final SEB gene at x-, y-vertical axis angulation 49.9⁰. GADD45B has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.8061E + 04, 9.8594E + 04, 2.029E + 03 and 2.2138E + 04 intergene bases. GADD45B has an uppesebssiwaa and dppesebssiwaa of 2.0045E + 04 and 6.0366E + 04 intergene bases with a Peff of 0.332 esebssiwaagoTQ units (Table 6).

ALAS1 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 50.9⁰. ALAS1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.929E + 03, 2.9633E + 04, 2.7615E + 04 and 6.7836E + 04 intergene bases. ALAS1 has an uppesebssiwaa and dppesebssiwaa of 1.5772E + 04 and 4.8734E + 04 intergene bases with a Peff of 0.324 esebssiwaagoTQ units (Table 6).

DBP is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 55.8⁰. DBP has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.499E + 03, 4.4612E + 04, 2.3594E + 04 and 4.7496E + 04 intergene bases. DBP has an uppesebssiwaa and dppesebssiwaa of 1.3046E + 04 and 4.6054E + 04 intergene bases with a Peff of 0.283 esebssiwaagoTQ units (Table 6).

RXRB is a 4 A 7 final SEB gene at x-, y-vertical axis angulation 56.0⁰. RXRB has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.075E + 03, 8.3710E + 04, 3.9078E + 04 and 8.3775E + 04 intergene bases. RXRB has an uppesebssiwaa and dppesebssiwaa of 2.3576E + 04 and 8.3743E + 04 intergene bases with a Peff of 0.282 esebssiwaagoTQ units (Table 6).

PPARGC1A is a 6 M 13 initial and final SEB gene at x-, y-vertical axis angulation 56.3⁰. PPARGC1A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.98293E + 05, 4.43060E + 05, 4.2797E + 04 and 4.21495E + 05 intergene bases. PPARGC1A has an uppesebssiwaa and dppesebssiwaa of 1.20545E + 05 and 4.32277E + 05 intergene bases with a Peff of 0.279 esebssiwaagoTQ units (Table 6).

SCD is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 56.9⁰. SCD has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.0705E + 04, 7.4127E + 04, 1.1708E + 04 and 1.11966E + 05 intergene bases. SCD has an uppesebssiwaa and dppesebssiwaa of 2.6206E + 04 and 9.3046E + 04 intergene bases with a Peff of 0.282 esebssiwaagoTQ units (Table 6).

MT1A is a 3 M 7 initial and final SEB gene at x-, y-vertical axis angulation 57.0⁰. MT1A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.9593E + 04, 4.5208E + 04, 1.365E + 03 and 3.1603E + 04 intergene bases. MT1A has an uppesebssiwaa and dppesebssiwaa of 1.0479E + 04 and 3.8405E + 04 intergene bases with a Peff of 0.273 esebssiwaagoTQ units (Table 6).

SREPF1 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 61.4⁰. SREPF1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.6701E + 04, 4.6217E + 04, 8.727E + 03 and 6.1076E + 04 intergene bases. SREPF1 has an uppesebssiwaa and dppesebssiwaa of 1.2714E + 04 and 5.3646E + 04 intergene bases with a Peff of 0.237 esebssiwaagoTQ units (Table 6).

DIO1 is a 2 A 4 NCA final SEB gene at x-, y-vertical axis angulation 60.7⁰. DIO1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.0841E + 04, 8.6335E + 04, 6.342E + 03 and 7.1284E + 04 intergene bases. DIO1 has an uppesebssiwaa and dppesebssiwaa of 1.8591E + 04 and 7.8810E + 04 intergene bases with a Peff of 0.236 esebssiwaagoTQ units (Table 6).

FABP5 is a 3 M 7 initial and final SEB gene at x-, y-vertical axis angulation 63.0⁰. FABP5 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.2075E + 04, 1.38023E + 05, 1.2397E + 04 and 1.50392E + 05 intergene bases. FABP5 has an uppesebssiwaa and dppesebssiwaa of 3.2236E + 04 and 1.44208E + 05 intergene bases with a Peff of 0.224 esebssiwaagoTQ units (Table 6).

TIPARP is a 2 A 4 NCA stIMfM final SEB gene at x-, y-vertical axis angulation 63.1⁰. TIPARP has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.0872E + 04, 1.44564E + 05, 1.7547E + 04 and 2.7819E + 04 intergene bases. TIPARP has an uppesebssiwaa and dppesebssiwaa of 1.9209E + 04 and 8.6191E + 04 intergene bases with a Peff of 0.223 esebssiwaagoTQ units (Table 6).

SIN3A is a 2 M 7 NCA final SEB gene at x-, y-vertical axis angulation 63.0⁰. SIN3A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.2660E + 04, 5.6611E + 04, 4.082E + 03 and 6.3132E + 04 intergene bases. SIN3A has an uppesebssiwaa and dppesebssiwaa of 1.3371E + 04 and 5.9872E + 04 intergene bases with a Peff of 0.223 esebssiwaagoTQ units (Table 6).

PPARG is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 63.2⁰. PPARG has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.1238E + 04, 9.3514E + 04, 2.140E + 03 and 1.47194E + 05 intergene bases. PPARG has an uppesebssiwaa and dppesebssiwaa of 2.6689E + 04 and 1.20354E + 05 intergene bases with a Peff of 0.222 esebssiwaagoTQ units (Table 6).

RARB is a 4 A 9 initial and final SEB gene at x-, y-vertical axis angulation 63.2⁰. RARB has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.6685E + 04, 2.28760E + 05, 4.5444E + 04 and 9.6325E + 04 intergene bases. RARB has an uppesebssiwaa and dppesebssiwaa of 3.6064E + 04 and 1.62543E + 05 intergene bases with a Peff of 0.222 esebssiwaagoTQ units (Table 6).

CYP1A1 is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 63.9⁰. CYP1A1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.620E + 03, 5.2602E + 04, 1.9646E + 04 and 4.5892E + 04 intergene bases. CYP1A1 has an uppesebssiwaa and dppesebssiwaa of 1.0633E + 04 and 4.9247E + 04 intergene bases with a Peff of 0.216 esebssiwaagoTQ units (Table 6).

CYP1A2 is a 3 A 9 ACM final SEB gene at x-, y-vertical axis angulation 65.7⁰. CYP1A2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.1688E + 04, 1.11934E + 05, 1.9604E + 04 and 4.3582E + 04 intergene bases. CYP1A2 has an uppesebssiwaa and dppesebssiwaa of 1.5646E + 04 and 7.7758E + 04 intergene bases with a Peff of 0.210 esebssiwaagoTQ units (Table 6).

ESRRG is a 5 A 9 ACM final SEB gene at x-, y-vertical axis angulation 64.7⁰. ESRRG has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.8238E + 04, 3.07603E + 05, 5.5149E + 04 and 1.38670E + 05 intergene bases. ESRRG has an uppesebssiwaa and dppesebssiwaa of 4.6694E + 04 and 2.23137E + 05 intergene bases with a Peff of 0.209 esebssiwaagoTQ units (Table 6).

NR1H3 is a 2 M 7 ACM final SEB gene at x-, y-vertical axis angulation 64.7⁰. NR1H3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.1881E + 04, 2.3346E + 04, 8.567E + 03 and 7.4260E + 04 intergene bases. NR1H3 has an uppesebssiwaa and dppesebssiwaa of 1.0224E + 04 and 4.8803E + 04 intergene bases with a Peff of 0.209 esebssiwaagoTQ units (Table 6).

NRF1 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 65.8⁰. NRF1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.803E + 03, 9.6944E + 04, 3.2897E + 04 and 1.11479E + 05 intergene bases. NRF1 has an uppesebssiwaa and dppesebssiwaa of 2.0850E + 04 and 1.04212E + 05 intergene bases with a Peff of 0.200 esebssiwaagoTQ units (Table 6).

ESRRA is a 3 M 9 ACM final SEB gene at x-, y-vertical axis angulation 64.7⁰. ESRRA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 9.619E + 03, 2.5863E + 04, 5.972E + 03 and 5.3534E + 04 intergene bases. ESRRA has an uppesebssiwaa and dppesebssiwaa of 3.9699E + 04 and 3.9699E + 04 intergene bases with a Peff of 0.196 esebssiwaagoTQ units (Table 6).

ARNTL is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 66.9⁰. ARNTL has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.7408E + 04, 4.4697E + 04, 1.2785E + 04 and 1.13014E + 05 intergene bases. ARNTL has an uppesebssiwaa and dppesebssiwaa of 1.5097E + 04 and 7.8855E + 05 intergene bases with a Peff of 0.191 esebssiwaagoTQ units (Table 6).

EXOC7 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 67.1⁰. EXOC7 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.265E + 03, 9.381E + 03, 2.119E + 03 and 2.9570E + 04 intergene bases. EXOC7 has an uppesebssiwaa and dppesebssiwaa of 3.692E + 03 and 1.9475E + 04 intergene bases with a Peff of 0.190 esebssiwaagoTQ units (Table 6).

ESR1 is a 4 A 9 ACM (-2) NCA (+2) final SEB gene at x-, y-vertical axis angulation 67.8⁰. ESR1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.4317E + 04, 3.26647E + 05, 7.5809E + 04 and 2.18623E + 05 intergene bases. ESR1 has an uppesebssiwaa and dppesebssiwaa of 5.0063E + 04 and 2.72635E + 05 intergene bases with a Peff of 0.184 esebssiwaagoTQ units (Table 6).

DIO2 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 67.9⁰. DIO2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.1126E + 04, 4.10031E + 05, 6.5612E + 04 and 1.19045E + 05 intergene bases. DIO2 has an uppesebssiwaa and dppesebssiwaa of 4.8369E + 04 and 2.64538E + 05 intergene bases with a Peff of 0.183 esebssiwaagoTQ units (Table 6).

RARA is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 68.1⁰. RARA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.0934E + 04, 1.76592E + 05, 1.8669E + 04 and 4.2109E + 04 intergene bases. RARA has an uppesebssiwaa and dppesebssiwaa of 1.9801E + 04 and 1.09351E + 05 intergene bases with a Peff of 0.181 esebssiwaagoTQ units (Table 6).

NCOR2 is a 4 M 9 initial and final SEB gene at x-, y-vertical axis angulation 68.5⁰. NCOR2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.6316E + 04, 3.4858E + 04, 1.52E + 04 and 1.42541E + 05 intergene bases. NCOR2 has an uppesebssiwaa and dppesebssiwaa of 1.5758E + 04 and 8.8699E + 04 intergene bases with a Peff of 0.178 esebssiwaagoTQ units (Table 6).

THRA is a 2 M 7 ACM final SEB gene at x-, y-vertical axis angulation 68.6⁰. THRA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.1732E + 04, 4.7912E + 04, 9.383E + 03 and 1.27923E + 05 intergene bases. THRA has an uppesebssiwaa and dppesebssiwaa of 1.5557E + 04 and 8.7918E + 04 intergene bases with a Peff of 0.177 esebssiwaagoTQ units (Table 6).

NRIP1 is a 2 M 7 ACM final SEB gene at x-, y-vertical axis angulation 69.1⁰. NRIP1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.36743E + 05, 5.72072E + 05, 4.6198E + 04 and 1.059404E + 06 intergene bases. NRIP1 has an uppesebssiwaa and dppesebssiwaa of 1.41470E + 05 and 8.15738E + 05 intergene bases with a Peff of 0.173 esebssiwaagoTQ units (Table 6).

CYP1B1 is a 5 M 11 initial and final SEB gene at x-, y-vertical axis angulation 69.6⁰. CYP1B1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.4259E + 04, 1.90422E + 05, 5.8349E + 04 and 5.36193E + 05 intergene bases. CYP1B1 has an uppesebssiwaa and dppesebssiwaa of 6.1304E + 04 and 3.63307E + 04 intergene bases with a Peff of 0.169 esebssiwaagoTQ units (Table 6).

ALDH3A1 is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 69.7⁰. ALDH3A1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.446E + 03, 9.0420E + 04, 1.3274E + 04 and 3.2789E + 04 intergene bases. ALDH3A1 has an uppesebssiwaa and dppesebssiwaa of 1.0360E + 04 and 6.1604E + 04 intergene bases with a Peff of 0.168 esebssiwaagoTQ units (Table 6).

ACSM2A is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 70.9⁰. ACSM2A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.452E + 03, 1.14103E + 05, 1.2592E + 04 and 1.8897E + 04 intergene bases. ACSM2A has an uppesebssiwaa and dppesebssiwaa of 1.0522E + 04 and 6.6500E + 04 intergene bases with a Peff of 0.158 esebssiwaagoTQ units (Table 6).

NQO1 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 72.2⁰. NQO1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.720E + 03, 1.85367E + 05, 2.8226E + 04 and 6.5249E + 04 intergene bases. NQO1 has an uppesebssiwaa and dppesebssiwaa of 1.8473E + 04 and 1.25308E + 05 intergene bases with a Peff of 0.147 esebssiwaagoTQ units (Table 6).

ESR2 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 73.6⁰. ESR2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.810E + 03, 1.26875E + 05, 2.5861E + 04 and 7.6369E + 04 intergene bases. ESR2 has an uppesebssiwaa and dppesebssiwaa of 1.3835E + 04 and 1.01622E + 05 intergene bases with a Peff of 0.136 esebssiwaagoTQ units (Table 6).

ME1 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 73.7⁰. ME1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.2685E + 04, 1.58850E + 05, 2.6415E + 04 and 4.27755E + 05 intergene bases. ME1 has an uppesebssiwaa and dppesebssiwaa of 3.9550E + 04 and 2.92302E + 05 intergene bases with a Peff of 0.135 esebssiwaagoTQ units (Table 6).

CYP3A7 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 76.6⁰. CYP3A7 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.9558E + 04, 5.2160E + 04, 2.4091E + 04 and 3.42328E + 05 intergene bases. CYP3A7 has an uppesebssiwaa and dppesebssiwaa of 2.1824E + 04 and 1.97244E + 05 intergene bases with a Peff of 0.111 esebssiwaagoTQ units (Table 6).

UGT1A7 is a 2 M 5 ACM final extended SEB gene at x-, y-vertical axis angulation 77.2⁰. UGT1A7 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.4610E + 04, 3.4472E + 04, 4.4440E + 04 and 5.20736E + 05 intergene bases. UGT1A7 has an uppesebssiwaa and dppesebssiwaa of 2.9540E + 04 and 2.77604E + 05 intergene bases with a Peff of 0.106 esebssiwaagoTQ units (Table 6).

DIO3 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 78.4⁰. DIO3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.463E + 03, 6.6352E + 04, 2.545E +03 and 6.385E + 03 intergene bases. DIO3 has an uppesebssiwaa and dppesebssiwaa of 3.504E + 03 and 3.6368E + 04 intergene bases with a Peff of 0.096 esebssiwaagoTQ units (Table 6).

ARNT is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 82.4⁰. ARNT has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.424E + 03, 1.23406E + 05, 5.151E + 03 and 1.2359E + 04 intergene bases. ARNT has an uppesebssiwaa and dppesebssiwaa of 4.287E +03 and 6.7882E + 04 intergene bases with a Peff of 0.063 esebssiwaagoTQ units (Table 6).

TSPAN14 is a 2 A 8 ACM ACM final SEB gene at x-, y-vertical axis angulation 83.1⁰. TPSAN14 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.5608E + 04, 4.94044E + 05, 1.4376E + 04 and 3.3255E + 04 intergene bases. TSPAN14 has an uppesebssiwaa and dppesebssiwaa of 1.4992E + 04 and 2.63650E + 05 intergene bases with a Peff of 0.057 esebssiwaagoTQ units (Table 6).

co-planar polychlorinated biphenyl.

HNF4A is a 2 A 5 NCA ACM final SEB gene at x-, y-vertical axis angulation 38.4⁰. HNF4A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.0705E + 04, 1.08134E + 05, 1.47071E + 05 and 2.61534E + 04 intergene bases. HNF4A has an uppesebssiwaa and dppesebssiwaa of 7.8888E + 04 and 1.84834E + 05 intergene bases with a Peff of 0.427 esebssiwaagoTQ units (Table 7).

thumbnail
Table 7. Effective intracellular pressure mapping of gene activation by co-planar polychlorinated biphenyl via the AhR-Erα/β (Arnt): Nrf-2:: Rev-Erb β, Errα: Dio3/Dio2 (Trα) pathway.

https://doi.org/10.1371/journal.pone.0236446.t007

PCK1 is a 3 M 7 ACM ACM final SEB gene at x-, y-vertical axis angulation 49.5⁰. PCK1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.04153E + 05, 2.22857E + 05, 1.2995E + 04 and 1.29275E + 05 intergene bases. PCK1 has an uppesebssiwaa and dppesebssiwaa of 5.8574E + 04 and 1.76066E + 05 intergene bases with a Peff of 0.333 esebssiwaagoTQ units (Table 7).

RESP18 is a 3 M 5 ACM q term final SEB gene at x-, y-vertical axis angulation 50.5⁰. RESP18 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.9633E + 04, 1.16462E + 05, 3.133E + 05 and 4.4955 + 05 intergene bases. RESP18 has an uppesebssiwaa and dppesebssiwaa of 2.6383E + 04 and 8.0709E + 04 intergene bases with a Peff of 0.327 esebssiwaagoTQ units (Table 7).

CYP5A is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 52.6⁰. CYP5A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.1825E + 04, 3.21263E + 05, 1.14755E + 05 and 1.84810E + 05 intergene bases. CYP5A has an uppesebssiwaa and dppesebssiwaa of 7.8290E + 04 and 2.53036E + 05 intergene bases with a Peff of 0.309 esebssiwaagoTQ units (Table 7).

RARG is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 52.7⁰. RARG has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.847E + 03, 4.4654E + 04, 2.5927E + 04 and 5.1723E + 04 intergene bases. RARG has an uppesebssiwaa and dppesebssiwaa of 1.4887E + 04 and 4.8189E + 04 intergene bases with a Peff of 0.309 esebssiwaagoTQ units (Table 7).

CYCS is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 54.1⁰. CYCS has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.1987E + 04, 2.02726E + 05, 1.3747E + 04 and 8.5931E + 04 intergene bases. CYCS has an uppesebssiwaa and dppesebssiwaa of 4.2867E + 04 and 1.44328E + 05 intergene bases with a Peff of 0.297 esebssiwaagoTQ units (Table 7).

FASN is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 56.4⁰. FASN has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.6097E + 04, 5.0211E + 04, 1.472E + 04 or 1.2875E + 04 intergene bases. FASN has an uppesebssiwaa and dppesebssiwaa of 8.785E + 03 and 3.1543E + 04 intergene bases with a Peff of 0.278 esebssiwaagoTQ units (Table 7).

NOS1 is a 3 A 7 ACM final SEB gene at x-, y-vertical axis angulation 58.4⁰. NOS1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.496E + 03, 3.6292E + 04, 1.8694E + 04 and 4.4605E + 04 intergene bases. NOS1 has an uppesebssiwaa and dppesebssiwaa of 1.0595E + 04 and 4.0449E + 04 intergene bases with a Peff of 0.262 esebssiwaagoTQ units (Table 7).

GADD45A is a 3 M 7 ext final SEB gene at x-, y-vertical axis angulation 60.4⁰. GADD45A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.3412E + 04, 8.5949E + 04, 6.470E + 03 and 1.17960E + 05 intergene bases. GADD45A has an uppesebssiwaa and dppesebssiwaa of 2.4941E + 04 and 1.01955E + 05 intergene bases with a Peff of 0.245 esebssiwaagoTQ units (Table 7).

NRID2 is a 2 A 6 ext final SEB gene at x-, y-vertical axis angulation 60.8⁰. NRID2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.6660E + 04, 3.30263E + 05. 8.8163E + 04, 1.86423E + 05 intergene bases. NRID2 has an uppesebssiwaa and dppesebssiwaa of 6.2412E + 04 and 2.58343E + 05 intergene bases with a Peff of 0.242 esebssiwaagoTQ units (Table 7).

CAT is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 63.4⁰. CAT has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.0584E + 04, 7.9950E + 04, 5.293E + 03 and 8.3295E + 04 intergene bases. CAT has an uppesebssiwaa and dppesebssiwaa of 1.7938E + 04 and 8.1622E + 04 intergene bases with a Peff of 0.220 esebssiwaagoTQ units (Table 7).

COX6C is a 2 A 4 ACM final SEB gene at x-, y-vertical axis angulation 64.5⁰. COX6C has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.3278E + 04, 1.13133E + 05, 1.3550E + 04 and 2.03011E + 05 intergene bases. COX6C has an uppesebssiwaa and dppesebssiwaa of 3.3414E + 04 and 1.58072E + 05 intergene bases with a Peff of 0.211 esebssiwaagoTQ units (Table 7).

GSTM2 is a 2 M 5 NCA ACM final SEB gene at x-, y-vertical axis angulation 59.6⁰. GSTM2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.2001E + 04, 4.1822E + 04, 6.033E + 03 and 1.24474E + 05 intergene bases. GSTM2 has an uppesebssiwaa and dppesebssiwaa of 1.4017E + 04 and 8.3148E + 04 intergene bases with a Peff of 0.169 esebssiwaagoTQ units (Table 7).

LGALS1 is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 74.2⁰. LGALS1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.039E + 03, 8.6386E + 04, 7.672E + 03 and 1.8783E + 04 intergene bases. LGALS1 has an uppesebssiwaa and dppesebssiwaa of 6.856E + 03 and 5.2584E + 04 intergene bases with a Peff of 0.130 esebssiwaagoTQ units (Table 7).

ortho-planar intracellular, ortho-co-planar extracellular polychlorinated biphenyl.

DCAKD is a 2 M 5 acm final SEB gene at x-, y-vertical axis angulation 72.1⁰. DCAKD has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.7286E + 04, 1.07727E + 05, 3.77E + 02 and 5.3956E + 04 intergene bases. DCAKD has an uppesebssiwaa and dppesebssiwaa of 3.3832E + 04 and 8.0842E + 04 intergene bases with a Peff of 0.418 esebssiwaagoTQ units (Table 8).

thumbnail
Table 8. Effective intracellular pressure mapping of gene activation by (co-) ortho-planar polychlorinated biphenyls and metabolites via the Car/PxR, Rarγ: Pparα/γ, Rxrβ (Srebf1, -LxRβ): Arnt (AhR-Erβ)/Ar:: Dio1/Dio2 (Trβ) pathway.

https://doi.org/10.1371/journal.pone.0236446.t008

PPARA is a 2 A 4 NCA final SEB gene at x-, y-vertical axis angulation 39.7⁰. PPARA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.7120E + 04, 1.23677E + 05, 2.116E + 03 and 1.8633E + 04 intergene bases. PPARA has an uppesebssiwaa and dppesebssiwaa of 2.9618E + 04 and 7.1155E + 04 intergene bases with a Peff of 0.416 esebssiwaagoTQ units (Table 8).

DDIT3 is a 3 M 5 NCA ACM final SEB gene at x-, y-vertical axis angulation 40.97°. DDIT3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.2432E + 04, 1.09617E + 05, 6.288E + 03 and 3.5032E + 04 intergene bases. DDIT3 has an uppesebssiwaa and dppesebssiwaa of 2.9360E + 04 and 7.2324E + 04 intergene bases with a Peff of 0.406 esebssiwaagoTQ units (Table 8).

NR1I3 is a 3 M 5 ACM final SEB gene at x-, y-vertical axis angulation 43.2⁰. NR1I3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.3252E + 04, 1.04908E + 05, 2.9155E + 04 and 1.33970E + 05 intergene bases. NR1I3 has an uppesebssiwaa and dppesebssiwaa of 4.6203E + 04 and 1.19293E + 05 intergene bases with a Peff of 0.387 esebssiwaagoTQ units (Table 8).

FOXA1 is a 3 M 7 ACMx2 final SEB gene at x-, y-vertical axis angulation 43.6⁰. FOXA1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.365E + 03, 5.8310E + 04, 1.02576E + 05 and 2.30487E + 05 intergene bases. FOXA1 has an uppesebssiwaa and dppesebssiwaa of 5.5470E + 04 and 1.44398E + 05 intergene bases with a Peff of 0.384 (0.3841) esebssiwaagoTQ units (Table 8).

FKBP5 is a 2 A 7 ACM final SEB gene at x-, y-vertical axis angulation 48.7⁰. FKBP5 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 9.472E + 03, 6.3245E + 04, 4.1261E + 04 and 8.5032E + 04 intergene bases. FKBP5 has an uppesebssiwaa and dppesebssiwaa of 2.5366E + 04 and 7.4138E + 04 intergene bases with a Peff of 0.342 esebssiwaagoTQ units (Table 8).

NCOA1 is a 3 M 7 stIMfA NCA ACM final SEB gene at x-, y-vertical axis angulation 50.8⁰. NCOA1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.5277E + 04, 1.69917E + 05, 1.1065E + 04 and 9.6413E + 04 intergene bases. NCOA1 has an uppesebssiwaa and dppesebssiwaa of 4.3171E + 04 and 1.33165E + 05 intergene bases with a Peff of 0.324 esebssiwaagoTQ units (Table 8).

CYP2B6 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 50.9⁰. CYP2B6 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.4887E + 04, 3.2241E + 04, 3.224E + 03 and 2.3693E + 04 intergene bases. CYP2B6 has an uppesebssiwaa and dppesebssiwaa of 9.056E + 03 and 2.7967E + 04 intergene bases with a Peff of 0.324 esebssiwaagoTQ units (Table 8).

NR1I2 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 52.3⁰. NR1I2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.0367E + 04, 1.00223E + 05, 4.4883E + 04, 7.6998E + 04 intergene bases. NR1I2 has an uppesebssiwaa and dppesebssiwaa of 2.7625E + 04 and 8.8611E + 04 intergene bases with a Peff of 0.312 esebssiwaagoTQ units (Table 8).

CIDEA is a 2 A 3 stIMfA final SEB gene at x-, y-vertical axis angulation 54.7⁰. CIDEA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.9350E + 04, 2.09403E + 05, 2.1519E + 04 and 3.4977E + 04 intergene bases. CIDEA has an uppesebssiwaa and dppesebssiwaa of 3.5735E + 04 and 1.22190E + 05 intergene bases with a Peff of 0.292 esebssiwaagoTQ units (Table 8).

THRB is a 3 A 9 stIMfA final SEB gene at x-, y-vertical axis angulation 55.2⁰. THRB has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.9549E + 04, 2.47380E + 05, 1.08453E + 05 and 1.96893E + 05 intergene bases. THRB has an uppesebssiwaa and dppesebssiwaa of 6.4001E + 04 and 2.22137E + 05 intergene bases with a Peff of 0.288 esebssiwaagoTQ units (Table 8).

MBP is a 2 A 3 NCA ACM q term final SEB gene at x-, y-vertical axis angulation 62.9⁰. MBP has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.8325E + 04, 2.97769E + 05, 7.6708E + 04 and 2.16048E + 05 intergene bases. MBP has an uppesebssiwaa and dppesebssiwaa of 5.7628E + 04 and 2.57020E + 05 intergene bases with a Peff of 0.224 esebssiwaagoTQ units (Table 8).

CYP3A4 is a 2 A 3 ACM final SEB gene at x-, y-vertical axis angulation 56.1⁰. CYP3A4 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.3755E + 04, 3.8086E + 04, 1.379E + 03 and 1.5851E + 04 intergene bases. CYP3A4 has an uppesebssiwaa and dppesebssiwaa of 7.567E + 03 and 2.6969E + 04 intergene bases with a Peff of 0.281 esebssiwaagoTQ units (Table 8).

NR1H2 is a 2 M 5 final SEB gene at x-, y-vertical axis angulation 57.3⁰. NR1H2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.4733E + 04, 6.2238E + 04, 1.1164E + 04 and 7.0526E + 04 intergene bases. NR1H2 has an uppesebssiwaa and dppesebssiwaa of 1.7949E + 04 and 6.6382E + 04 intergene bases with a Peff of 0.270 esebssiwaagoTQ units (Table 8).

CEACAM5 is a 2 A 4 stIMfA final SEB gene at x-, y-vertical axis angulation 59.5⁰. CEACAM5 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.1447E + 04, 5.6869E + 04, 6.140E + 03 and 5.2392E + 04 intergene bases. CEACAM5 has an uppesebssiwaa and dppesebssiwaa of 1.3793E + 04 and 5.4631E + 04 intergene bases with a Peff of 0.252 esebssiwaagoTQ units (Table 8).

MAFG is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 59.6⁰. MAFG has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.819E + 03, 5.4643E + 04, 1.4233E + 04 and 3.3022E + 04 intergene bases. MAFG has an uppesebssiwaa and dppesebssiwaa of 1.1026E + 04 and 4.3832E + 04 intergene bases with a Peff of 0.252 esebssiwaagoTQ units (Table 8).

SCD5 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 59.6⁰. SCD5 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.7158E + 04, 1.60532E + 05, 4.3087E + 04 and 3.17760E + 05 intergene bases. SCD5 has an uppesebssiwaa and dppesebssiwaa of 6.0123E + 04 and 2.39146E + 05 intergene bases with a Peff of 0.251 esebssiwaagoTQ units (Table 8).

MBP is a 2 A 4 ACM q term final SEB gene at x-, y-vertical axis angulation 60.5⁰. MBP has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.9347E + 04, 1.76854E + 05, 7.6708E + 04 and 2.16048E + 05 intergene bases. MBP has an uppesebssiwaa and dppesebssiwaa of 4.8027E + 04 and 1.96451E + 05 intergene bases with a Peff of 0.244 esebssiwaagoTQ units (Table 8).

CUL2 is a 2 A 3 NCA ACM final SEB gene at x-, y-vertical axis angulation 56.4⁰. CUL2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.8848E + 04, 2.74921E + 05, 2.08721E + 05, 5.41134E + 05 intergene bases. CUL2 has an uppesebssiwaa and dppesebssiwaa of 1.13635E + 05 and 4.08028E + 05 intergene bases with a Peff of 0.278 esebssiwaagoTQ units (Table 8).

ALAS2 is a 2 A 3 p term final SEB gene at x-, y-vertical axis angulation 62.55⁰. ALAS2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.0152E + 04, 2.56510E + 05, 6.1069E + 04 and 1.00950E + 05 intergene bases. ALAS2 has an uppesebssiwaa and dppesebssiwaa of 4.0611E + 04 and 1.78730E + 05 intergene bases with a Peff of 0.227 esebssiwaagoTQ units (Table 8).

NCOR1 is a 2 A 5 NCAx3 final SEB gene at x-, y-vertical axis angulation 70.6⁰. NCOR1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.2911E + 04, 2.4777E + 04, 9.52E + 03 and 1.14781E + 05 intergene bases. NCOR1 has an uppesebssiwaa and dppesebssiwaa of 1.1215E + 04 and 6.9779E + 04 intergene bases with a Peff of 0.161 esebssiwaagoTQ units (Table 8).

CASP3 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 70.7⁰. CASP3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.2778E + 04, 4.4665E + 04, 1.8640E + 04 and 2.14308E + 05 intergene bases. CASP3 has an uppesebssiwaa and dppesebssiwaa of 2.0709E + 04 and 1.29486E + 05 intergene bases with a Peff of 0.160 esebssiwaagoTQ units (Table 8).

CES2 is a 2 A 4 ACM final SEB gene at x-, y-vertical axis angulation 70.8⁰. CES2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.0860E + 04, 9.0630E + 04, 7.68E + 02 and 1.08260E + 05 intergene bases. CES2 has an uppesebssiwaa and dppesebssiwaa of 1.5772E + 04 and 9.9445E + 04 intergene bases with a Peff of 0.159 esebssiwaagoTQ units (Table 8).

CYP3A5 is a 3 M 5 NCAx2 ACM final SEB gene at x-, y-vertical axis angulation 71.05⁰. CYP3A5 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.3739E + 04, 3.3986E + 04, 7.215E + 03 and 9.9566E + 04 intergene bases. CYP3A5 has an uppesebssiwaa and dppesebssiwaa of 1.0477E + 04 and 6.6776E + 04 intergene bases with a Peff of 0.157 esebssiwaagoTQ units (Table 8).

AR is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 71.1⁰. AR has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.9384E + 04, 3.80800E + 05, 5.6075E + 04 and 1.01739E + 05 intergene bases. AR has an uppesebssiwaa and dppesebssiwaa of 3.7729E + 04 and 2.41270E + 05 intergene bases with a Peff of 0.156 esebssiwaagoTQ units (Table 8).

CYP4A11 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 72.0⁰. CYP4A11 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.4063E + 04, 3.9722E + 04, 1.2582E + 04 and 1.38786E + 05 intergene bases. CYP4A11 has an uppesebssiwaa and dppesebssiwaa of 1.3322E + 04 and 8.9254E + 04 intergene bases with a Peff of 0.149 esebssiwaagoTQ units (Table 8).

GTF2IRD1 is a 2 M 7 ACM final SEB gene at x-, y-vertical axis angulation 73.1⁰. GTF2IRD1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.9160E + 04, 5.2809E + 04, 2.697E + 03 and 1.75310E + 05 intergene bases. GTF2IRD1 has an uppesebssiwaa and dppesebssiwaa of 1.5928E + 04 and 1.14060E + 05 intergene bases with a Peff of 0.140 esebssiwaagoTQ units (Table 8).

PPP1R9B is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 74.4⁰. PPP1R9B has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.2770E + 04, 1.02872E + 05, 3.5391E + 04 and 5.04863E + 05 intergene bases. PPP1R9B has an uppesebssiwaa and dppesebssiwaa of 3.9081E + 04 and 3.03867E + 05 intergene bases with a Peff of 0.129 esebssiwaagoTQ units (Table 8).

FABP3 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 74.5⁰. FABP3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.2880E + 04, 1.56459E + 05, 9.227E + 03 and 1.6822E + 04 intergene bases. FABP3 has an uppesebssiwaa and dppesebssiwaa of 1.1053E + 04 and 8.6640E + 04 intergene bases with a Peff of 0.128 esebssiwaagoTQ units (Table 8).

FABP6 is a 2 M 4 final SEB gene at x-, y-vertical axis angulation 78.3⁰. FABP6 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.8309E + 04, 7.63245E + 05, 1.9768E + 04 and 4.6206E + 04 intergene bases. FABP6 has an uppesebssiwaa and dppesebssiwaa of 3.9038E + 04 and 4.04726E + 05 intergene bases with a Peff of 0.096 esebssiwaagoTQ units (Table 8).

van der Waals diameter, structural lipophilicity and pressure regulation grade half-life parameters for small molecules with exterior structural lipophilicity

Aldosterone (C21H28O5) has a Log P of 1.06, a vdWD of 0.856 nm and a Log P/vdWD of 1.23 nm-1. Aldosterone has a calc Lexternal structure/Hpolar group ratio of 1.31, and a nl calc Lexternal structure/Hpolar group quotient of 0.478. The t1/2 at receptor·receptor count (t1/2·Rcount) for aldosterone at MR is 2.366E + 04 min·count, at GR is 6.610E + 03 min·count, and the Σ min·count is 3.0270E + 04 (Table 9).

thumbnail
Table 9. Effective intracellular pressure grade of effect for molecular size-excluded steroid axis small molecule ligands at cell membrane receptors.

https://doi.org/10.1371/journal.pone.0236446.t009

Cortisol (C21H30O5) has a Log P of 1.28, a vdWD of 0.861 nm and a Log P/vdWD of 1.49 nm-1. Cortisol has a calc Lexternal structure/Hpolar group ratio of 1.36, and a nl calc Lexternal structure/Hpolar group quotient of 0.495. The t1/2 at receptor·receptor count (t1/2·Rcount) for cortisol at MR is 7.605E + 03 min·count, at GR is 6.610E + 03 min·count, and the Σ min·count is 1.42E + 04 (Table 9).

Dexamethasone (DEX; C22H29FO5) has a Log P of 1.68, a vdWD of 0.873 nm and a Log P/vdWD of 1.92 nm-1. Corticosterone (Cort; C21H30O4) has a Log P of 2.02, a vdWD of 0.854 nm and a Log P/vdWD of 2.37 nm-1. Corticosterone has a calc Lexternal structure/Hpolar group ratio of 1.72, and a nl calc Lexternal structure/Hpolar group quotient of 0.627. The t1/2 at receptor·receptor count (t1/2·Rcount) for dexamethasone at MR is 1.183E + 03 min·count, at GR is 1.32200E + 05 min·count, and the Σ min·count is 1.33383E + 05 (Table 9).

Diethylstilbestrol (DES; C18H20O2) has a Log P of 5.19, a vdWD of 0.786 nm and a Log P/vdWD of 6.60 nm-1. DES has a calc Lexternal structure/Hpolar group ratio of 3.59, and a nl calc Lexternal structure/Hpolar group quotient of 1.31. The t1/2 at receptor·receptor count (t1/2·Rcount) for diethylstilbestrol at ERα is 1.863745E + 06 min·count (Table 9).

17β-estradiol (E2; C18H24O2) has a Log P of 3.75, a vdWD of 0.792 nm and a Log P/vdWD of 4.73 nm-1. E2 has a calc Lexternal structure/Hpolar group ratio of 4.73, and a nl calc Lexternal structure/Hpolar group quotient of 1.18. The t1/2 at receptor·receptor count (t1/2·Rcount) for 17β-estradiol at ERα is 1.2E + 06 min·count (Table 9).

Dihydroxytestosterone (DHT; C19H30O2) has a Log P of 3.41, a vdWD of 0.822 nm and a Log P/vdWD of 4.15 nm-1. DHT has a calc Lexternal structure/Hpolar group ratio of 3.16, and a nl calc Lexternal structure/Hpolar group quotient of 1.15. The t1/2 at receptor·receptor count (t1/2·Rcount) for dihydroxytestosterone at AR is 1.79812E + 05 min·count (Table 9).

Methyltrienolone (R1881; C19H24O2) has a Log P of 2.41, a vdWD of 0.800 nm and a Log P/vdWD of 3.16 nm-1. R1881 has a calc Lexternal structure/Hpolar group ratio of 2.56, and a nl calc Lexternal structure/Hpolar group quotient of 0.932. The t1/2 at receptor·receptor count (t1/2·Rcount) for methyltrienolone at AR is 2.47340E + 05 min·count (Table 9).

Insulin-like growth factor II (20.1 kDa) t1/2 at receptor·receptor count (t1/2·Rcount) at IGRIIR/M6P is 1.943502E + 06 min·count (Table 9, legend).

Gene expression effective pressure mapping for small molecule hormones and bisphenol as ligands of cell membrane steroid axis receptors (in pharmacokinetic non-competition)

GCLC is a 2 A 3 ACM final SEB gene at x-, y-vertical axis angulation 32.4⁰. GCLC has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.128E + 03, 3.8969E + 04, 1.39792E + 05 and 2.58868E + 05 intergene bases. GCLC has an uppesebssiwaa and dppesebssiwaa of 7.0960E + 04 and 1.48918E + 05 intergene bases with a Peff of 0.477 esebssiwaagoTQ units (Table 10).

thumbnail
Table 10. Effective intracellular pressure mapping of gene activation by molecular size-excluded small molecule hormones via cell membrane Gr, Mr, Erα/β and AR receptor pathways as compared to bisphenol Aǂ.

https://doi.org/10.1371/journal.pone.0236446.t010

PER1 is a 2 A 6 ACM final SEB gene at x-, y-vertical axis angulation 42.4⁰. PER1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.3824E + 04, 7.2463E + 04, 2.173E + 03 and 1.8993E + 04 intergene bases. PER1 has an uppesebssiwaa and dppesebssiwaa of 1.7998E + 04 and 4.5728E + 04 intergene bases with a Peff of 0.394 esebssiwaagoTQ units (Table 10).

PMCH is a 3 M 5 ACM final SEB gene at x-, y-vertical axis angulation 43.3⁰. PMCH has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.5883E + 04, 1.27508E + 05, 1.1105E + 04 and 7.1788E + 04 intergene bases. PMCH has an uppesebssiwaa and dppesebssiwaa of 3.8494E + 04 and 9.9848E + 04 intergene bases with a Peff of 0.386 esebssiwaagoTQ units (Table 10).

NR3C1 is a 2 A 3 ACM final SEB gene at x-, y-vertical axis angulation 44.5⁰. NR3C1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.2643E + 04, 2.26184E + 05, 2.10238E + 05, 3.65899E + 05 intergene bases. NR3C1 has an uppesebssiwaa and dppesebssiwaa of 1.11440E + 05 and 2.96042E + 05 intergene bases with a Peff of 0.376 esebssiwaagoTQ units (Table 10).

GPER1 is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 44.6⁰. NR3C1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.697E + 03, 3.4332E + 04, 5.6825E + 04 and 1.29323E + 05 intergene bases. NR3C1 has an uppesebssiwaa and dppesebssiwaa of 3.0761E + 04 and 8.1827E + 04 intergene bases with a Peff of 0.376 esebssiwaagoTQ units (Table 10).

INSL3 is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 47.9⁰ (act). INSL3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 6.248E + 03, 5.8905E + 04, 3.7545E + 04 and 6.6648E + 04 intergene bases (act). INSL3 has an uppesebssiwaa and dppesebssiwaa of 2.1896E + 04 and 6.2777E + 04 intergene bases with a Peff of 0.349 esebssiwaagoTQ units (act) (Table 10).

DLK1 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 48.3⁰. DLK1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.2336E + 04, 1.62011E + 05, 3.088E + 03 and 5.6714E + 04 intergene bases. DLK1 has an uppesebssiwaa and dppesebssiwaa of 3.7712E + 04 and 1.69362E + 05 intergene bases with a Peff of 0.345 esebssiwaagoTQ units (Table 10).

OLFM1 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 50.5⁰. OLFM1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.7728E + 04, 6.0118E + 04, 9.980E + 03 and 5.7711E + 04 intergene bases. OLFM1 has an uppesebssiwaa and dppesebssiwaa of 1.8854E + 04 and 5.7711E + 04 intergene bases with a Peff of 0.327 esebssiwaagoTQ units (Table 10).

ADAM8 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 52.8⁰. ADAM8 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.0415E + 04, 6.0950E + 04, 9.529E + 03 and 6.8596E + 04 intergene bases. ADAM8 has an uppesebssiwaa and dppesebssiwaa of 1.9972E + 04 and 6.4773E + 04 intergene bases with a Peff of 0.308 esebssiwaagoTQ units (Table 10).

SIM1 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 54.9⁰. SIM1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.9304E + 04, 1.50699E + 05, 3.3038E + 04 and 5.4889E + 04 intergene bases. SIM1 has an uppesebssiwaa and dppesebssiwaa of 3.1171E + 04 and 1.02794E + 05 intergene bases with a Peff of 0.303 esebssiwaagoTQ units (Table 10).

RAPGEFL1 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 55.9⁰. RAPGEFL1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.474E + 03, 3.2272E + 04, 1.4334E + 04 and 3.7835E + 04 intergene bases. RAPGEFL1 has an uppesebssiwaa and dppesebssiwaa of 9.904E + 03 and 3.5054E + 04 intergene bases with a Peff of 0.283 esebssiwaagoTQ units (Table 10).

CDKNIA is a 3 A 5 ACM stIMfA extended final SEB gene at x-, y-vertical axis angulation 56.7⁰. CDKN1A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.400E + 03, 6.4050E + 04, 4.2285E + 04 and 1.05247E + 05 intergene bases. CDKN1A has an uppesebssiwaa and dppesebssiwaa of 2.3343E + 04 and 8.4648E + 04 intergene bases with a Peff of 0.276 esebssiwaagoTQ units (Table 10).

FABP4 is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 58.1⁰. FABP4 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.6724E + 04, 2.66777E + 05, 8.0092E + 04 and 1.76219E + 05 intergene bases. SIM1 has an uppesebssiwaa and dppesebssiwaa of 5.8408E + 04 and 2.21498E + 05 intergene bases with a Peff of 0.264 esebssiwaagoTQ units (Table 10).

NR3C2 is a 4 A 9 initial and final SEB gene at x-, y-vertical axis angulation 58.4⁰. NR3C2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.4496E + 04, 1.86526E + 05, 7.8774E + 04 and 2.08855E + 05 intergene bases. NR3C2 has an uppesebssiwaa and dppesebssiwaa of 5.1635E + 04 and 1.97691E + 05 intergene bases with a Peff of 0.261 esebssiwaagoTQ units (Table 10).

MEG3 is a 2 A 2 ACMx2 ext final SEB gene at x-, y-vertical axis angulation 58.9⁰. MEG3 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 5.197E + 03, 1.77555E + 05, 1.05830E + 05 and 2.53278E + 05 intergene bases. MEG3 has an uppesebssiwaa and dppesebssiwaa of 5.5514E + 04 and 2.15416E + 05 intergene bases with a Peff of 0.258 esebssiwaagoTQ units (Table 10).

DFFA is a 3 A 5 initial and final SEB gene at x-, y-vertical axis angulation 58.9⁰. DFFA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.4323E + 04, 1.44368E + 05, 5.9771E + 04 and 1.43444E + 05 intergene bases. DFFA has an uppesebssiwaa and dppesebssiwaa of 3.7047E + 04 and 1.43906E + 05 intergene bases with a Peff of 0.257 esebssiwaagoTQ units (Table 10).

FOS is a 3 A 9 ACM final SEB gene at x-, y-vertical axis angulation 59.1⁰. DFFA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.5182E + 04, 1.39901E + 05, 4.4895E + 04 and 9.5063E + 04 intergene bases. FOS has an uppesebssiwaa and dppesebssiwaa of 3.0039E + 04 and 1.17482 + 05 intergene bases with a Peff of 0.256 esebssiwaagoTQ units (Table 10).

TIMM8B is a 3 A 8 ACMx2 ext final SEB gene at x-, y-vertical axis angulation 60.2⁰. TIMM8B has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.5423E + 04, 2.04260E + 05, 5.3871E + 04 and 1.16735E + 05 intergene bases. TIMM8B has an uppesebssiwaa and dppesebssiwaa of 3.9647E + 04 and 1.60497E + 05 intergene bases with a Peff of 0.247 esebssiwaagoTQ units (Table 10).

MIAT is a 2 M 6 acm final SEB gene at x-, y-vertical axis angulation 65.2⁰. MIAT has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.1481E + 04, 1.9667E + 04, 1.408E + 03 and 4.3151E + 04 intergene bases. MIAT has an uppesebssiwaa and dppesebssiwaa of 6.444E + 03 and 3.1409E + 04 intergene bases with a Peff of 0.205 esebssiwaagoTQ units (Table 10).

CYP17A1 is a 3 A 5 NCA ACM final SEB gene at x-, y-vertical axis angulation 65.8⁰. CYP17A1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.4406E + 04, 1.79367E + 05, 4.2836E + 04 and 1.07414E + 05 intergene bases. CYP17A1 has an uppesebssiwaa and dppesebssiwaa of 2.8621E + 04 and 1.43391E + 05 intergene bases with a Peff of 0.200 esebssiwaagoTQ units (Table 10).

PLEKHG4 is a 2 A 9 ACMx2 final SEB gene at x-, y-vertical axis angulation 66.6⁰. PLEKHG4 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.609E + 03, 7.7744E + 04, 1.0374E + 04 and 2.0179E + 04 intergene bases. PLEKHG4 has an uppesebssiwaa and dppesebssiwaa 9.490E + 03 and 4.8961E + 04 intergene bases with a Peff of 0.194 esebssiwaagoTQ units (Table 10).

FLNA is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 67.8⁰. FLNA has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 9.480E + 03, 8.6967E + 04, 1.2954E + 04, 3.5033E + 04 intergene bases. FLNA has an uppesebssiwaa and dppesebssiwaa of 1.1214E + 04 and 6.1000E + 04 intergene bases with a Peff of 0.184 esebssiwaagoTQ units (Table 10).

CEBPD is a 5 M 11 initial and final SEB gene at x-, y-vertical axis angulation 69.7⁰. CEBPD has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.8872E + 04, 1.85923E + 05, 5.5818E + 04 and 6.74877E + 05 intergene bases. CEBPD has an uppesebssiwaa and dppesebssiwaa of 7.2345E + 04 and 4.30400E + 05 intergene bases with a Peff of 0.168 esebssiwaagoTQ units (Table 10).

SLC9A1 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 69.8⁰. SLC9A1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.8999E + 04, 7.1281E + 04, 7.895E + 03 and 1.49186E + 05 intergene bases. SLC9A1 has an uppesebssiwaa and dppesebssiwaa of 1.8447E + 04 and 1.10234E + 05 intergene bases with a Peff of 0.167 esebssiwaagoTQ units (Table 10).

TFF1 is a 3 M 7 initial and final SEB gene at x-, y-vertical axis angulation 72.2⁰. TFF1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.0485E + 04, 7.8313E + 04, 1.5753E 04 and 2.36160E + 05 intergene bases. TFF1 has an uppesebssiwaa and dppesebssiwaa of 2.3119E + 04 and 1.57237E + 05 intergene bases with a Peff of 0.147 esebssiwaagoTQ units (Table 10).

GSTA1 is a 2 M 7 final SEB gene at x-, y-vertical axis angulation 72.35⁰. GSTA1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 7.761E + 03, 2.6442E + 04, 7.148E + 03 and 5.1039E + 04 intergene bases. GSTA1 has an uppesebssiwaa and dppesebssiwaa of 7.454E + 03 and 5.1039E + 04 intergene bases with a Peff of 0.146 esebssiwaagoTQ units (Table 10).

CYP11B2 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 76.5⁰. CYP11B2 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.4767E + 04, 2.73740E + 05, 7.246E + 03 and 1.2312E + 04 intergene bases. CYP11B2 has an uppesebssiwaa and dppesebssiwaa of 1.6007E + 04 and 1.43026E + 05 intergene bases with a Peff of 0.112 esebssiwaagoTQ units (Table 10).

CYP11B1 is a 3 M 7 initial and final SEB gene at x-, y-vertical axis angulation 78.1⁰. CYP11B1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.8541E + 04, 4.5978E + 04, 9.853E + 03 and 2.41300E + 05 intergene bases. CYP11B1 has an uppesebssiwaa and dppesebssiwaa of 1.4197E + 04 and 1.43639E + 05 intergene bases with a Peff of 0.099 esebssiwaagoTQ units (Table 10).

TGIF1 is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 80.3⁰. TGIF1 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.2126E + 04, 4.50996E +05, 1.6366E + 04 and 3.0205E + 04 intergene bases. TGIF1 has an uppesebssiwaa and dppesebssiwaa of 1.9246E + 03 and 2.40600E + 05 intergene bases with a Peff of 0.099 esebssiwaagoTQ units (Table 10).

Gene expression effective pressure mapping for diethylstilbestrol (DES) as a ligand of the cell membrane ERα/β steroid axis receptor

A2M is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 43.1⁰. A2M has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 8.931E + 03, 5.9005E +04, 5.7966E + 04 and 1.32425E + 05 intergene bases. A2M has an uppesebssiwaa and dppesebssiwaa of 3.3448E + 04 and 8.6274E + 04 intergene bases with a Peff of 0.388 esebssiwaagoTQ units (Table 11).

thumbnail
Table 11. Effective intracellular pressure mapping of directional gene activation by DES via the cell membrane ERα receptor in the mullerian axis in differentiation.

https://doi.org/10.1371/journal.pone.0236446.t011

HOXA13 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation 48.2⁰. HOXA13 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.04360E + 05, 2.55391E + 05, 1.9369E + 04 and 1.02576E + 05 intergene bases. HOXA13 has an uppesebssiwaa and dppesebssiwaa of 6.1864E + 04 and 1.78884E + 05 intergene bases with a Peff of 0.346 esebssiwaagoTQ units (Table 11).

HOXA11 is a 2 M 8 ACM final SEB gene at x-, y-vertical axis angulation 49.9⁰. HOXA11 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 1.14015E + 05, 2.54118E + 05, 1.2758E + 04 and 1.27288E + 05 intergene bases. HOXA11 has an uppesebssiwaa and dppesebssiwaa of 6.3386E + 04 and 1.90703E + 05 intergene bases with a Peff of 0.332 esebssiwaagoTQ units (Table 11).

HOXA9/HOXA10 is a 2 M 5 initial and final SEB gene at x-, y-vertical axis angulation ≥ 56.6⁰. HOXA9/HOXA10 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 4.34614E + 04, 9.8407E + 04, 9.552E + 03 and 9.3991E + 04 intergene bases. HOXA9/HOXA10 has an uppesebssiwaa and dppesebssiwaa of 2.6583E + 04 and 9.6199E + 04 intergene bases with a Peff of ≥ 0.2763 esebssiwaagoTQ units.

KLF4 is a 3 A 7 initial and final SEB gene at x-, y-vertical axis angulation 60.65⁰. KLF4 has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 2.9538E + 04, 3.7755E + 05, 7.8294E + 04 and 1.66138E + 05 intergene bases. KLF4 has an uppesebssiwaa and dppesebssiwaa of 5.3916E + 04 and 2.21844E + 05 intergene bases with a Peff of 0.243 esebssiwaagoTQ units (Table 11).

WNT5A is a 2 A 5 initial and final SEB gene at x-, y-vertical axis angulation 73.6⁰. WNT5A has an uppasebssiwa, dppasebssiwa, uppmsebssiwa and dppmsebssiwa of 3.4162E + 04, 4.41140E + 05, 3.3572E + 05 and 5.7151E + 04 intergene bases. WNT5A has an uppesebssiwaa and dppesebssiwaa of 3.3867E + 04 and 2.49146E + 05 intergene bases with a Peff of 0.1359 esebssiwaagoTQ units (Table 11).

van der Waals diameter, structural lipophilicity and hydrophilicity parameters for small molecules with exterior or interior structural lipophilicity

Tetradotoxin (C11H18N31+O8) has a Log D of -6.84, a vdWD of 0.774 nm and a Log D/vdWD of -8.84 nm-1. 2,4-diazatetracyclotetradecane (C11H18N2O2) has a Log P of 0.847, a vdWD of 0.624 nm and a Log P/vdWD of 1.36 nm-1. Tetradotoxin has a calc Linternal structure/Hpolar group ratio of 0.2323, and a nl calc Linternal structure/Hpolar group quotient of 0.085 (Table 12).

thumbnail
Table 12. Small molecules with external hydrophilicity and interior or exterior lipophilicity as ligands for cell membrane receptors or channels.

https://doi.org/10.1371/journal.pone.0236446.t012

Saxitoxin (C10H19N71+,1+O4; 1+ SS 1+) has a Log D of -7.12, a vdWD of 0.764 nm and a Log D/vdWD of -9.32 nm-1. 3,4-pyrrolo-4,5-imidazolo-6-methyl-piperazine (C9H16N4) has a Log P of 0.13, a vdWD of 0.682 nm and a Log P/vdWD of 0.19 nm-1. Saxitoxin has a calc Linternal structure/Hpolar group ratio of 0.2784, and a nl calc Linternal structure/Hpolar group quotient of 0.101 (Table 12).

m-xylenediamine (C8H14N22+) has a Log D of -5.84, a vdWD of 0.635 nm and a Log D/vdWD of -9.20 nm-1. 1,2-dimethylbenzene (C8H10) has a Log P of 3.00, a vdWD of 0.598 nm and a Log P/vdWD of 5.02 nm-1. m-xylenediamine has a calc Lexternal structure/Hpolar group ratio of 0.252, and a nl calc Lexternal structure/Hpolar group quotient of 0.092 (Table 12).

Phthalate (C8H4O42-) has a Log D of -4.70, a vdWD of 0.633 nm and a Log D/vdWD of -7.42 nm-1. Benzene (C8H10) has a Log P of 1.97, a vdWD of 0.532 nm and a Log P/vdWD of 3.70 nm-1. Phthalate has a calc Lexternal structure/Hpolar group ratio of 0.215, and a nl calc Lexternal structure/Hpolar group quotient of 0.078 (Table 12).

1,2-diaminocyclohexane (C6H16N22+) has a Log D of -6.07 (-2.05), a vdWD of 0.622 nm and a Log D/vdWD of -9.76 (-3.34) nm-1. Cyclohexane (C6H12) has a Log P of 2.67, a vdWD of 0.699 nm and a Log P/vdWD of 4.67 nm-1. m-xylenediamine has a calc Lexternal structure/Hpolar group ratio of 0.233 (0.470), and a nl calc Lexternal structure/Hpolar group quotient of 0.085 (0.171) (Table 12).

N-acetylneuraminic acid (C21H30O4; Neu5ac) has a Log D of -7.40, a vdWD of 0.790 nm and a Log D/vdWD of -9.37 nm-1. Pentane has a Log P of 2.69, a vdWD of 0.561 nm and a Log P/vdWD of 4.97 nm-1. Neu5ac has a calc Lexternal structure/Hpolar group ratio of 0.2189, and a nl calc Lexternal structure/Hpolar group quotient of 0.0796 (Table 12).

Discussion

Molecular philicity interval for facilitated transport though cell membrane channels as determined by Lexternal structure ∙ Hpolar group-1 of C1 –C4 alkane hydroxylate isomers

The molecular philicity interval limit for facilitated transport though cell membrane channel pores is determined in this study by in silico modeling of transporter threshold for mono-, di- and poly-hydroxylate transport through the high affinity aquaporin-9 (hAQP-9) transport channel, which has a low-micromolar (uM) transport constant (Km) as determined in oocyte plasmid transfectants [19,20]. Since hAQP-3 and hAQP-9 have the lowest reflection coefficients (σ, a.u.) to the flux of 1,3-propanediol and 2,3-glycer-1-ol as the polarity-specific transport substrates, in this study the lipophilicity per molecular polarity is determined for C1 –C4 hydroxylates (Lexternal structure ∙ Hpolar group-1). Based on study findings, 2,3-glycer-1-ol has an external structure lipophilicity Log P/vdWD of 3.71 nm-1 with an unadjusted Log Palkane ∙ vdWD alkane -1/Log POH ∙ vdWDOH-1 of 0.428 (0.545 nm; -3.38 nm-1) in reference to methan-1-ol (L∙ H-1, 2.75 (1.00); 1.275 nm-1), while S-(+)-1,2-propanediol has a Lexternal structure ∙ Hpolar group-1 of 1.047, which is a competitive inhibitor for polarity-specific transport of glycerol through hAQP-9 [19]. Furthermore, based on study findings, hydroxylates, 1,3-propanediol with a L∙ H-1 of 1.113 (vdWD: 0.527 nm), 1,2-butanediol with a L∙ H-1 of 1.207 (vdWD: 0.562 nm) will be non-specific passive transport substrates for glyceroaquaporin-9, as compared to 1,2-ethanediol with a L∙ H-1 of 0.535 (vdWD: 0.486 nm), more hydrophilic channel substrates, mannitol (L∙ H-1, 0.304; vdWD: 0.672 nm, -5.55 nm-1) and lactate (L∙ H-1, 0.272, -1; vdWD: 0.526 nm, -7.04 nm-1), of which the latter demonstrates increased flux in its un-ionized form (L∙ H-1, 0.328, -0.893 nm-1) with maintained polarity-specificity for the channel. Therefore, based on the study findings, a Lexternal structure ∙ Hpolar group-1 of ≥ 1.07 is the molecular structure lipophilicity limit for non-specific carrier-mediated transmembrane diffusion through polarity-selective transport channels of the cell membrane (Table 1, Fig 1).

thumbnail
Fig 1. Molecular structural lipophilicity per polar group hydrophilicity intervals for acyclic and cyclic small molecule hormone receptor axis endogenous ligands and inverse agonists.

The Lexternal · Hpolar group-1 interval for non-selective carrier-mediated diffusion through polarity-specific transport channels is ≤ 1.07, which includes alkanols (1-propanol, 1.28; 1,2-butanediol, 1.21; 1,3-propanediol, 1.13; 1-ethanol, 1.07; vdWD, 0.463–0.562 nm) in addition to bisphenols [BPA—BPE, 1.08–1.12, intracellular (ERRγ/ERRα), vdWD 0.727–0.742 nm; BPC, intracellular–BPAF, extracellular 1.17–1.23, vdWD 0.744–0.774 nm (ERα/ERβ, GPER)], and diethylstilbestrol (DES; 1.31, vdWD 0.786 nm) as toxicants within the Lexternal · Hpolar group-1 interval 1.08–1.31, and PCB metabolites 4-OH-PCB-54, 2.78 (vdWD 0.727 nm), 4’-OH-PCB-208, 3.91 (0.801 nm) and 4’-CH3-SO2-PCB-132, 1.95 (0.811 nm), and p-dioxin (TCDD), 4.31 (0.735 nm) as toxicants within the Lexternal · Hpolar group-1 interval 1.95–4.31 (OH-PCB-3, L · H-1 = 2.13; not shown). The Lexternal · Hpolar group-1 interval for endogenous small molecule hormone ligands for the CM MR receptor is within the interval 0.478 (Aldosterone) and 0.495 (Cortisol), and for the CM GR receptor is around 0.627 (Corticosterone). The Lexternal · Hpolar group-1 for complete OH-Iodothyroxine (T4) zwitterion adjusted for intervening ether is 0.591, while the Lexternal · Hpolar group-1 for (4’-hydroxy-3’,5’-diiodophenoxy)-1-ethyl-3,5-diiodophenyl (non-zwitterion part-T4) is 3.24. The Lexternal · Hpolar group-1 interval for the broad selectivity CM hydroxylate channel polarity-specific substrates is between 0.328–0.428 (vdWD range 0.526–0.672 nm). Saxitoxin (STX) with internal structural lipophilicity has a Lexternal · Hpolar group-1 of 0.101 (not shown), as compared to m-xylenediamine with external structural lipophilicity and a Lexternal · Hpolar group-1 of 0.098. The Lext · H-1 interval ranges for substrate binding affinity to CYP450 monooxygenases, UDP-glucouronosyl-/sulfo-transferases, and ester hydrolases is 1.91–4.31 (p-dioxin, OH-p-2,3,7-TriCDD), 1.73–2.69 (OH-α-tocopherol, UGT1A_; OH-PCB-3, SULT1A_) and 0.322–1.49 (mono-butylphthalate, MBP; dibutylphthalate, DBP), respectively. The Lext · H-1 interval (min) for glucouronidation is 0.419 (glucouronate-2,3,7-TriCDD)– 0.459 (glucouronate-α-tocopherol). Methanol reference standard, 1 * Thyroxine, vdWD is adjusted for x, y plane-dimensional aspect (0.745 nm).

https://doi.org/10.1371/journal.pone.0236446.g001

Pressure regulated gene activation by C2 –C4 halogenates, C9 –C12 alcohols and unsubstituted biphenyl with asphyxiant properties

The part-molecular structural Lexternal structure ∙ Hpolar group-1 of C2 –C4 halogenates and halogenate ethers (-O-) with vdWD in the 0.554–0.610 nm range was studied as a determinant of the potency of the halogenate-mediated effect on gene activation, as vdWD is shown to be an independent predictive determinant of end-tidal minimum alveolar concentration (MAC; vol %) based on trichloromethane (CHCl3; 0.505 nm), halothane (C2HBrClF3; 0.554 nm), isoflurane and enflurane (C3H2ClF5O, 0.588 nm), and sevoflurane (C4H3F7O; 0.610 nm) as standards 0.73 (R2 = 0.73) compared to respective molecular weights (da) (R2 = 0.29; Table 2). Further, based on the study findings, 1,1,1-trifluoro-2-chloroethane (C2H2ClF3; 3.48 nm-1), 1-chloro-1,2,2-trifluoroethane (C2H2ClF3; 2.99 nm-1) and 1,1,1-trifluoro-2-fluoroethane (C2H2F4; 2.70 nm-1) are the primary determinant moieties of overall structural Lexternal structure ∙ Hpolar group-1 for Isoflurane (L∙ H-1: 4.09), Enflurane (L∙ H-1: 3.72) and Desflurane (L∙ H-1: 3.50); 1,1,1,3,3,3-hexaflouropropane (C3H2F6; 3.85 nm-1) and fluoromethane (CH2-3F; 0.939 nm-1) are co-determinant moieties of overall structural L∙ H-1 for Sevoflurane (3.83), which bell curve (ꓵ) rank orders anesthetic potency of part-structure halogenates inclusive of Desflurane that deviates from the Meyer-Overton rule due to lower part-structural structural Lexternal structure ∙ Hpolar group-1, as do the aliphatic alcohols due to a lower Log P/carbon; particularly C2 –C8 carbon length within a lower Log P/vdWD range [23] that deviate less than their non-polar alkane counterparts [24], in comparison to Halothane with more lipophilic substitution (C2HBrClF3; 3.82 nm-1, L∙ H-1: n/a) and uM Kd affinity for cytochrome P450 catalysis under atmospheric pressure in vitro [25].

Studies on gene activation upon exposure to C2 –C4 halogenates have shown the differential expression of characteristic genes in response to Sevoflurane, Isoflurane and Halothane or to a combination (COMB) of non-inhalation (ie pentobarbital, midazolam) or chloral hydrate (CH) alone in a spectrum of cells (hippocampal neuron, type II alveolar cell, hepatocyte, T-lymphocyte). In these studies it is shown that cellular FOSB expression (Peff, 0.194) decreases with in vivo COMB or CH exposure while expression remains unchanged with Isoflurane exposure (4 vol %, 1 min) [26]; HMOX1 expression (Peff, 0.153) increases with in vivo Sevoflurane or Isoflurane exposure (2–4 vol %) [27]; SFTPC expression (Peff, 0.257) increases with in vitro Halothane exposure (1–4 vol %) or with in vivo Pentobarbital analog exposure, and decreases with in vivo Halothane exposure (1%, 4 hr) [28]; and that CASP3 (Peff, 0.160) expression can increase in vitro during exposure to high concentrations of Sevoflurane and Isoflurane (5–8 vol %, 24 hr) [29]. These discordances between gene expression in vitro and in vivo may be reconciled by maintained concentration exposure in vivo in the presence of system tissue macro-compliance (- Peff intracellular). Based on the effective intracellular pressure mapping findings of the study, there is contraction-expansion decrease in cell Peff beginning from > 0.344 esebssiwaagoTQ units, between a Peff 0.344 (CYP2E1) and Peff 0.160 (CASP3) - 0.153 (HMOX1) esebssiwaagoTQ units. The Peff 0.153–160 range appears to be the convergent peri-nadir for the in vivo inhalational anesthesia regulatory effect at equipotency and pro-apoptotic as CREB1 (Peff 0.154) is transcriptionally active, one that involves intermediate Peff stages at 0.331 (NFE2L2) for expression of HMOX1 (HO-1), and in addition to cell compliance maintenance at 0.267 (JUN, TFB2M) for the respective genes (Table 3).

Molecular size-exclusion limit for facilitated transport though cell membrane channels as determined by differential Peff mapping of higher-substituted biphenyls

The molecular size-exclusion limit for facilitated transport though cell membrane channel pores is determined by study of the differential Peff response to higher-substituted polychlorinated biphenyls, 3,4,4’,5,5’-co-planar PCB-126 (0.749 nm) and co-, ortho-planar 2’,3,4,4’,5’,6-PCB-153 (0.758 nm). During applied exposure to 3’-OH-3,4,4’,5,5’-co-planar PCB-126 in silico as a representative co-planar PCB at a chiral carbon x, y, z-plane van der Waals diameter of 0.752 nm, the lower limit of Peff decreases to the x, z-plane alignment pressure for DIO3 (Peff, 0.096) during which the upper limit of Peff decreases to 0.379 (CEACAM1a [22]) and 0.331 (NFE2L2, NRF-2 [22]) esebssiwaagoTQ units during which contraction occurs; whereas, during applied exposure to PCB-153, the lower limit of Peff decreases to 0.057 (TSPAN12) with contraction to Peff 0.159 (CES2). Thus, there are distinct alterations in cell micro-compliance in response to TCDD and co-planar PCB (ie 5-OH-PCB-126; 2-OH-3,3’,4, 4’-PCB-77) in comparison to applied co-, ortho-planar PCB (ie 5-OH-PCB-153; 4-OH-PCB-54), which implies a lower affinity Dio-2 enzyme non-exothermy inactivation pathway for the former (co-planar; 3’-OH-PCB-126, vdWD: 0.752 nm) relative to the higher affinity Dio-1/-3 enzyme inactivation pathway in case of the latter (co-, ortho-planar; PCB-153, vdWD: 0.758).

C6 –C13 carbon length straight alcohols of increasing n-alkyl chain length and molecular weight (Da) have been shown to exert concentration dependent inhibitory effects on the P450 cytochrome monooxygenase activity (aminopyrine demethylase) in vitro, with disassociation constants (Ki) ranging between 1.3 mM (C6, hexanol) and 2.66 mM (C13, tridecanol) with uM inhibition by dodecanol (C12; 35 uM) [30, 31], indicative of a cutoff of enzyme activity at a chain length of between 12- and 13-C (vdWD: 0.744–0.762 nm) at the cell membrane channel pore vdWD, in which case C2-ethanol (mM) is non-exothermic (-ΔT; ᵒC) as compared to C16-hexadecan-1-ol (C16H34O, cetyl; uM) with inhibitory effect at a CM receptor [32]. Therefore, the decrease in cell Peff (0.153–0.160) due to C2-4 halogenate-mediated inner mitochondrial membrane (IMM) micro-compliance alteration is attributable to resultant ATP deficit, and synergistic with the affinity perturbation of CM by larger poly-substituted alcohols (ie C16H34O4 isomers) [33], which are convergent mechanisms of decreased cell micro-compliance (-Δ Cmicro) initially, prior to protein adduct effects on Cmicro. These findings support the study determinations of cell membrane channel pore size of > 0.752 and < 0.758 nm based on a 3-D ellipsoid model (substituted biphenyl), and within the molecular diameter size range 0.744 and 0.762 nm based on a 2-D elliptical model (acyclic alcohol) (Tables 2,4 and 5).

Cell micro-compliance increase due to 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure results in activation of the AhR-Erβ (Arnt): Nrf-2:: Pparδ, Errγ (LxRα): Dio3/Dio2 (Trα) pathway with limited response

There is an increase or decrease in the Peff duration at the transcriptionally active zero (0)-degree x, z-transcription plane of genes as compared to a set of genes at baseline expression, for example as result of subacute in vivo exposure to TCDD, PCB-126 and PCB-153 in a rodent model (p.o.) [34, 35]. Based on the differential gene expression Peff mapping of these genes as standards, it is determined that there is an increase in cell micro-compliance (Δ) that results in the activation of the AhR pathway by TCDD, as p-dioxin can be considered an unaspected size molecular standard with a non-chiral carbon 2-D spherical vdWD at 0.735 nanometers, as it has been shown to localize intracellularly [36]. The AhR-p-dioxin-(Arnt)-Erβ limb of the pathway is transcriptional active between a Peff interval of between 0.381–0.379 and 0.106 (UGT1A7), as IGHM (Peff 0.088) [37, 38] or other gene at equivalent Peff decreases in expression with minimal contraction response. There is increased duration of activation (+Δ%) at Peff cell pressures of 0.381 (COX8C; Cox8h ortholog, +10.2), 0.379 (CEACAM1; Ceacam10 ortholog, +20.3), 0.373 (NR1D1, Rev-Erbα +0.16), 0.331 (Nrf-2, NFE2L2, +0.07), 0.283 (DBP, +0.3), 0.282 (SCD; Scd2 ortholog, +0.16), 0.273 (MT1A, +0.07), 0.224 (FABP5, +0.07), 0.216 (CYP1A1, +33.5), 0.201 (CYP1A2, +0.10), 0.190 (EXOC7; Exoc3 ortholog, +1.05), 0.169 (CYP1B1, +24.3), 0.168 (ALDH3A1, +1.9), 0.147 (NQO1, +0.65), 0.135 (ME1, +0.10) and 0.106 (UGT1A7, +2.8), in which additional genes with increases place at Peff pressures of 0.376 (SLC2A4, Glut-4), 0.374 (RXRA), 0.332 (GADD45B), 0.282 (RXRB), 0.223 (TIPARP), 0.223 (SIN3A), 0.222 (RARB), 0.209 (NR1H3, ESRRG), 0.191 (ARNTL, aka Bmal1), 0.178 (NCOR2), 0.177 (THRA), 0.173 (NRIP1), 0.136 (ESR2) and 0.096 (DIO3); and during which there is decreased duration of activation (-Δ %) at Peff cell pressures of 0.348 (DAO, -4.1), 0,324 (ALAS1, - 0.54), 0.183 (DIO2, -0.54), 0.158 (ASCM2A, -7.0) and 0.111 (CYP3A7, -37.6), in which additional genes with decreases place at Peff pressures of 0.200 (NRF1), 0.196 (ESRRA), 0.184 (ESR1) and 0.179 (RARA) (Table 6, Fig 2 [top bracket]).

thumbnail
Fig 2. Alterations in cell micro-compliance due to sub-acute exposure to polychlorinated biphenyl high affinity metabolites with specificity for intracellular or extracellular deiodinases.

Lower limit of the lower tier Peff for transcriptional activation is increased to 0.106 (Ugt1a7) during a Cmicro contraction response with a decrease in Peff Cmicro to < 0.106 > 0.088 (Ighm) esebssiwaagoTQ units during the expansion response; and the lower limit of the upper tier Peff is increased to between ~0.395 (AhR) to 0.381 (Cox8c) - 0.379 (Ceacam1a) with an interval increase in Peff Cmicro in juxtaposition to ≤ 0.416 (Pparα) ≥ 0.395 (AhR) esebssiwaagoTQ units. The upper tier apparent interval Peff Cmicro contraction response is between a Peff of 0.348 (Dao1) - 0.331 (Nfe2l2) and 0.379 esebssiwaagoTQ units. The Cmicro contraction-expansion response range is 0.225–0.275 (min BoR; Cox8c, Nfe2l2; Ugt1a7) to 0.243–0.293 (max BoR; Cox8c, Nfe2l2; Ighm) [p-dioxin (TCDD), upper bracket, no. 1]. In the AhR-Erβ (Arnt), Pparδ, Errγ (LxRα): Dio3/Dio2 (Trα) pathway, the minimum expansion response phase of the positive Peff contraction-expansion is a result of transient Errα decrease in activation-mediated de-repression of Dio2. Lower limit of the lower tier Peff for transcriptional activation is increased to 0.130 (Lgal1) during a Cmicro contraction response with a decrease in Peff Cmicro to < 0.088 ≥ 0.080 (Tgif1) -0.075 (Ighg3) esebssiwaagoTQ units during the expansion response; and the lower limit of the upper tier Peff is increased to between > 0.395 (AhR) and 0.387–0.381 (Cox8c) with an interval increase in Peff Cmicro in juxtaposition to < 0.416 (Pparα) > 0.395 (AhR) esebssiwaagoTQ units. The upper tier apparent interval Peff Cmicro contraction response is between a Peff of > 0.327 (Resp18) - 0.331 (Nfe2l2) and 0.381 esebssiwaagoTQ units. The Cmicro contraction-expansion response range is 0.201–0.251 (min BoR; Nfe2l2, Cox8c - Lgal1) to 0.2585–0.3085 [max BoR; Cox8c, Nfe2l2; Ighm, Tspan12 (avg)]. The range of delta (Δ) micro-compliance (Δ Cmicro) for the bracket no. 2 (co-planar PCB-126) and no. 1 (TCDD, std) comparison is between 0.024 (0.89) [Δ, ratio contraction] and 0.0155 (1.05) [Δ, ratio expansion; a.u.]. In the AhR-Erα (Arnt): Nrf-2:: Rev-Erbβ, (+,-) Errα: Dio3/Dio2 (Trα) pathway, the expansion response phase of the positive Peff contraction-expansion is a result of Trα-mediated overactivation of Dio3. Lower limit of the lower tier Peff for transcriptional activation is increased to 0.159 (Ces2) during a Cmicro contraction response with a decrease in Peff Cmicro to between < 0.080 ≥ 0.063–0.057 (Tspan14) esebssiwaagoTQ units during the expansion response, and the lower limit of the upper tier Peff is increased to between 0.387 (Nr1h3, CAR; Trfc) and 0.384 (FoxA1) with an interval increase in Peff Cmicro in juxtaposition to between 0.427 (Hnf4a) and 0.418 (Pparα)– 0.416 (Dcakd) esebssiwaagoTQ units. The upper tier apparent interval Peff Cmicro contraction response is between a Peff of 0.324 (Cyp2b6, Ncoa1) and 0.312 (Nr1I2) esebssiwaagoTQ units. The Cmicro contraction-expansion response range is 0.165 [min BoR; Cyp2b6, Ces2] to 0.346 [max BoR; Dcakd, Nr1h3 (avg); Tspan12]. The range of delta (Δ) micro-compliance (Cmicro) for the bracket no. 3 (ie PCB-95, -153) and no. 1 (TCDD, std) comparison is between 0.060 (0.73) [Δ, ratio contraction] and 0.053 (1.18) [Δ, ratio expansion; a.u.]. In the Car (Pxr), Rarγ: Pparα/γ, Rxrβ (Srebf1 -Lxrβ): Arnt (AhR-Er)/Ar:: Dio1/Dio2 (Trβ) pathway, in which the expansion response phase of the positive Peff contraction-expansion is a result of Trβ-mediated overactivation of Dio1 and transcriptional repression of Dio2 at Peff (esebssiwaagoTQ units). plain text, increase in duration at Peff in reference to baseline; text in italics, increase in duration at Peff in reference to p-dioxin; and grey text in italics, decrease in duration at Peff in reference to baseline Legend text: maximum bounds of range (max BoR); minimum bounds of range (min BoR).

https://doi.org/10.1371/journal.pone.0236446.g002

Based on the differential increases in Peff pressure duration and interactions of characterized pathways, there is overactivation of the i) AhR (Peff 0.395) [TCDD] ERβ—RIP140 and intracellular ligand (E1, E2 or E3)-tuned overactivation of both CYP1A1 and CYP1B1 with the former being dependent on Erβ recruitment by AhR to XRE than the latter [39] for maximal nano-stability of transcription complex at z, x-plane alignment Peff. and its maximal activation, while the latter being sensitive to ERα/β-mediated transcription repression during recruitment to ERE and obligatory presence of common co-adapter RIP140 for ER and ERR, and the former via high affinity interaction. There is ii) Nrf-2 (Peff 0.331) overactivation of MT1A [3], with overexpression of MT1A attributable to a decrease in % duration at Peff 0.200 (NRF1) and NRF1 underexpression with resultant overactivation of both HMOX1 (Peff 0.153) and NQO1 (Peff 0.147) in the presence of transcription factor Nrf-2 and a potential Maf as an enhancer as co-adaptor. Furthermore, there is overexpression of proximal and distal UGT1A_ locus genes (5’) UGT1A7 and UGT1A6 (3’), with a concomitant decrease in expression of UGT1A1 [34, 40], which are AhR and Nrf-2 transcription factor-responsive genes at Peff 0.106, while UGT1A1 is transcriptionally active during the presence of CAR (PXR). There is iii) an increase in the Peff duration of transcriptional activation between Peff interval 0.216 to 0.236, in which PPARγ and TIPARP are activated, and ESR1 gene transcriptional repressor SIN3A [41] are overexpressed, while ESR2 remains activated at Peff 0.136, as does RAPGEFL1 (Link-GEFII; Peff 0.283). There is likely a minimal increase in FABP5 expression (Peff 0.224) [34] during Δ Cmicro duration at Peff due to the presence of RARB gene activation (Peff 0.222) along with binding partner for 9-cis-retinoic acid-RXRα (Peff 0.374) and transcriptional repression of RARA at Peff 0.181 by ERRγ, which is transcriptional co-adaptor complex regulator for PPARD (Peff 0.339) [42] that is expressed, in addition to at half-site TRE response elements of deiodinase genes with co-recruited TRα/β. Furthermore, an increased duration of Rev-Erbα at Peff (Peff 0.373; +0.16) results in the overactivation of thyroid responsive target genes at half-site RRE response elements (AGGTCA) by overexpression of ARNTL, prior to auto-repression [43], which is an additional gene enhancer of DBP gene activation (Peff 0.283) in combination with TRα (RXRα/β) that increases 9x-overfold in expression [34]. And, there will be iv) the basal transcriptional activation of PPARGC1A (PGC1α; Peff 0.279) as co-activator adaptor of SREBF1 (Peff 0.237), in addition to ERRγ (Peff 0.209), is within the Peff interval for SCD gene overexpression (Peff 0.282) [44] during the transcriptional overactivation of LXRα (Peff 0.209). Thus, a transcriptional duration at Peff increase of +0.16% for SCD is commensurate with minimal increased duration at Peff % for PGC1α and LXRα; and analogous to Nrf-2 (Peff 0.331, +0.07)-mediated target gene activation upon Peff z, x-plane alignment, in which case a common co-activator such as Maf-g (Peff 0.251) will be involved for activation of ALDH3A1 (Peff 0.168, +1.9) as another non-canonical pathway gene (Table 6).

In addition to direct overactivation of the AhR (Arnt): Nrf-2 pathway by p-dioxin (TCDD), the other indirect pathways involved include the (+,-) Errγ and Dio2 (TRα), in addition to PPARG gene auto-repression due to the overexpression of SMRT (NCOR2; Peff 0.178) interaction that results in a non-increase, during which TRα (THRA, Peff 0.177) transcription will also increase due to the presence of PCB-displaced free T4 ligand. The (+, -) Errγ pathway will result in re-activation of gene Arntl (Peff 0.191) as there is an overactivation of std gene Rev-Erbα at Peff, in which ARNTL will be overexpressed and enhance the transcription of GLUT-4 as does SREBF1, prior to Rev-Erbα autorepression [45] This is further supported by the experimental data that Arntl gene mRNA levels increase in Revβ-/shRevβ knockdown cells, in which NR1D1 (Rev-Erbα, Peff 0.373) levels decrease with NR1D2 (Rev-Erb β, Peff 0.242) knockdown [46]. During TCDD mediated co-activation of the (+, -) Errγ pathway, there is inactivation of ARNTL (Peff 0.191) and cytochrome C (CYCS, Peff 0.297), which are both ERRα target genes [47].

Based on study findings, hEXOC7 (Peff 0.190) is overactivated, in which case rodent Exoc3 may be a remnant exocyst in humans (Peff u.d.), as Exoc7 is a plasma membrane post-golgi vesicular docking complex protein such as Exoc4 [48]. EXOC7 is the Exoc3 gene homolog is supported by the finding that it is required for Glut-4 channel expression (SLC2A4, Peff 0.376) and exocytosis [49], however PPARγ gene transcription is not affected at Peff 0.222 upon mutant Exoc7 induction, which is a dioxin response element (DRE) responsive gene. There is an increase in duration at Peff to +1.05 around the Arntl gene expression of Peff at 0.191, based on which it is determined that there can be a decrease in Peff via cell membrane (CM) exocytosis, and it is proposed to be the reason for the z, x-plane horizontal alignment of genes ESR1 (Peff 0.184) and DIO2 (Peff 0.183) for repressor interaction within the Peff 0.183–0.186 interval in the TCDD pathway (Table 6). There is re-expression activation of ARNTL in this pathway at Peff 0.191, which is proposed to be due to coupling of exocytosis transcription (Peff 0.184) and endocytosis transcription (Peff 0.191). The (+,-) Errγ pathway will be active during an increase in duration at upward contraction shift lower Peff interval at 0.208–0.209 matched with an upper interval in-between 0.381 (COX8C) - 0.376 (SLC2A4) units.

Antagonism of the intracellular T4/rT3-Dio2 enzyme pathway by thyroxine (T4) structural mimicry is proposed to be the umbrella mechanism for the decrease in delta (Δ)-Cmicro from the maximum expression range of this pathway (0.361, max; 0.79), which is the Cmicro range of the expansion response of the Arnt (AhR) pathway. The Cmicro contraction in response to p-dioxin to within the < 0.183 to 0.169 Peff units range in addition results in the transcriptional activation of THRA (TRα, Peff 0.177) and will its target genes via intracellularly-accumulated T3 agonism [49, 50], as the transcription of both std genes ME1 (Peff 0.135) and DBP (Peff 0.283). Furthermore, since NRIP1 is z, x-plane aligned at Peff 0.173, RIP140 can function either as a higher-binding affinity partner for (AhR) ERα/β (Peff 0.136, 0.184) [51], or as a lesser binding affinity co-adapter for ERRα/γ (Peff 0.196/0.209) in comparison to related receptor affinity for PGC1α (Peff 0.279) [52], which is via its dual ligand binding domains for estrogen receptor and related receptors. Therefore, p-dioxin (TCDD) exposure results in gene activation of AhR (Arnt)-ERβ, Nrf-2, Rev-Erbα, Errγ, LxRα and T4/rT3-Trα limbs in which there is an increase in retinoic X receptor α expression (RXRA, Peff 0.374) with a decrease in cell micro-compliance (Cmicro) due to high affinity intracellular Dio2 enzyme antagonism when at lesser than 10−12 affinity for the aryl hydrocarbon receptor (AhR) associated with CYP450 metabolism of p-dioxin.

Cell micro-compliance increase due to co-planar polychlorinated biphenyl exposure results in activation of the AhR-Erα/β (Arnt): Nrf-2:: Rev-Erbβ, Errα: Dio3/Dio2 (Trα) pathway with contraction-expansion response

The AhR-co-planar PCB-(Arnt)-ERα limb of the pathway is transcriptional active between duration of increase at Peff of greater than (>) 0.381–0.379 to < 0.096 (DIO3) > 0.057 (TSPAN14) inclusive of expansion response, with contraction increases in Peff at 0.331 (NFE2L2) and 0.130 (LGAL1) of the positive Cmicro response. There is increased duration of activation (+Δ% or ratio) at Peff cell pressures of 0.331 (NFE2L2, 1.14), 0.309 (CYP5A, +2.2), 0.297 (CYCS, +0.30), 0.273 (MT1A, 1.57), 0.241 (COL1A1, +0.60), 0.245 (GADD45A, +0.34), 0.220 (CAT, +0.87), 0.216 (CYP1A1, 1.28), 0.211 (COX6C, +0.34), 0.201 (CYP1A2, 2.60), 0.1686 (GSTM2, +6.6), 0.147 (NQO1, 1.22), 0.135 (ME1, 1.53) and 0.130 (LGAL1, +0.90), in which additional genes with increases place at Peff pressures of 0.262 (NOS1), 0.242 (NRID2, Rev-Erb β), 0.196 (ESRRA), 0.184 (ESR1) and 0.096 (DIO3); and during which there is decreased duration of activation (-Δ %) at Peff cell pressures of 0.427 (HNF4A, - 0.24), 0.384 (CEACAM1, 0.68–0.69), 0.381 (COX8C, 0.24–0.25), 0.331 (PCK1, - 0.36), 0.327 (RESP18, - 0.84), 0.324 (ALAS1, -0.24), 0.278 (FASN, -0.72), 0.190 (EXOC7; Exoc3 ortholog, 0.22), 0.1687 (CYP1B1, 0.81), 0.168 (ALDH3A1, 0.10), 0.237 (SREBF1, - 0.24), 0.183 (DIO2, -0.24), 0.131 (IGHA1, -0.84) and 0.106 (UGT1A7, 0.19), in which additional genes with decreases place at Peff pressures of 0.376 (SLC2A4), 0.374 (RXRA), 0.279 (PPARGC1A), 0.223–0.222 (TIPARP, SIN3A, PPARG), 0.200 (NRF1), 0.191 (ARNTL) and 0.136 (ESR2) (Table 7., Fig 2 [middle bracket]).

The difference between the AhR-co-planar PCB and AhR-TCDD pathway Peff regulation limb includes a Peff contraction shift to within the 0.135 (ME1) to 0.147 (NQO1) esebssiwaagoTQ units interval with micro-expansion in-between a Peff interval of 0.147 and 0.136 (ESR2), and similarly contraction within the 0.211 (COX6C) to 0.220 (CAT) Peff gene expression interval, which results in an increase in the transcription of CYP1A1 (Peff 0.216) during increased overall ER expression (ERα) at Peff due to decreased SIN3A activation at Peff, thus increased ERα recruitment to ERE for decreased nano-stability at promoter, and relative CYP1B1 gene de-activation during activation of CYP1A1 at Peff with AHR (Peff 0.395) bound-xenobiotic response elements (Table 7). The decrease in expression of std gene DBP (Peff 0.283) [34], is consistent with increased CRY1 at the DBP promoter E-box motif (CANNTG) [47], and an increase in lower affinity Rev-Erbβ (Peff 0.242) at RRE response elements with limited availability of co-adapter BMAL1 (ARNTL1, Peff 0.191), which is ERRα activated only on reporter assay [47] in the 0.191–0.196 Peff interval during a concomitant increase in the activation of ME1 at Peff 0.135 (1.53x) [34, 53], as both Dbp and Me1 are T3 liganded-TRα (RXRα) TRE-response pathway regulated genes [49]. The intracellularly accumulated T3-TRα/β pathway is the higher affinity pathway (Kd, 10−10) [54] than the T4/rT3-extracellular (Dio-1/-3) or -intracellular (Dio-2) deiodinase enzyme pathways (Kd, 10−7 to 10−9) [55]. Therefore, the probability exists that chiral configuration halogenated molecules (ie PCBs) with 1- to 2-orders lower affinity co-planar affinity for AhR could be higher affinity substrates for deiodinases as antagonists as proposed.

There are also Peff contraction shifts in activation to in-between 0.297 (CYCS) and 0.309 (CYP5A) and to in-between 0.262 (NOS1) [56] and 0.273 (MT1A) from deactivation within the 0.278–0.282 Peff interval by which activation of FASN decreases (-0.72, std) decreases in which Peff interval genes PPARGC1A and RXRB transcribe. The increase in activation of CYCS (Peff 0.297) [57], as well as COX6C (Peff 0.211) as a NRF1-responsive gene [58], is attributable to the transient overexpression of ERRα (Peff 0.196) and target gene CYCS (Peff 0.297) due to lesser duration EXOC7 gene activation (Peff 0.208, 0.22x) and decrease in Cmicro as compared to during sub-acute TCDD exposure; whereas, increases in activation of MT1A and GSTM2 can be attributed to an increase in in duration at Peff for NFE2L2 and a common Maf co-activator during the decrease in Peff at 0.200 and NRF1 inactivation. A Peff contraction-expansion shift to Peff at 0.130 results in LGAL1 activation in response to co-planar PCB-126 metabolite exposure, a half-site TRE and ERE containing gene [59], as an example of gene that is activated at a preferred intracellular pressure uppesebssiwaa, dppesebssiwaa point increase in duration at Peff to 0.130 during Cmicro expansion within the Peff > 0.131 (IGHA1) ≤ 0.135 interval (ME1), and during a contraction within the Peff ≥ 0.262 (NOS1) < 0.278 interval (FASN); there is a ~2.5-fold increase in LGAL1 expression by qRT-PCR in response to applied IL-1β [60] at the upper bounds of the expansion interval, which is thus delineable as being at Peff 0.130, during which the increase in activation at its Peff setpoint results in an increase in pJUN (Peff 0.267)-, pFOS (Peff 0.256)-bound ½ site TRE response elements; whereas, the decrease in the same (LGAL1) in response to the combination of IL-1β and dexamethasone (Dex) is attributable to an upward shift of the Peff contraction interval with expansion, when de-phosphorylation of AKT and ERK1/2 occurs (+Δ Cmicro) during decreased cell compliance. Furthermore, the extracellular Dex-induced repression of LGALS1 activation via intracellularly-liganded GR (Dex/Cort)/MR (Cortisol) (Peff 0.261) recruited to dephosphorylated JUN at LGALS1 promoter TRE response elements, within which interval Dex-mediated contraction Peff responsive DUSP1 activation will occur at Peff 0.272 during recruitment to GREs (GR). Therefore, co-planar PCB exposure (ie PCB-126) exposure results in gene activation of AhR-(Arnt), Nrf-2, Rev-Erbβ, (+,-) Errα and T4/rT3-Trα limbs, in which retinoic acid X receptor (RXRA) remains transcribable (Peff 0.374) while RXRB gene transcription decreases (Peff 0.282) with a Δ Cmicro contraction response due to high affinity PCB metabolite antagonism of cell surface Dio3 enzymatic deiodoexothermy, which is a TRα activated gene [61], in addition to intracellular Dio2 (Peff 0.183, -0.24%) antagonism by CM channel substrates (-PCB-OH, -S (= O)-Ch3) with its repression at minimum during de-activation of ESRRA (Peff 0.183) [62], in competition with AhR at equivalent or lower concentration in a binding affinity dependent manner.

The pathway overactivation following co-planar-PCB-126 metabolite exposure represents the hepatocyte cell population subset at-risk for neotransformation, which are at a differential Peff basal over contraction-expansion response within the lower limit Peff interval range of ≥ 0.080 (Tgif1) ≤ 0.088 (Ighm) units. The basal transcription Peff setpoint(s) preference for differential gene expression for the co-planar-PCB-126 metabolite exposed cell population is determined in case of interposed genes, ESR1 (Peff 0.184) as an example of one that is determined to be decreased in duration at Peff, in comparison to ESR2 (Peff 0.136) as an example of one that is determined to be increased in duration at Peff based on reporter assay Peff expression correlation, as there is a requirement of estradiol (E1-3) for activation of a non-integrated ERβ reporter plasmid (+E2) [63], which requires endogenously transcribed ESR2 in its native locus position that expresses at Peff 0.136, whereas a ERα reporter plasmid can be expressed in control conditions (-E2). This finding implies that a Peff 0.184 is one basal transcription Peff setpoint within an interval of the same in a viro-immortalized well-differentiated cell type (ie HepG2) [64] with an above baseline contraction lower bounds for differentiated cells, which are (GPER+)/ERα+/Erβ- and AR- cell types that are at risk for a switch to GPER+/ERα+/Erβ+ status [65].

Cell micro-compliance increase due to co-, ortho-/ortho-planar polychlorinated biphenyl exposure results in activation of the Car (PxR, Rarγ): Pparα, Rxrβ (Srebf1, -Lxrβ): Arnt (AhR-Erβ)/Ar:: Dio1/Dio2 (Trβ) pathway with contraction-expansion response

In comparison to the p-dioxin and co-planar PCB pathways, the extracellular co-, ortho-planar PCB pathway is transcriptional active between duration of increase at Peff of 0.387 (NR1I3, CAR) to 0.096 (FABP6, DIO3) with maximal apparent expansion increases intermittently to 0.418 (DCAKD) from 0.387 and from 0.106 to 0.057 (TSPAN14) during delta (Δ) expansion of 0.053 Peff Cmicro units (ratio, 1.18) as compared to the same for cellular response to applied p-dioxin (TCDD) modeled in silico, wherein the contraction response limb results in maximum transcriptional gene activation at Peff point 0.324 (CYP2B6, NCOA1) in addition to between 0.157 – 0.159 (CYP3A5, CES2) esebssiwaagoTQ units, delta-contraction of 0.060 Peff Cmicro units (ratio, 0.73). There is increased duration of differential activation (+Δ%) at Peff of 0.384 (FOXA1, +0.7), 0.331 (DCAKD, +1.0), 0.3238 (CYP2B6, Cyp2b2 ortholog; +30.3), 0.292 (CIDEA, +1.3), 0.285 (MIR132), 0.278 (CUL2, +1.0), 0.282 (SCD, +7.2), 0.227 (ALAS2, +0.7), 0.159 (CES2, +1.3), 0.157 (CYP3A5, CYP2B15/-12 ortholog; +44.7), 0.096 (FABP6, +1.0) and 0.057 (TSPAN14, +2.0), in which additional genes with increases place at Peff pressures of 0.416 (PPARA), 0.406 (DDIT3, alias CHOP), 0.387 (TFRC), 0.387 [NR1I3, CAR], 0.374 (RXRA), 0.373 (NR1D1) 0.342 (FKBP5), 0.312 (NR1I2, PxR), 0.309 (RARG), 0.288 (THRB), 0.282 (RXRB), 0.252 (CEACAM5), 0.252 (MAFG), 0.251 (SCD5), 0.237 (SREBF1), 0.236 (DIO1), 0.223 (TIPARP), 0.222 (PPARG), 0.161 (NCOR1), 0.160 (CASP3), 0.156 (AR), 0.136 (ESR2), 0.149 (CYP4A11), 0.129 (PPP1R9B), 0.128 (FABP3), 0.106 (UGT1A1) and 0.063 (ARNT). There is decreased duration of differential activation (-Δ%) at Peff of 0.333 (PCK1), 0.272 (DUSP1), 0.224 (MBP), 0.183 (DIO2) and 0.140 (GTF2IRD1), in which additional genes with decreases place at Peff of 0.395 (AHR), 0.324 (NCOA1), 0.281 (CYP3A4), 0.270 (NR1H2, LxRβ), 0.184 (ESR1) and 0.096 (DIO3) (Table 8, Fig 2 [bottom bracket]).

Based on study findings, the common mechanism pathway for extracellular co-, ortho-planar PCBs and higher affinity-substituted PCB metabolites (-OH, -MeSO4; ie 4’-OH-2,2’,3,4’,5,5’,6-PCB-172 (0.781 nm; 9.92 nm-1), and applicable to cell membrane (CM)-permeable co-, ortho-PCBs (ie 4’-OH-PCB-95; 0.752 nm, 8.43 nm-1) also, is the constitutive androstane receptor (NR1I3, Peff 0.387) regulatory pathway as duration at Peff increases at target genes CYP2B6 (Peff 0.324) [66], CYP3A4 (Peff 0.281) [66], CES2 (Peff 0.159) and UGT1A1 (Peff 0.106) [46], during pregame X receptor (PxR) recruitment (NR1I2, Peff 0.312) to phenobarbital responsive elements (PBREM; ie CYP2B6) and/or CAR recruitment to PXRE response elements (ie CYP3A4). The expression of PPARα (Peff 0.416) results in the transcriptional activation of target genes at various durations at Peff and x, z-plane aligned for transcription, which include CIDEA (Peff 0.292) [67, 68], CYP4A11 (Peff 0.149) [69], FABP3 (Peff 0.128) and FABP6 (Peff 0.096; +1.0) [70], including SREBF1 (Peff 0.236) with a predicted increase in the transcription factor gene RXRB (Peff 0.282), which can be a recruited co-adapter, in addition to the presence of RXRA (Peff 0.222) [71]. And, the activation of SREBF1 at Peff 0.237 will result in the transcriptional activation of target genes SCD (Peff 0.282; +30.3) and SCD5 (Peff 0.251), for which the increase in duration at Peff will be attributable to a decrease in LXRβ (Peff 0.270), during over-basal transcription at Peff 0.209 (ERRγ, LXRα) and 0.222 (PPARγ), which is with interaction between LXRα or CAR and SRC-1; the pathway limbs are thus mutually antagonistic on known pathway gene expression, murine CYP2B10 (hCyp2b6) and CYP3A11, which are induced by CAR pathway agonist, 1,4-Bis[2-(3,5-Dichloropyridyloxy)] benzene (TCPOBOP) with activity at nM concentration in vivo [72]; while, the underexpression of LXRβ is transcriptionally synergistic. Furthermore, there is secondary lesser involvement of the common AhR-Arnt pathway [73] can be expected as per study determination, and limited by transcription of the AHR gene with a decrease in duration for Peff at 0.395 during the expansion response phase with an increase in intracellular Peff at 0.063 that favors transcription of the ARNT gene and the presence of Arnt as the obligate transcription factor for activation of CYP1A1 [74], which will be in addition to CAR enhanced gene activity at proximal cis-ER8 motif PBREM binding elements with recruited pregnane X receptor [75]. Thus, CAR/PXR pathway limb become primary, as compared to the AhR driven by Arnt, during sub-acute ortho-planar PCB exposure, for which the preferred co-adapter is PGC1α (PPARGC1A, Peff 0.279) [76], as it is for SREBF1 during decreased ERRγ/α in response to Δ Cmicro (E/C, 1.18/0.73). Furthermore, gene NCOR1 is overexpressed at Peff 0.161 in this pathway based on study findings, which thus is the other co-regulator of co-, ortho-planar pathway-activated limbs and will serve as the adaptor for ligand-dependent TRβ-mediated gene transcription (ie Dio1, Thrb) as compared to NCOR2 (Peff 0.178; Dio3, Thra), and consistent with the intracellular presence or absence of liganded TRα/β (rT3, T3) [77], which appears to result in lesser suppression of PPARγ and target genes as compared in the applied TCDD model in silico.

Rodent Cyp2b15/-12 shows high expression in normal un-differentiated cells of skin origin (keratinocytes, sebaceocytes) [78], and skin microsomal CYP Cyp2b2 shows antibody reactivity [79]; thus, based on esebssiwaagoTQ determinations of keratinocyte marker CYPs 2B6 (Peff 0.324), 2E1 (Peff 0.344) and 3A5 (Peff 0.157) [80], respective human orthologs of rCyp2b2 and rCyp2b15/-12 can be CYP2B6 (Peff +7.2) and CYP3A5 (Peff +44.7), as only these two place at the respective predicted (pred) constitutive intracellular pressures for overexpression in the Peff interval at which NCOA1 (SRC-1) is with interaction while CYP2B6 is overactivated, and in the Peff interval of 0.157–0.159 within which CES2 increases in duration at Peff with CYP3A5, which is an alternatively activated CAR/PXR pathway gene with EMSA supershift indicative of CAR dimerization possibly at full site PBREM [81], while CYP3A4 is PxR (SRC-1) activatable during presence of FOXO1 [82]. Thus, since CYP2B6 as the only B series hCYP, and CYP3A5, are both constitutively overexpressed in normal human keratinocytes, as are genes hSCD and hSCD5 in murine epidermis-dermal junction at a common post-natal day [43], while CYP3A4 is dexamethasone (Dex)-inducible [8183] in contrast to std marker gene DUSP1 (Peff 0.272), which is deactivated at Peff in response to Dex [60]; therefore, this finding is consistent with partial trans-differentiation to alternative lineage in a co-, ortho-/ortho-planar PCB-treated hepatocyte (Table 8), and will be applicable to other differentiated cell types.

The overactivation pathway following co-, ortho-planar PCB metabolite exposure results in delta (Δ) Cmicro activation of gene locus within the 0.384 to 0.387 Peff interval, which include FOXA1 at Peff 0.384, PMCH at Peff 0.386 in addition to NR1I3 (CAR) at Peff 0.387, in relation to a Δ Cmicro-mediated increase in activation duration at Peff for transcription of SREBF1 at Peff 0.236 and PPARG at Peff 0.222 and target genes (ie FABP3, Peff 0.128) based on study determination, during which there can be tuned de-activation of genes such as PCK1 (Pepck; Peff 0.333) in the basal presence of Creb binding protein (CBP) with decreases in NF-IB, NF-1X [84] and/or Errγ. Additionally, there is a Δ Cmicro activation relationship between gene activation at Peff 0.236 and Peff 0.156 (AR), and furthermore, at Peff 0.223–0.222, at which there is relative activation of TIPARP, a AhR/Arnt-p-dioxin responsive but a Dht (AR) activatable gene at Peff [85], during which there is relative de-activation of PPARG (Peff 0.222) as a result of SREBF1 recruitment by AR/Kruppel-like factor (KLF) [86] to the subset of Δ Cmicro activatable AR/KLF pathway target genes including FKBP5 at Peff 0.342, a GRE element-containing gene with a significantly-enriched distal intronic ARE (AR) [87], which is a low affinity binding sequence for co-adapter SRC-1 (NCOA1, Peff 0.324). Therefore, since NCOA1 is transcriptionally repressed during increased duration at Peff 0.324, NCoR1 will be the binding partner for T3-TRβ (THRB, Peff 0.288) for transcriptional activation of DIO1 at Peff 0.236 during Δ Cmicro contraction phase, that results in the expansion phase during exposure to ortho-planar PCBs (ie PCB-95, -136, -153). This mechanistic correlation is in agreement with DIO1 being transcriptionally active at in vivo at Peff during the availability of T3, TRβ [88] and co-adaptors SRC-1 [9], or NCOR1 and NCOR2 for ligand independent activation of TRH and TSH genes [89], for high affinity TRE (AF-2) sequence-bound transcription in NCOA1-/-/THRBE457A/E457A and T3-TRβ ligand-dependent TSH gene repression [9], which is in lieu of activation by TRα variant isoforms (THRA, Peff 0.177) [90], as it is the lower affinity TRE-binding partner for DIO1 (Peff 0.236). Furthermore, apoptotic trans-differentiation occurs with Peff interval matches of 0.285 (MIR132) - 0.292 (CIDEA) [34; 67, 68] and 0.155 (CREB1) - 0.160 (CASP3) [91], in addition to decreased transcription around 0.241 (COL1A1) [22] and 0.224 (MBP) Peff intervals for induction of focal adhesion kinase, and with an increased risk for neurotoxicity [92, 93] during transcriptional activation of myelin basic protein gene repressor DDIT3 (Peff 0.406) in this pathway [94]. The findings of this study by further delineation of specific pathways are thus consistent with trans-differentiation to a sex steroid receptor expression pattern of ectodermal origin cells, sebaceocytes of the dermis epidermis junction [95,96], in which there is Δ Cmicro co-activation of ESR2 at Peff 0.136, in addition to AR at Peff 0.156, with a decrease in ESR1 gene expression (Peff 0.184) during transcriptional repression by Sin3A (Peff 0.223) with interaction.

Spectrum of p-dioxin, co-planar and co-, ortho-/ortho-planar polychlorinated biphenyl metabolite exposure-related cell micro-compliance contraction-expansion response

Exposure to co-, ortho-OH-PCB-107 (intracellular), -PCB-136 and -PCB-146, or co-, ortho-planar PCBs OH-PCB-172 and -PCB-187 (extracellular), respectively, has been assessed in dual cohort studies of maternal exposure and infant response, in which it is shown that there is graded homuncular toxicity of the developmental eLMN-to-UMN neuroaxis in association with thyroid axis/deiodinase type 3 enzyme (Dio3) dysfunction [97], and in which a decrease in serum TSH level has been shown to be a sensitive indicator of exposure to biphenyl [98], as it has for exposure to penta-/hexa-substituted brominated diphenyl ethers such as BDE-100 and BDE-153 (vdWD: 0.775–0.793 nm) with available-3, 3’ positions for hydroxylation bioactivation [99]. Based on this proposed mechanism as per study determination, the increase in T3/rT3 ratio, elevation in serum thyroxine-T4 and -T3 [97] is due to co-, ortho-planar PCB metabolite inhibition of the high affinity, high Vmax deiodinase activity-exothermy of CM Dio3 (contraction phase) [55] during a decrease in intracellular TRα concentration ([]) and DIO3 gene de-activation at Peff with a resultant decrease in T4 to rT3 conversion in contraction phase, and an increase in intracellular T3 liganded-TRβ [] in DIO1 gene transcription at Peff at higher serum T4 [] in expansion phase (transient hyperthyroidism), and T3 liganded-TRα/β [] TSH gene inactivation. Furthermore, the finding of increased blubber tissue levels of both TRα and TRβ can be considered [100], if pan-exposure is considered with mutual-inclusivity of pathways involved (p-dioxin, co-planar PCB and ortho-planar PCB); and since there is decreased duration at Peff for ALAS1 (Peff 0.324) in the p-dioxin pathway, and increased duration at Peff for ALAS2 (Peff 0.227) in the co-, ortho-planar PCB pathway, for example due to 2’,2’,3,3’,4,4’-PCB-128 (Arochlor 1260, vdWD: 0.758 nm) exposure [101], Alas1, Alas2 mRNA levels could be indicators for exposure assessment.

Loss of neuronal extension has been determined in response to intracellular co-, ortho-planar 4-OH-2’,3,3’,4’,5’-PCB-106 (vdWD: 0.752 nm) and extracellular 4-OH-2,3,3’,4’,5,5’-PCB-162 (vdWD: 0.767 nm) at high affinity binding concentration (10−11 to 10−12 M) [102] relative to the binding affinity of hydroxylated PCBs (KD, 33–90 nM) for thyroid hormone receptor beta (TRβ) [103]. This favors an affinity concentration gradient between serum transthyretin (pre-albumin) and sulfated (Ch3-SO4) PCBs (KD, 20 nM) [104] for high affinity CM deiodinase exothermy antagonism (Do-1,2,3), in potential spatial association of, to a CM or RER receptor such as the ryanodine (RyR1/R2) with low binding affinity for ortho-polychlorinated biphenyls (ie PCB-95 and 4-OH-PCB-30), which is suggestive of an interrelationship between Δ Cmicro contraction-expansion response and opening of the RyR-associated Mg2+ deactivated Ca2+ channel. In further support of the contraction-expansion mechanism as determined is a decrease in osteoblast cell width observed in the murine double D1/D2KO gene transgenic efficiency model, in which male mutants have been determined to have decreased appendicular bone volume with resultant increased stiffness and development of brittle bone disease [105], and agrees morphologically with the study determination of enhanced cellular contraction during deiodinase antagonism, however with an expansion response in WT cells. Additionally, sexually dimorphic axial and appendicular skeletal morphometric responses have been observed in offspring in response to dam PCB-180 exposure (7–10 d, acute, p.o.), in which 0.1 mm decreases in buccolingual molar spacing are noted in female pups, while the opposite trend is noted in male pups [106], which as per study determination is attributable to an estradiol (E2)-opposed contraction response with resultant expansion at minima [E2 expansion (e) + co-, ortho-planar PCB contraction-expansion (c/e)], and dihydroxytestosterone (Dht)-agonism contraction response with resultant expansion at maxima [Dht c/e + co-, ortho-planar PCB c/e], and 0.1 increased separation of molars in male pups.

It has been determined in a pituitary GH3 luciferase reporter cell model that a TRE reporter plasmid is activated only secondarily after CYP450 monooxygenase activation (CYP1A1), and presumably due to the formation of PCB hydroxylate metabolites [107]. Since in this study, it is shown that there is a minimal 0.5x-over fold increase in LUC activity over control due to applied PCB 6 mix with co-, ortho-planar PCBs (PCB-138, -153) as opposed to a 2.5x-over fold increase during T3 application that the activation, this further supports the study mechanism of z, x-plane aligned TRE sequence-containing genes being activated by intracellular thyroxine-T3 displaced from endogenous Dio1 enzyme due to OH-/Ch3(S)O2-PCB in competition, and in the would be presence of TRβ. Furthermore, since the Δ Cmicro contraction-expansion interface for the co-, ortho-planar PCB pathway is within the 0.140 (Gft2ird1) - 0.149 (Cyp4a11) Peff interval, there is an inactivation of gene TFF1 (pS2, Peff 0.147) with applied co-, ortho-planar PCB-104 [108]. Thus, when paraquat, a weakly intracellularly-localizing endocytic agent with 1+ IS/SS 1+ ionicity at the lower limit of cationicity [109], results in a (+) Peff Δ Cmicro contraction-expansion response when it is applied in a PCB model (co-, or ortho-) [110], it potentiates a convergent oxidative stress pathway with gene re-activation.

Peff grade of effect on delta-cell micro-compliance for regulation of gene transcription

Corticosteroids, sex steroids and the subset of inverse agonist ligands can be studied by overall structural log partition coefficient (P) · vdWD-1 ratio (nm-1), based on which probable steroid axis ligand-to-receptor interaction can be determined as mineralocorticoid/glucocorticoid (Ald, 1.23 –Dex, 1.92 nm-1), estrogen/estrogen-related receptor (E2, 4.73 –Des, 6.60 nm-1), and androgen (R1881, 3.16—Dht, 4.15 nm-1), within which intracellular and extracellular bisphenols (Bpa -e, 0.727–0.744 nm; Bfap, 0.774 nm) classify as xenoestrogens based on overall structural partitioning parameters (Bpa, 5.14 –Bpaf, 6.17 nm-1). The grade of Peff duration for effect is then determined for the extracellular subset of small molecule hormone nuclear receptor ligands (Ch4O nl Lexternal structure/Hpolar group: 0.461, Dex– 1.31, Des) with molecular diameters within the 0.774 nm (Bpaf)– 0.873 nm (Dex) vdWD range with a minimum of di-polar hydroxylation hydrophilicity (- 2.10 nm-1), which is on the basis of small molecule hormone and inverse agonist potential for disassociation over range of exposure concentration (Kd) and binding affinity over time (t1/2) [111115] as plotted independent variables for semi-exponential power-regression extrapolation of half-life at receptor of unknowns (R2 = 0.955), and applied whole cell receptor density based on magnetic bead-enhanced amphometric detection or radioligand competition assay studies (Bmax; n) [115,116] for multiplicative in silico modeling of pressure regulatory grade of effect for gene expression in a mono-compliant cell type. The half-lives at receptor (t1/2) for diethylstilbestrol (Des) at ERα is 663 min, and that for dihydrotestosterone (Dht) and methyltrienolone (R1881) at AR are within the 38–53 minutes (min) interval, as the Kd approximates 0.9–1.0 nM (see ref 118). The strata order for ligand · receptor grade of duration at Peff, from positive with contraction-expansion response-to-negative, is 1.4215E + 04 [Cort · MR (GR)], 3.0270E + 04 [Ald · MR (GR)], 1.33383E + 05 [Dex ~ Corticosterone · GR (MR)], 1.79812E + 05 (Dht · AR), 2.47340E + 05 (R1881 · AR), 1.2E +06 (E2 · ERα), 1.863745E + 06 (DES · ERα) adjusted for whole cell receptor count (Σ min·count), from positive to negative (Table 9).

Bisphenol AF with an inhibitory constant (IC50) of 19 and 53 nM, as compared to 17β-estradiol (E2) with an IC50 of 0.88 and 2.17 nM (ERα, Erβ), will be an inverse agonist in pharmacokinetic non-competition at trough E2 levels, and result in a positive (+) Δ Cmicro bisphenol AF effect at CM ERα/β with upward shift in the contraction-expansion and in non- activation of the ESR2 gene (Peff 0.136), however with maintained ESR1 gene transcription at around Peff 0.184 as is at a Δ Cmicro Peff 0.290 (see ref 128), as in LUC ERE reporter plasmid transfected Hela cells with pcDNA3.1 integrated ESR1 and ESR2 genes [117]. Thus, based on study determinations, the gene expression pattern for small molecule hormone receptor interaction between the 2.6 x 105 to 2.1 x 106 min·count range results in a negative Δ Cmicro response and an initial downward shift in the contraction with unilateral expansion as compared to positive Δ Cmicro response with contraction and bidirectional expansion, and irrespective of the specific steriod axis receptor class (ER, AR). Furthermore, it appears that an initial negative (-) Δ Cmicro response within the 1.86 x 106 to 1.94 x 106 (IGF-II · IGF-IIR) min·count range is coupled to a positive Δ Cmicro response, as Dht or R1881 · CM AR (1.79E + 05–2.45E + 05, + Peff) results in the transcription of pro-proliferative genes [118,119], that is proposed to be by an initial (-) Peff Χ then an (+) Peff Υ intermediate step coupled to resultant transcriptional activation of MKI67 (Peff 0.329) [Part I, not cited; 38] (Table 9); thus, expression of a focal adhesion or endocytic component may be involved, which would apply to calvarial osteoblasts that overexpress the IGF-IIR/M6P receptor [120], and similarly to transformed cells with Peff shift to IGF1R expression [121], and could result in altered cell phenotype such as mononucleated: multinucleated [5], or lineage commitment such as glial: non-glial during the pre: post exposure period without interaction [122].

Several further studies point in the direction of paradoxical responses to dexamethasone (Dex) treatment, as example of a biologic mimic that produces a parabolic peak grade of positive Peff response and corticosterone surrogate, in which case observed divergent gene expression responses upon applied Dex are in dissimilar cell types [123], due to dose response and variant GR receptor affinity [124], or during the tuned activation of Dex responsive genes with GRE sequence sites in proximity to the TSS [125]. The magnitude of differential gene expression response in cultured primary astrocyte and neurons to Dex stimulation is consistent with respective increases in duration at Peff contraction-expansion phase gene expression in a less and more compliant cell type to the same agent (ie PER1, FKBP5; 5.3x) [123], in which case it appears that the difference in magnitude of differential gene expression achieved in-between cell types is unlikely attributable to ligand · receptor min·count, as astrocyte GR mRNA is 3x-overfold neuronal in which case only an apparent difference in t1/2 at receptor exists; whereas, the same in the high affinity variant porcGR (ala610val) transgenic model, in which an under-expression of GCLC (Peff 0.477) and PCK1 (Peff 0.333), and overexpression of FKBP5 (Peff 0.342) follows a saturable dose-escalation differential gene expression pattern [124], and is attributable to an upward contraction-expansion shift in Peff response with maintained range of ligand · receptor affinity. Moreover, the finding that there is repression of genes with Dex responsive intergenic sequences 10e4 to 10e5 kb of the transcription start site (TSS) [125], is consistent with Δ Cmicro z, x-plane alignment of the majority of Dex responsive genes at Peff for gene transcription, as 70% of GR (Dex/Cort)-responsive genes are unbound by GR, while the tuned transcriptional activation of genes with half-site GRE: half-TRE sequences within around 10e3 of the TSS within intronic promoter regions.

Peff at duration intervals for endogenous steriod axis ligands

Based on study determinations, the grade of Peff at duration results in positive Peff contraction with negative Peff expansion responses for endogenous ligands at cell membrane (CM) receptors that results in Peff regulated maximal transcription of NR3C2 (MR; Peff 0.261) during the presence of either Cort · GR or Ald · MR at the promoter site P2 with basal transcription of the non-integrated plasmid being at 3x-fold [126, 127], of NR3C1 (GR; Peff 0.376) during the minimum presence of Cort · GR with ½ GRE site co-activators over 35 bases at a P site (ie -4559–4525) [128], and of constitutive transcriptional activation of AR (Peff 0.376) by Dht (or Dhea) with binding partner SREBF1 or KLF [ie PMCH, Peff 0.376; 85]. Furthermore, exogenous intracellularly-localizing ligands directly at nuclear receptors ERRγ and ERRα (Bpa), also result in increased Peff intervals from the respective peri-nadir, for example to between < 0.146 (GSTA1; ERRγ/α · Bpa) > 0.135 (ME1) as compared to Peff ≥ 0.168 (CEBPD) in response to Dex/Cort (GR) and Peff ≥ 0.156 (AR) in response to Dht (AR), which results in the partial activation of TIPARP (Peff 0.261) and FKBP5 (Peff 0.342) in lieu of overactivation by AhR and Dex/Corticosterone, respectively. In comparison, there is a decrease in the Peff contraction interval to in-between 0.290 (CCND1) and 0.147 (TTF1) esebssiwaagoTQ units, these being nuclear ERα · E1, 2 or 3 transcriptionally-tuned genes during duration at Peff with GR (JUN) recruitment to half-site GRE during Δ Cmicro FOXA1 (Peff 0.384) co-activation within which Peff at 0.290 (CCND1) remains transcribable at Δ Cmicro (E2; E2 + Dex) [117, 129], and associated with a concomitant negative Peff expansion Δ Cmicro response with a decrease in Peff interval to between Peff 0.147 (Tff1) and 0.111 (Cyp3a7) (Table 10, Fig 3).

thumbnail
Fig 3. Directional alterations in cell micro-compliance by small molecule hormone ligands of steroid axis receptors and exposure-related bisphenol A and DES as high affinity inverse agonists.

CORT/DEX pathway increases in duration at Peff include at 0.394 (Per1; PC12 cell, A549 lung ca), 0.342 (Fkbp5; astrocyte, neuron), Peff 0.281 (Cyp3a4)– 0.279 (Dusp1; PC12 cell, A549), Peff 0.168 (Cebpd, A549 cell) and Peff 0.057 (Tspan14, B-cell ALL) with decreases in Peff duration at 0.376 (Nr3c1, GR; A549 lung ca), Peff 0.194 (FosB, PV neuron) and Peff 0.099 (Cyp11b1; adrenal cortex, nl). The CORT/DEX pathway Δ Cmicro contraction-expansion response increase in the lower Peff interval is 0.111 from the maximum expansion interval (punctate bracket). DHT pathway increases in duration at Peff include at 0.386 (Pmch; neuroendocrine, hypothal), Peff 0.200 (Cyp17a1, 17,20-lysase; Leydig) and 0.156 (Ar, PC cell) with decreases in Peff duration at 0.120 (Ighg1; B-cell, nl) and Peff 0.075 (Ighg3). The DHT pathway Δ Cmicro contraction-expansion response increase in the lower Peff interval is 0.067 from the maximum expansion interval (punctate bracket). BPA pathway increases in duration at Peff include at 0.349 (Insl3, Leydig cell)– 0.345 (Dlk1, pre-adipocyte stromal cell), Peff 0.308 (Adam8)– 0.303 (Sim1, whole brain), Peff ≤ 0.258 (Meg3)– 0.256 (Fos, spermatocyte), Peff 0.205 (Miat) and Peff 0.194 (Plekhg4) with a decrease in duration at Peff at 0.146 (Gsta1). BPAF pathway increases in duration at Peff include at 0.276 (Cdkn1a) and 0.245 (Gadd45a). The pathway Cmicro contraction-expansion response increase in the lower Peff interval is ≥ 0.040 from the maximum expansion interval (punctate bracket) for bisphenol A (BPA, intracellular) and bisphenol AF (BPAF, extracellular). DES pathway increases in duration at Peff include at 0388 (A2m), 0.27633 (Hoxa9, uterine), 0.243 (Klf4) and 0.136 (Wnt5a, Esr2) with decreases in duration at Peff 0.27630 (Hoxa10, uterine) and Peff 0.332 (Hoxa11). The DES pathway upwards shift in Cmicro contraction is to Peff 0.1359–0.1361 (Wnt5a, Esr2) with response expansion to ~0.099 (Cyp11b1) [(+) upward shift Δ Cmicro contraction with maxima expansion pathway] In comparison, Estradiol (E2) pathway increases in duration at Peff include at 0.290 (Ccnd1; MCF-7 cell), Peff 0.147 (Tff1, pS2; MCF), with decreases in Peff duration at 0.136 (Esr2, skeletocyte). The E2 pathway results in downward shift Cmicro contraction is a Peff 0.14703 (Tff1) and a Peff setpoint lower with minimal expansion [(-) downward shift Δ Cmicro contraction with minima expansion pathway]. black text, dexamethasone (Dex)/corticosterone common GR receptor pathway; magenta brown text, dihydroxytestosterone (Dht) AR receptor pathway; blue text, estradiol (E2) ER receptor pathway; green text, intracellular bisphenol inverse agonist pathway; teal text, extracellular bisphenol pathway; gold text, diethylstilbesterol (DES) ER receptor pathway; italics text, decreases in Peff duration at activation or increases in repression duration at Peff (2ndary); solid black bracket, max contraction interval during increase in duration at Peff (co-, ortho-planar PCB std); dotted brackets, lower Peff expansion intervals; dashed brackets, lower limit range of Peff expansion interval.

https://doi.org/10.1371/journal.pone.0236446.g003

In the A549 lung carcinoma/HepG2 HCC cell model for AhR gene reporter plasmid expression [64], applied TGFβ1 results in activation of z, x-plane transcription-ready plasmid upon endogenous TGIF1 transcription at Peff 0.080 as the SMAD co-adapter is required for RNA polymerase transcription, however without the need for applied TGFβ1 in A549 cells that demonstrate a bidirectional negative expansion Δ Cmicro response Peff of 0.080 as compared the nadir for HepG2 cells, which would between Peff 0.130 (LGAL1) and 0.106 (UGT1A1). The in vitro application of aldosterone (Ald) to SkBr3 mammary carcinoma and tumor-associated endothelial cells results in the transcriptional overactivation of GPER1 (GPR30; Peff 0.376) and SLC9A1 (NHE-1, Peff 0.167) [130], and will result in an increase in GR expression concomitantly (NR3C1, Peff 0.376) (Table 10), with an increase in pEGFR/ERK1,2 levels as part of the negative Cmicro expansion response phase, as will occur with application of a combination of E2 and inverse agonist(s) [131] with a resultant equivalent increase in intracellular pressure to Peff 0.112 at which CYP11B2 (Ald Synthase) transcription increases at Peff during Δ Cmicro contraction; whereas, the in vivo application of Dex (~Corticosterone) to normal adrenocortical cells results in a 0.5x-fold decrease in CYP11B1 (11-β-hydroxylase; Peff 0.099) decrease at duration at Peff while an increase with ACTH [132], while GABPA (Peff 0.494) and TSPAN14 (Peff 0.057) increase in duration at Peff during maintained sensitivity to Dex at CM GR in human B-cell ALL in a viro-transformed cell type [133], which reaffirms Peff 0.057 as the maximum lower limit of the contraction-negative Peff Cmicro expansion response to positive Peff regulation away from Peff 0.088 (Ighm) [37], 0.088 (Ighm) and 0.075 (Ighg3) [134]. Since the maximum Peff Cmicro contraction-expansion response to Dex is at the lower limit of cell expansion Peff and equivalent to the Δ Cmicro response applied co-, ortho-planar PCB-153, this implies GRE and TRE site-tuned parallel pathway involvement (ie CAR, AR), as there is known GR · half-site GRE enhancement of THRB gene transcription [135] with the potential for JUN (FOS) recruitment of GR to half-site TRE [89] and regulation of DIO1 (Peff 0.236) gene transcription at Peff.

Bisphenol A grade of Peff at duration effect on gene transcription as a high affinity agonist for the Estrogen-Related Receptor (ERR)-PGC1α and NcoR1, NcoR2-TR pathway overactivation with contraction-expansion response

The biological effects of high affinity bisphenols with the potential for health effect at biological concentration exposure doses in comparison to non-specific concentration-dependent effects [136, 137], in the absence or presence of an extracellular high affinity ER inverse agonist with potentially-extended t1/2 at receptor due to substituted external structure (ie ICI 182,780; C32H47F5O3S), for determination of ER ligand gene expression effects solely attributable to GPR30 receptor inverse agonism [138], as its mid-affinity nuclear/RER receptor intracellular pathway effect. It has been further determined that there exists the potential for sexually dimorphic-imprinted polymorphism for a subset of certain genes sensitive to residual BPA dose effect, for example in progeny of exposed murine dams and/or mates (ie F0 –F2) in a ~20 μg/kg per day subacute consumption study model [139].

Based on determination of gene expression Δ Cmicro Peff of bisphenol A-induced genes, it appears that low dose biologic exposure results in BPA mediated high affinity binding of ERRγ to PGC1α (Peff 0.279), in parallel to binding of NcoR1/NcoR2 (TRα/β), with repression of THRA/THRB gene transcription but with an increase in TSH gene transcription at nM (10−9) [140,141]. The putative recruitment to ERREs of highly-enriched target genes [49] such as TIMM8B at Peff 0.247 is proposed, which is within Δ Cmicro Peff interval of convergence with bisphenol AF (BPAF) effects at CM ERα/β receptors and overactivation of apoptotic pathway gene GADD45A at Peff 0.245. The transcriptional activation of the direct pathway limb, during which there is shown to be a dimorphic response on mRNA levels of ESRRG (Peff 0.209) [142]. As per this mechanism, there is underactivation of BPA responsive genes begins at nM concentration and includes adiponectin (ADIPOQ) [143], which could would be due to deficit in PGC1α, as a binding partner for SREBF1 or PPARγ transcriptional activators at Peff, and decreased NcoR1 and NcoR2 co-adapter activity at PPARG (Peff 0.222) due to BPA-enhanced recruitment to TRβ-integrin β3 [141].

There is an increase in duration at Peff for activation of genes within Peff interval at 0.153 (HMOX1), 0.194–0.196 (PLEKHG4 [139]; ESRRA, FOSB), 0.256 to 0.258 (MEG3 [140], FOS [138]; DFFA), 0.264 to 0.267 (FABP4, aP2 [144]; JUN), and 0.345 to 0.349 (DLK1, Pref-1; INSL3 [136]), in addition to a decrease in duration at Peff for deactivation of AR pathway genes, PMCH (Peff 0.386) [139] and CYP17A1 (steriod lysase, Peff 0.200), which is rate-limiting, as part of the indirect limb(s) of the high affinity BPA pathway, within which there is less of an increase in pCREB [145] during a delayed duration Peff expansion as compared to with applied estradiol E2 and minimal expansion (Table 10, Fig 3). The concurrent limbs of pathway for low-dose applied BPA for sub-acute duration exposure (≥ 1–2 d) at octimolar concentration (10−8 M) include the NRF1 de-activation/NFE2L2 activation (GCLC, Peff 0.477; UGT1A1, Peff 0.106) with possible Jun (Fos)/AP-1 at half-site TRE repression of GSTA1 (Peff 0.146) as an additionally involved indirect limb of the intracellular pathway based on study determination, during which HMOX1 (Peff 0.153) is un-repressed and transcriptionally active at Peff 5 to 25 μg/kg per day in a 1-month cummulative exposure to BPA male rodent model [146], while GADD45B (Peff 0.332) is transcriptionally active at ≤ 5 μg/kg per day, which is agreement with secondary activation of the Nrf2 (Nrf1) limb at the 20 μg/kg per day subacute BPA exposure dose. Since UGT1A1 is overexpressed at Peff ≥ 0.10640 at the positive pole in the UGT1A7 (UGT1A1-UGT1A6) readthrough locus, this implies that the CAR/PXR minus LXRβ pathway is involved (hybrid co-pathway).

BFAP exposure and extracellular ligand · CM ERα/β pathway activation, also results in co-activation of common Nrf2 (Nrf1) limb pathway genes at Peff, which include CYP1A1 (Peff 0.216) and UTG1A1 (Peff 0.106), while distinct genes activated at Peff include CDKNIA (Peff 0.276) and GADD45A (Peff 0.245) [138], which are involved in cell cycle cessation and p53-mediated apoptosis, and activatable at a minimum concentration of 10−8 to 10−9 M concentration [117, 138]. Thus, the secondarily-activated AhR/Nrf2 (NFE2L2) limb co-dominates during saturation of the ERRγ (α) pathway-associated limbs, since there exists a contraction-expansion response with apparent upper and lower limits at Peff 0.477 (GCLC) and 0.106 (UGT1A1) similar to the delta (Δ)-Cmicro due to subacute p-dioxin/ exposure (13 wk). In further comparison, higher dose, lower affinity binding partner recruitment effect [PPARγ · BPA (PGC1α)] occurs at 70 μg/kg per day of subacute exposure [147,148]. Therefore, the overall effect of BPA on otherwise normal cells appears to be overactivation of ERR (PGC1α) and concurrent pathway limbs [Nrf2 (Nrf1)/AP-1] with resultant dysregulation of both stem cell progenitor (DLK1) and differentiated cell gene expression (INSL3; CYP17A1) in addition to apoptosis stage (DFFA), thus results in pre-mature cell fate determination and depleted stem cell population. Furthermore, since overactivation of the Nrf2 (Nrf1)/AP-1 limb results in BPA exposed cells, which are transiently apoptotic, there exists the potential for cell cycle progression to proliferation in neotransformed (SkBr3, GPER+/ERβ+) [149,150] and associated cells subject to 30-min short-term duration BPA exposure with ERRγ, GPR30 pathway activation in a high affinity, low affinity inverse agonist in vitro model [151]. The differences between the Cmicro contraction-expansion responses of normal epithelial cells, and mammary carcinoma cells such as T47D (GPER+/ERα+/Erβ+) and SkBr3, to BPA are attributable to high affinity binding of endogenous estradiol (E2) to ERα and GPR30 (Kd, 10−10) [11, 112] delta (Δ)-Cmicro downward shift in Peff with resultant activation of additional anisotropic genes (EGR1 Peff 0.199; CCN2, CTGF Peff 0.166 [22]) [150], inclusive of gene transcription at Δ Cmicro Peff 0.184, at which variant ESR1 and FLNA co-express with potential for polymorphism [93, 152]. Therefore, it appears that the intermittent negative Δ Cmicro response (E2 expansion) in neotransformed cell types results in an intermediate (+) Δ Cmicro step within the Peff > 0.235 (EMD [22]) and < 0.256 interval that results in oscillatory progression into the G1/S cell cycle phase.

Diethylstilbestrol as a small molecule receptor ligand at cell membrane receptor due to positive contraction shift-expansion delta-micro cell compliance

Diethylstilbestrol is known to be toxic to reproductive axis cells along continuum of developmental teratogen to carcinogen over age based on subsequent follow-up of a prospective cohort [153]. With local intraperitoneal (i.p.) exposure of dams for example, ERα-dependent homeobox cluster A (HOXA_) gene expression is dysregulated in the developing mullerian system [154], with resultant differential expression of single locus readthrough genes, reverse strand (-) HoxA9 and HoxA10 genes (Peff ≥ 0.2763) in uterine tissue cells, during which there is a decrease in HoxA10 transcription, and an increase in HoxA9 (Peff (5-digit adj) 0.27633) with a decrease in oviductal expression of the same. Therefore, based on this study’s findings, it appears that multiple promoter locus genes can be transcribed during (+) Δ Cmicro, and in a (+) to (-) Peff gradient direction (5’ to 3’), particularly at less sensitive Cmicro intracellular pressure intervals inclusive of at around Peff 0.267 (Jun) and 0.256 (Fos) (Table 11, Fig 3). Furthermore, during study of high dose cummulative p.o. DES effects on WT ERα+/- transgenic mice pups [155], similar uterine effects are noted for HoxA10 and HoxA11 (Peff 0.332) in addition to differential expression of Wnt5a (Peff 0.1359) as compared to autoregulatory genes Wnt4 and Wnt7a in response [156]. Based on this study’s findings on std marker gene expression cell micro-compliance Peff considered together, DES exposure results in contraction shift to Peff 0.136 due to a coupled-positive Peff response (ie focal adhesion) due to the grade of DES at CM receptor interaction (1.863745E + 06 min·count) with a range of 0.388 (A2M [157])– 0.136 (WNT5A, ESR2), and contraction response expansion proposed to be to ~0.099 esebssiwaagoTQ units (CYP11B1), which is within the interval range for transformed cell types (Tcdd, co-planar PCB). In comparison, applied E2 results in downward shift contraction to a Peff of 0.147 (TFF1) and setpoint lower with minimal expansion, during an intra-locus shift in gene transcription from positive Peff pole (Hoxa10) to negative (Hoxa9, Peff 0.27633). There appears to be directional Peff-mediated gene transcription due to the proximal intra-oviductal pressure potential, which appears to result from relatively increased in intracellular Peff (decreased Δ Cmicro) compared to the distal ambient atmospheric pressure potential required for HoxA13 gene expression (Peff 0.346). Furthermore, Peff at 0.256 (FOS) is an in-sensitive intracellular pressure, since transcription increases in case of both Bpa and Des exposures, while re-expression of stem cell required factor Klf4 at Peff 0.243, and Wnt5A or Esr2 that are expressed at Peff 0.136 could be considered markers for an increased early developmental risk of neotransformation, or temporally for delayed clear cell carcinoma risk in aged cells with acquired mutations over time.

Molecular philicity interval grades of increase for bioelimination of small molecule lipophiles as compared to grade of molecular philicity for molecular exclusion at the cell surface glycocalyx

CYP1A1 CYP450 monooxygenase hydroxylation of p-dioxin (Lext· H-1: 4.31) followed by UGT1A6/7 transferase glucuronidation of 8-OH-2,3,7-TriCDD (Lext· H-1: 1.91) to 2,3,7-TriCDD glucouronate (Lext· H-1: 0.419) in-between the philicity per polar group interval of 0.328 (Lext· H-1 Lactic acid) and 0.428 (Lext· H-1 2,3-glycer-1-o1) results in hepatobiliary bioelimination [158], as an example of the primary mode of bioactivation metabolism and bioelimination clearance of polyhalogenates (PDBE, PCDD) in addition to PCBs, co-planar and co-, ortho-planar. This is in comparison to bioabsorption metabolism of smaller, less hydrophilic vdWD phthalates ≤ 0.81 nm [21] by esterase hydrolysis, which includes mono-n-butylphthalate (BP, 1-; vdWD: 0.724 nm; Lext · H-1: 0.322) that are permeable across epidermis interepithelial junctional complexes [159], as opposed to di-n-butyl phthalate (DBP, vdWD: 0.797 nm; Lext · H-1: 1.49) at the cusp for mono-/part-neutral small molecule permeation in absence of endocytosis-enhanced junctional permeability (ie GI barrier); whereas, the non-absorption of phthalate (2-, Lext · H-1: 0.078; vdWD: 0.633 nm) upon skin esterase BP conversion is due to the hydrophilicity barrier to transepithelium absorption [21]. Furthermore, above the Lext · H-1: interval ranges for binding affinity to CYP450 (1.91–4.31), glucoronosyltransferase (UGT, 1.73–2.69) and esterase (0.322–1.49) is the hydrophilicity binding affinity interval for binding affinity to N-acetyl-neuraminic acid (Neu5Ac; 0.790 nm, -9.37 nm-1; Lint · H-1: 0.080) based on study determination (Fig 1), the upper limit of which is at a Lint · H-1 of 0.101 (saxitoxin ester amide; vdWD: 0.764 nm) with a lower limit of Lext · H-1 around 0.092 (m-xylenediamine). Therefore, exogenous small molecule hydrophiles that stratify as such, stand to be toxins or toxicants with extended duration bioactivity due to a cell surface glycocalyx hydrophilicity barrier to clearance, with 1,2-diaminocyclohexane (vdWD: 0.622 nm; Lext · H-1: 0.085, 0.171) being an example of an older epoxy part-resin known to cause type I hypersensitivity in painters [38, 160], which is could be an endocytic agent at a cell membrane (CM) receptor by caveolar mechanisms within the Lexternal · H-1: 0.085–0.171 interval, and during co-exposure to aliphatics. Based on findings, m-xylenediamine (Lext · Hpolar group-1: 0.092) · CM receptor aliphatic solvent co-exposure APC pathway activation in previously primed B-cells (IgE+) will result in a type I contact hypersensitivity response [38] due to a synergistic Δ Cmicro contraction-expansion response. Saxitoxin ester amide (STX) and tetradotoxin (TTX; Lint · H-1: 0.085–0.101) are puffer fish gland toxins that demonstrate nM affinity for sodium (Na+) channel subunit V (NaV) (unlabeled STX Kd = 2.1 nM) as channel blockers [161,162], application of which dissipates membrane potential, and the negative (-) Δ Cmicro results in a pan-depression in gene transcription at an apparent Peff with the lowest probability for a decrease in duration at Peff for mitochondrial genes, TFB2M (Peff 0.267; JUN) and COX6C (Peff 0.211) [163], which is suggestive of additional compensatory molecular weight-maintained micro-compliance, and supported by the recent finding of limited gene overaction in AHR gene silenced cells [164].

α-tocopherol transfer protein (αTTP) binds reserved ligands α-tocopherol (tocotrienol; Lext · H-1, 2.92; vdWD: 0.960) and 13’-hydroxy-α-tocopherol (Lext · H-1, 1.73) for extended serum/ half-life [165], and is a gene that can be transcriptionally-activated by LXRα/β [166] during overexpression of SCD (Peff 0.282), while α-tocopherol as a ligand agonist of PxR [167] results in the overactivation of genes, CYP3A4 (mCyp3a11, Peff 0.281) and CYP3A5 (Peff 0.157) in the proposed minus LXRβ/PPARα pathway, in addition to CAR pathway genes with co-recruitment (ie CYP2B6, Peff 0.324). co-planar PCB exposure (ie OH-PCB-77, -126) results in significant over-fold expression of α-tocopherol responsive genes such as CAT (Peff 0.220), and SOD to a lesser extent [168,169], during the concurrent activation of ERRα pathway (- Peff) and biometabolism / bioactivation pathway genes (+ Peff), which is indirectly indicative of α-tocopherol overutilization deficit during oxidative stress-mediated pathway activation as it has been shown to be in γ-TMT poor plants, and could be due to decreased αTTP protein levels. Since hepatobiliary neotransformation can result from applied p-dioxin (0.225, Δ Ccontraction; 0.293, Δ Cexpansion) > co-planar PCB (0.201, Δ Ccontraction; 0.3085, Δ Cexpansion), as compared to with co-, ortho-/ortho-planar PCB (0.165, Δ Ccontraction; 0.346, Δ Cexpansion) exposure, maintained α-tocopherol levels would be protective, as two in series Lext · H-1 intervals are required to ready toxicants for glucounidation elimination (Lext · H-1, 0.419–0.459). Furthermore, since cell coupled nucleus mechanics can be also be studied in vitro, by direct tension generation measurements (N/m; AFM), study of nuclear protein displacement (MSD) or chromatin condensation parameters (EED) [170], the application effects of such toxicants (ie PCB, bisphenol) on intracellular effective pressure are to be further confirmed in pluripotent stem cell populations in bioengineered systems [171], as the findings herein apply to differentiated cells that activate either of the three primary detoxification pathways in response, and de- or re-differentiate.

Conclusions

In silico modeling of molecular philicity by part structure reveals that a Lexternal structure ∙ Hpolar group-1 of ≥ 1.07 is the molecular structure lipophilicity limit for non-specific carrier-mediated transmembrane diffusion through CM polarity-selective transport channels for small molecules with a vdWD < 0.758 (3-D ellipsoid, chiral) - 0.762 nm (2-D elliptical), the subset of halogenated vapors that initially perturb the inner MM categorize, for which vdWD is predictive of the required MAC for anesthetic potency. It also reveals that the L ∙ Hpolar group-1 interval range for the cell surface glycocalyx hydrophilicity barrier is between 0.101 (Saxitoxin, Stx; Linternal structure ∙ Hpolar group-1) and 0.092 (m-xylenediamine, Lexternal structure · Hpolar group). In silico modeling of Δ Peff cell micro-compliance (Cmicro,) alterations in response to applied small molecule hormone ligands, biphenyls and bisphenols reveals that differential gene expression is a result of various grades of contraction-expansion response.

Subcellular or cell membrane Cyp-associated perturbation by non-endogenous molecules within a Lexternal structure ∙ Hpolar group-1 interval of 1.91–4.31 results in various grades of preferential transcriptional activation of either: i) the AhR (Erβ)/Nrf2 limb in addition to the Pparδ, ERRγ (LxRα), Dio3/Dio2 and TRα limbs with p-dioxin/metabolite (TCDD; OH-TCDD), in which increased duration at Peff includes for Ceacam1, Rarβ, Scd, Exoc7, Nrip1, Ncor2 and Slc2a4; ii) the AhR (Erα/β)/Nrf2 limb in addition to the Rev-Erbβ, ERRα, Dio3 and TRα limbs with OH-co-planar PCB as the toxicant in which increased duration at Peff includes for Ceacam1, Rarγ, Nrip1 and Exoc7 with a Δ Cmicro contraction of 0.89/Δ Cmicro expansion of 1.05 as compared to p-dioxin; or iii) the Car/PxR limb in addition to the Rarγ, Pparα/γ (Srebf1, -LXRβ), Arnt (AhR-Erβ)/Ar, Dio1, Trβ limbs with OH-co-, ortho-planar PCB in which increased duration at Peff includes for Cyp2B6, Cyp3a5, Pgc1α, Ncor1, Ceacam5, Mafg and Scd5 with a Δ Cmicro contraction of 0.73/Δ Cmicro expansion of 1.18 consistent with trans-differentiation as compared to p-dioxin. Therefore, based on study determination of PCB exposure pathway limbs, the mechanism for toxicantity is via alterations in cell micro-compliance via p-dioxin/PCB metabolite Dio enzyme exothermy-antagonism (Δ contraction) coupled with T4/rT3-TRα or TRβ agonism and Dio3/Dio2 or Dio1 gene transcription (Δ expansion), which implies the intervals of altered cell compliance that result in increased risk for neotransformation (Tcdd, co-planar PCB; Des), or trans-differentiation (co-, ortho-planar PCB).

Bisphenol A, as small molecule ligand within a Lexternal struct ∙ Hpolar group-1 of 1.08–1.12 (BPA, BPE), results in direct transcriptional activation of the ERRγ-[intracellular bisphenol]-PGC1α pathway (Timm8b) with an expansion phase Δ Cmicro of 0.040 (Dffa) and indirect activation of a DEX responsive hybrid AhR/Nrf-2, Car/Pxr co-limb pathway during a decrease in duration at Peff at Nrf1 gene transcription and consistent with cell de-differentiation. Since the Dht · AR Δ Cmicro expansion phase is 0.067 with a grade of duration at Peff (min·count) of 1.8–2.53x105 (Dht/R1881), sexually dimorphic differences result in gene transcription duration at Peff with co-exposure (Dht, Bpa) due to an additive (+) Δ Cmicro contraction-expansion phase, as compared to a coupled (+) Δ Cmicro Peff increase to 0.136 (Wnt5a, Esr2) with applied DES (1.86x106) as compared to estradiol E2.

Based on study determinations of PCB and bisphenol actions in the biological system modeled in silico as mutually exclusive inverse ligands of endogenous small molecule hormone receptors or enzymes, the mechanism for toxicantity is via alterations in cell micro-compliance via p-dioxin, co-planar or co-, ortho-planar PCB metabolite liganded deiodinase enzyme exothermy-antagonism/liganded TRα or TRβ agonism. Furthermore, Δ Cmicro z, x-plane alignment of genes with respect to intergene distance tropy results in differential gene activation, in which case non-aligned genes are inactive unless bound by a repressor at Peff interaction. Δ Cmicro results in z, x-plane alignment of genes with respect to intergene distance tropy and in differential gene activation, in which case non-aligned genes are inactive as are repressor-bound genes at Peff. Study findings will be applicable to the field as it offers perspective on the basis for pressure regulated gene transcription by alterations in cell micro-compliance with maintenance of the effective pressure potential.

References

  1. 1. Beischlag T.V., Morales J.L., Hollingshead B.D., Perdew G.H. The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression. Crit Rev in Eukar Gene Expr, 2008; 18 (3): 207–50.
  2. 2. Miao W., Hu L., Scrivens P.J., Batist G. Transcriptional Regulation of NF-E2 p45-related Factor (NRF2) Expression by the Aryl Hydrocarbon Receptor-Xenobiotic Response Element Signaling Pathway: Direct Cross-talk between Phase I and II Drug-Metabolizing Enzymes. J Biol Chem, 2005; 280 (21), 20340–8. pmid:15790560
  3. 3. Ohtsuji M., Katsuoka F., Kobayashi A., Aburatani H., Hayes J.D., Yamamoto M. Nrf1 and Nrf2 Play Distinct Roles in Activation of Antioxidant Response Element-dependent Genes. J Biol Chem. 2008; 283 (48), 33554–62. pmid:18826952
  4. 4. Zhai Y., Wada T., Zhang B., Khadem S., Ren S., Kuruba R., et al. A functional cross-talk between liver X receptor-α and constitutive androstane receptor links lipogenesis and xenobiotic responses. Mol Pharm, 2010; 78 (4), 666–674.
  5. 5. Sarin H. Horizontal alignment of 5′ -> 3′ intergene distance segment tropy with respect to the gene as the conserved basis for DNA transcription. Future Sci OA, 2016; 3 (1), FSO160. pmid:28344824
  6. 6. Madak-Erdogan Z., Katzenellenbogen B.S. Aryl Hydrocarbon Receptor Modulation of Estrogen Receptor α-Mediated Gene Regulation by a Multimeric Chromatin Complex Involving the Two Receptors and the Coregulator RIP140. Toxicol Sci, 2011; 125 (2), 401–11. pmid:22071320
  7. 7. Ahmed S., Valen E., Sandelin A. and Matthews J. Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters. Toxicol Sci, 2009; 111 (2), 254–266. pmid:19574409
  8. 8. Klinge C.M. Estrogen receptor interaction with estrogen response elements. Nucl Acids Res, 2001; 29 (14), 2905–2919. pmid:11452016
  9. 9. Alonso M., Goodwin C., Liao X., Ortiga-Carvalho T., Machado D.S., Wondisford F.E., et al. In vivo interaction of steroid receptor coactivator (SRC)-1 and the activation function-2 domain of the thyroid hormone receptor (TR) beta in TRbeta E457A knock-in and SRC-1 knockout mice. Endocrinol, 2009; 150 (8), 3927–34.
  10. 10. Okada H., Tokunaga T., Liu X., Takayanagi S., Matsushima A., Shimohigashi Y. Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-γ. Environ Health Perspect, 2008; 116 (1), 32–38. pmid:18197296
  11. 11. Prossnitz E.R., Arterburn J.B., and Larry A. Sklar, L.A. GPR30: a G protein-coupled receptor for estrogen. Mol Cell Endocrinol, 2007; 265–266, 138–142.
  12. 12. Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgartten FJR, Schoenfelder G. Urinary, Circulating, and Tissue Biomonitoring Studies Indicate Widespread Exposure to Bisphenol A. Environ Health Perspect, 2010; 18 (8), 1055–70.
  13. 13. Berg MV, Birnbaum L, Bosveld AT, Brunström B, Cook P, Feeley M, et al. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ Health Perspect, 1998; 106 (12), 775–92. pmid:9831538
  14. 14. Kafafi SA, Afeefy HY, Ali AH, Said HK, Kafafi AG. Binding of polychlorinated biphenyls to the aryl hydrocarbon receptor. Environ Health Perspect, 1993; 101(5), 422–8. pmid:8119253
  15. 15. Chu S, Covaci A, Jacobs W, Haraguchi K, Schepens P. Distribution of methyl sulfone metabolites of polychlorinated biphenyls and p,p-DDE in human tissues. Environ Health Perspect, 2003; 111(9), 1222–24. pmid:12842777
  16. 16. Sandala G.M., Sonne-Hansen C., Dietz R., Muir D.C., Valters K., Bennett E.R., et al. Letcher Hydroxylated and methyl sulfone PCB metabolites in adipose and whole blood of polar bear (Ursus maritimus) from East Greenland. Sci Total Environ, 2004; 331(1–3), 125–41. pmid:15325145
  17. 17. Yilmaz B., Sandal S., Chen C.H., Carpenter D.O. Effects of PCB 52 and PCB 77 on cell viability, [Ca(2+)](i) levels and membrane fluidity in mouse thymocytes. Toxicol, 2006; 217 (2–3), 184–93.
  18. 18. Agre P., Preston G.M., Smith B.L., Jung J.S., Raina S., Moon C., et al. Aquaporin CHIP: the archetypal molecular water channel. Am J Physiol—Renal Physiol, 1993; 265 (4 Pt 2), F463–476.
  19. 19. Ohgusu Y., Ohta K. Y., Ishii M., Katano T., Urano K., Watanabe J., et al: Functional characterization of human aquaporin 9 as a facilitative glycerol carrier. Drug Metab Pharmacokinet, 2008; 23 (4), 279–284. pmid:18762715
  20. 20. Tsukaguchi H., Shayakul C., Berger U. V., Mackenzie B., Devidas S., Guggino W. B., et al: Molecular Characterization of a Broad Selectivity Neutral Solute Channel. J Cell Biol, 1998; 273 (38), 24737–43.
  21. 21. Sarin H. Permeation thresholds for hydrophilic small biomolecules across microvascular and epithelial barriers are predictable on the basis of conserved biophysical properties. In Silico Pharmacol, 2015; 3(5).
  22. 22. Sarin H. Anglemetry of neural axis cell differentiation genes by structural pressurotopy of DNA loop strand segment tropy in reference to tissue macro-compliance. Trans Med Comm, 2019; 4(19).
  23. 23. Fang Z., Ionescu P., Chortkoff B.S., Kandel L., Sonner J., Laster M.J., et al. Anesthetic potencies of n-alkanols: results of additivity and solubility studies suggest a mechanism of action similar to that for conventional inhaled anesthetics. Anesth Analg, 1997; 84(5), 1042–8. pmid:9141929
  24. 24. Rabovsky J., Judy D. J., Pailes W.H. In vitro effects of straight-chain alkanes (n-hexane through n-dodecane) on rat liver and lung cytochrome P-450. J Toxicol Environ Health, 1986; 18 (3), 409–421. pmid:3486981
  25. 25. Spracklin D. K., Hankins D. C., Fisher J. M., Thummel K. E., Kharasch E.D. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther, 1997; 281 (1), 400–411. pmid:9103523
  26. 26. Staib-Lasarzik I., Kriege O., Timaru-Kast R., Pieter D., Werner C., Engelhard K., et al. Anesthesia for Euthanasia Influences mRNA Expression in Healthy Mice and after Traumatic Brain Injury. J of Neurotrauma, 2014; 31, 1664–1671.
  27. 27. Hoetzel A., Geiger S., Loop T., Welle A., Schmidt R., Humar M., et al. Differential Effects of Volatile Anesthetics on Hepatic Heme Oxygenase–1 Expression in the Rat. Anesthesiology, 2002; 97, 1318–21. pmid:12411824
  28. 28. Paugam-Burtz C., Molliex S., Lardeux B., Corinne Rolland T.A., Aubier M., Desmonts J-M. M.D, et al. Differential Effects of Halothane and Thiopental on Surfactant Protein C Messenger RNA In Vivo and In Vitro in Rats. Anesthesiology, 2000; 93, 805–10. pmid:10969314
  29. 29. Loop T., Dovi-Akue D., Frick M., Roessiein M., Egger L., Humar M., et al. Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology, 2005; 102, 1147–57. pmid:15915027
  30. 30. LaBella F. S., Chen Q. M., Stein D., Queen G. The site of general anaesthesia and cytochrome P450 oxygenases: similarities defined by straight chain and cyclic alcohols. Br J Pharmacol, 1997; 120 (6), 1158–1164. pmid:9134230
  31. 31. Nakahiro M., Arakawa O., Nishimura T., Narahashi T. Potentiation of GABA-induced Cl- current by a series of n-alcohols disappears at a cutoff point of a longer-chain n-alcohol in rat dorsal root ganglion neurons. Neurosci Lett, 1996; 205 (2), 127–30. pmid:8907333
  32. 32. Machta B. B., Gray E., Nouri M., McCarthy N. L. C., Gray E. M., Miller A. L., et al. Conditions that stabilize membrane domains also antagonize n-alcohol anesthesia. Biophys J, 2016; 111 (3), 537–545. pmid:27508437
  33. 33. Mohr J. T., Gribble G. W., Lin S. S., Eckenhoff R. G., Cantor R.S. Anesthetic potency of two novel synthetic polyhydric alkanols longer than the n-alkanol cutoff: evidence for a bilayer-mediated mechanism of anesthesia? J Med Chem, 2005: 48 (12), 4172–4176. pmid:15943489
  34. 34. Ovando B. J., Ellison C. A., Vezina C. M., Olson J.R. Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands. BMC Genomics, 2010; 11 (1), 583
  35. 35. Watson J.D., Prokopec S.D., Smith A.B., Okey A.B., Pohjanvirta R., Boutros P.C. TCDD dysregulation of 13 AHR-target genes in rat liver. Toxicology and Applied Pharmacology, 2014; 274(3), 445–54. pmid:24355419
  36. 36. Hankinson O. The Aryl Hydrocarbon Receptor Complex. Annual Review of Pharmacology and Toxicology, 1995; 35 (1), 307–40.
  37. 37. North C.M., Kim B-S., Snyder N., Crawford R.B., Holsapple M.P., Kaminski N.E. TCDD-mediated suppression of the in vitro anti-sheep erythrocyte IgM antibody forming cell response is reversed by interferon-gamma. Toxicol Sci, 2009; 107 (1), 85–92. pmid:18948302
  38. 38. Sarin H. B-cell antibody class switchings are pressuromodulated events: Part II, gene recombination. Trans Med Comms, 2018: 3 (1).
  39. 39. Beischlag T. V., Perdew G.H. ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem, 2005; 280 (22), 21607–11. pmid:15837795
  40. 40. Sugatani J. Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. Drug Metab Pharmacokinet, 2013; 28 (2), 83–92. pmid:23089802
  41. 41. Ellison-Zelski S.J., Solodin N.M., Alarid E.T. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol Cell Biol, 2009; 29(18).
  42. 42. Levi L., Wang Z., Doud M. K., Hazen S. L., Noy N. Saturated fatty acids regulate retinoic acid signalling and suppress tumorigenesis by targeting fatty acid-binding protein 5. Nat Commun, 2015; 6, 8794. pmid:26592976
  43. 43. Harding H.P., Lazar M.A. The orphan receptor Rev-ErbA alpha activates transcription via a novel response element. Mol Cell Biol, 1993; 13 (5), 3113–3121. pmid:8474464
  44. 44. Miyazaki M., Dobrzyn A., Elias P.M., Ntambi J.M. Stearoyl-CoA desaturase-2 gene expression is required for lipid synthesis during early skin and liver development. Proc Natl Acad Sci USA, 2005; 102 (35), 12501–506. pmid:16118274
  45. 45. Stratmann M., Stadler F., Tamanini F., van der Horst G.T., Ripperger J.A. Flexible phase adjustment of circadian albumin D site-binding protein (DBP) gene expression by cryptochrome1. Genes Dev, 2010; 24 (12), 1317–28. pmid:20551177
  46. 46. Bugge A., Feng D., Everett L.J., Briggs E.R., Mullican S.E. Wang F., et al. Rev-Erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function. Genes Dev, 2012; 26, 657–67. pmid:22474260
  47. 47. Dufour C. R., Wilson B. J., Huss J. M., Kelly D. P., Alaynick W. A., Downes M., et al. Genome-wide Orchestration of Cardiac Functions by the Orphan Nuclear Receptors ERRα and γ. Cell Metab, 2007; 5 (5), 345–356. pmid:17488637
  48. 48. Barkefors I., Fuchs P.F., Heldin J., Bergstro T., Forsberg-Nilsson K., Kreuger J. Exocyst complex component 3-like2 (EXOC3L2) associates with the Exocyst Complex and Mediates Directional Migration of Endothelial Cells. J Biol Chem, 2011; 286 (27), 24189–199. pmid:21566143
  49. 49. Amano I., Miyazaki W., Iwasaki T., Shimokawa N., Koibuchi N. The effect of hydroxylated polychlorinated biphenyl (OH-PCB) on thyroid hormone receptor (TR)-mediated transcription through native-thyroid hormone response element (TRE). Ind Health, 2010; 48(1), 115–8. pmid:20160415
  50. 50. Chatonnet F., Guyot R., Picou F., Bondesson M., Flamant F. Genome-Wide Search Reveals the Existence of a Limited Number of Thyroid Hormone Receptor Alpha Target Genes in Cerebellar Neurons. Plos One, 2012; 7 (3), e30703.
  51. 51. Castet A, Herledan A, Bonnet S, Jalaguier Sp, Vanacker J-M, Cavaillès V. Receptor-Interacting Protein 140 Differentially Regulates Estrogen Receptor-Related Receptor Transactivation Depending on Target Genes. Mol Endocrinol. 2006; 20 (5), 1035–47. pmid:16439465
  52. 52. Huss J. M., Kopp R. P., Kelly D. P. Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem, 2002; 277(43), 40265–74. pmid:12181319
  53. 53. Petty K.J., Desvergne B., Mitsuhashi T., Nikodem V.M. Identification of a thyroid hormone response element in the malic enzyme gene. J Biol Chem, 1990; 265(13), 7395–400. pmid:2332433
  54. 54. Spindler B. J., MacLeod K. M., Ring J., Baxter J. D. Thyroid hormone receptors. Binding characteristics and lack of hormonal dependency for nuclear localization. J Biol Chem, 1975; 250 (43), 4113–9.
  55. 55. Bianco A.C., Kim B.W. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest, 2006; 116(10), 2571–79. pmid:17016550
  56. 56. Aluru N., Karchner S.I., and Glazer L., Early Life Exposure to Low Levels of AHR Agonist PCB126 (3,3',4,4',5-Pentachlorobiphenyl) Reprograms Gene Expression in Adult Brain. Toxicol Sci, 2017; 160(2), 386–397. pmid:28973690
  57. 57. Wang S., Crisman L., Miller J., Datta I., Gulbranson D.R., Tian Y., et al. Inducible Exoc7/Exo70 knockout reveals a critical role of the exocyst in insulin in insulin-regulated GLUT4 exocytosis. J Biol Chem, 2019; 294(52), 19988–19996. pmid:31740584
  58. 58. Wong-Riley M.T.T. Bigenomic regulation of cytochrome c oxidase in neurons and the tight coupling between neuronal activity and energy metabolism. Adv Exp Med Biol, 2012; 748, 283–304. pmid:22729863
  59. 59. Salvatore P., Contursi C., Benvenuto G., Bruni C. B., Chiariotti L. Characterization and functional dissection of the galectin-1 gene promoter. FEBS Lett, 1995; 373(2), 159–63. pmid:7589457
  60. 60. Hirose I., Kanda A., Noda K., Ishida S. Glucocorticoid receptor inhibits Muller glial galectin-1 expression via DUSP1-dependent and -independent deactivation of AP-1 signalling. J Cell Mol Med, 2019; 23(10), 6785–96. pmid:31328390
  61. 61. Barca-Mayo O., Liao X-H, Alonso M., Di Cosmo C., Hernandez A., Refetoff S. et al. Thyroid hormone receptor α and regulation of type 3 deiodinase. Mol Endocrinol, 2011; 25(4), 575–583. pmid:21292823
  62. 62. Villena JA, Hock MB, Chang WY, Barcas JE, Giguere V, Kralli A. Orphan nuclear receptor estrogen-related receptor alpha is essential for adaptive thermogenesis. Proc Natl Acad Sci USA, 2007; 104(4), 1418–23. pmid:17229846
  63. 63. Lin Y., Velmurugan B. K., Yeh Y., Tu C. C., Ho T., Lai T. Y., et al. Activation of estrogen receptors with E2 downregulates peroxisome proliferator-activated receptor γ in hepatocellular carcinoma. Oncology Reports, 2013; 30 (6), 3027–3031. pmid:24126791
  64. 64. Wolff S., Harper P.A., Wong J.M., Mostert V., Wang Y., Abel J. Cell-specific regulation of human aryl hydrocarbon receptor expression by transforming growth factor-beta(1). Mol Pharmacol, 2001; 59(4), 718–24.
  65. 65. Shen M., Shi H. Estradiol and Estrogen Receptor Agonists Oppose Oncogenic Actions of Leptin in HepG2 Cells. PLoS One, 2016; 11(3), e0151455. pmid:26982332
  66. 66. Faucette S.R. Sueyoshi T., Smith C.M., Negishi M., Lecluyse E.L., Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther, 2006; 317 (3), 1200–9. pmid:16513849
  67. 67. Viswakarma N., Yu S., Naik S., Kashireddy P., Matsumoto K., Sarkar J., et al. Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma. J Biol Chem, 2007; 282 (25), 18613–24. pmid:17462989
  68. 68. Cherkaoui-Malki M., Meyer K., Cao W.Q., Latruffe N., Yeldandi A.V., Rao M.S., et al. Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis. Gene Expr, 2001; 9 (6), 291–304. pmid:11764000
  69. 69. Savas U., Machemer D.E., Hsu M.H., Gaynor P., Lasker J.M., Tukey R.H., et al. Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. J Biol Chem, 2009; 284 (24), 16541–52. pmid:19366684
  70. 70. Smathers R.L., Petersen D.R. The human fatty acid-binding protein family: Evolutionary divergences and functions. Human Genomics, 2011; 5 (3), 170–91. pmid:21504868
  71. 71. Fernandez-Alvarez A., Alvarez M-S., Gonzalez R., Cucarella C., Muntane J., Casado M. Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor α (PPARα). J of Biol Chem, 2011; 286 (24), 21466–477.
  72. 72. Lo R., Matthews J. High-Resolution Genome-wide Mapping of AHR and ARNT Binding Sites by ChIP-Seq. Toxicol Sci, 2012; 130 (2), 349–361. pmid:22903824
  73. 73. Patel R.D., Hollingshead B.D., Omiecinski C.J., Perdew G.H. Aryl-hydrocarbon receptor activation regulates constitutive androstane receptor levels in murine and human liver. Hepatology, 2007; 46 (1), 209–18. pmid:17596880
  74. 74. Tomita S., Sinal C.J., Yim S.H., Gonzalez F.J. Conditional disruption of the aryl hydrocarbon receptor nuclear translocator (Arnt) gene leads to loss of target gene induction by the aryl hydrocarbon receptor and hypoxia-inducible factor 1alpha. Mol Endocrinol, 2000: 14(10), 1674–81. pmid:11043581
  75. 75. Yoshinari K., Yoda N., Toriyabe T., Yamazoe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. Biochem Pharmacol, 2010; 79 (2), 261–9. pmid:19682433
  76. 76. Shiraki T., Sakai N., Kanaya E., Jingami H. Activation of orphan nuclear constitutive androstane receptor requires subnuclear targeting by peroxisome proliferator-activated receptor gamma coactivator-1 alpha. A possible link between xenobiotic response and nutritional state. J Biol Chem, 2003; 278 (13), 11344–50. pmid:12551939
  77. 77. Astapova I., Hollenberg A.N. The in vivo role of nuclear receptor corepressors in thyroid hormone action. Biochim Biophys Acta, 2013; 1830 (7), 3876–881. pmid:22801336
  78. 78. Keeney D.S., Skinner C., Travers J.B., Capdevila J.H., Nanney L.B., King L.E., et al. Differentiating Keratinocytes Express a Novel Cytochrome P450 Enzyme, CYP2B19, Having Arachidonate Monooxygenase Activity. J Biol Chem, 1998; 273 (48), 32071–9. pmid:9822682
  79. 79. Zhou Z.., Hotchkissa S.A., Boobis A., Edwards R.J. et al. Expression of P450 enzymes in rat whole skin and cultured epidermal keratinocytes. Biochem Biophys Res Comm, 2002; 207 (1), 65–70.
  80. 80. Baron J.M., Holler D., Schiffer R., Frankenberg S., Neis M., Merk H. F., et al. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol, 2001; 116(4), 541–8. pmid:11286621
  81. 81. Burk O., Koch I., Raucy J., Hustert E., Eichelbaum M., Brockmoller J., et al.The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem, 2004; 279 (37), 38379–85. pmid:15252010
  82. 82. Pavek P. Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions. Front Pharmacol, 2016; 7 (456).
  83. 83. Smith S.A., Colley H.E., Sharma P., Slowik K.M., Sison-Young R., Sneddon A., et al. Expression and enzyme activity of cytochrome P450 enzymes CYP3A4 and CYP3A5 in human skin and tissue-engineered skin equivalents. Experimental dermatology, 2018; 27 (5), 473–5. pmid:29227563
  84. 84. Leahy P., Crawford D.R., Grossman G., Gronostajski R.M., Hanson R.W. CREB Binding Protein Coordinates the Function of Multiple Transcription Factors Including Nuclear Factor I to Regulate Phosphoenolpyruvate Carboxykinase (GTP) Gene Transcription. J Biol Chem, 1999; 274 (13), 8813–22. pmid:10085123
  85. 85. Bolton E.C., So A.Y., Chaivorapol C., Haqq C.M., Li H., Yamamoto K.R. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev, 2007; 21 (16), 2005–17. pmid:17699749
  86. 86. Wilson S., Qi J., Filipp F.V. Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. Sci Rep, 2016; 6, 32611. pmid:27623747
  87. 87. Magee J.A., Chang L.W., Stormo G.D., Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinol, 2006; 147 (1), 590–8.
  88. 88. Jakobs T.C., Schmutzler C., Meissner J., Kohrle J. The promoter of the human type I 5'-deiodinase gene—mapping of the transcription start site and identification of a DR+4 thyroid-hormone-responsive element. Euro J Biochem, 1997; 247 (1), 288–97.
  89. 89. Tagami T., Madison L.D., Nagaya T., Jameson J.L. Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol, 1997; 17 (5), 2642–8. pmid:9111334
  90. 90. Katz D., Lazar M.A. Dominant negative activity of an endogenous thyroid hormone receptor variant (alpha 2) is due to competition for binding sites on target genes. J Biol Chem, 1993; 268 (28), 20904–10. pmid:8407924
  91. 91. Jeon Y.J., You k, E S., Lee S.H., Suh J., Na Y.J., Kim H.M. Polychlorinated biphenyl-induced apoptosis of murine spleen cells is aryl hydrocarbon receptor independent but caspases dependent. Toxicol Appl Pharmacol, 2002; 181 (2), 69–78. pmid:12051990
  92. 92. Lesiak A., Zhu M., Chen H., Appleyard S.M., Impey S., Lein P.J., et al. The environmental neurotoxicant PCB 95 promotes synaptogenesis via ryanodine receptor-dependent miR132 upregulation. J Neurosci, 2014; 34 (3), 717–725. pmid:24431430
  93. 93. Kania-Korwel I., Lukasiewicz T., Barnhart C.D., Stamou M., Chung H., Kelly K.M., et al. Congener-specific disposition of chiral polychlorinated biphenyls in lactating mice and their offspring: Implications for PCB developmental neurotoxicity. Toxicol Sci, 2017; 158 (1), 101–115.
  94. 94. Sheedy C., Mooney C., Jimenez-Mateos E., Sanz-Rodriquez A, Langa E., Mooney C., et al. De-repression of myelin-regulating gene expression after status epilepticus in mice lacking the C/EBP homologous protein CHOP. Int J Physiol Pharmacol, 2014; 6 (4), 186–198.
  95. 95. Thornton M., Taylor A.H., Mulligan K., Al-Azzawi F., Lyon C.C., O'Driscoll J., et al. The Distribution of Estrogen Receptor β Is Distinct to That of Estrogen Receptor α and the Androgen Receptor in Human Skin and the Pilosebaceous Unit. J Invest Dermatol, 2003; 8 (1), 100–103.
  96. 96. Zouboulis C.C. Sebaceous gland receptors. Dermato-endocrinol, 2009; 1 (2), 77–80.
  97. 97. Soechitram S.D., Berghuis S.A., Visser T.J., Sauer P.J.J. Polychlorinated biphenyl exposure and deiodinase activity in young infants. Sci Total Environ, 2017; 574, 1117–1124. pmid:27710904
  98. 98. Berghuis S.A., Soechitram S., Sauer P.J., Bos A.F. Prenatal exposure to polychlorinated biphenyls and their hydroxylated metabolites is associated with neurological functioning in 3-month-old infants. Toxicol Sci, 2014; 142 (2), 455–62. pmid:25246668
  99. 99. Chevrier J., Harley K.G., Bradman A., Gharbi M., Sjödin A., Eskenazi B. Polybrominated diphenyl ether (PBDE) flame retardants and thyroid hormone during pregnancy. Environ Health Perspect, 2010; 118 (10), 1444–49. pmid:20562054
  100. 100. Tabuchi M., Veldhoen N., Dangerfield N., Jeffries S., Helbing C.C., Ross P.S. PCB-related alteration of thyroid hormones and thyroid hormone receptor gene expression in free-ranging harbor seals (Phoca vitulina). Environ Health Perspect. 2006;114 (7):1024–31. pmid:16835054
  101. 101. Vos J.G, Strik J.J., van Holsteyn C.W., Pennings J.H. Polychlorinated biphenyls as inducers of hepatic porphyria in Japanese quail, with special reference to δ-aminolevulinic acid synthetase activity, fluorescence, and residues in the liver. Toxicol and Applied Pharmacol, 1971; 20 (2), 232–40.
  102. 102. Kimura-Kuroda J., Nagata I., Kuroda Y. Hydroxylated metabolites of polychlorinated biphenyls inhibit thyroid-hormone-dependent extension of cerebellar Purkinje cell dendrites. Dev Brain Res, 2005; 154 (2), 259–263.
  103. 103. Cheek A. O., Kow K., Chen J., McLachlan J. A. Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. Environ Health Perspect, 1999; 107 (4), 273–278. pmid:10090705
  104. 104. Grimm F. A., Lehmler H.-J., He X., Robertson L.W., & Duffel M. W. Sulfated metabolites of polychlorinated Biphenyls are high-affinity ligands for the thyroid hormone transport protein transthyretin. Environ Health Perspect, 2013; 121 (6), 657–662. pmid:23584369
  105. 105. Bassett J.H., Boyde A., Howell P.G., Bassett R.H., Galliford T.M., Archanco M., et al. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci USA, 2010; 107 (16), 7604–9. pmid:20368437
  106. 106. Romero A.N., Herlin M., Finnila M., Korkalainen M., Hakansson H., Viluksela M., et al. Skeletal and dental effects on rats following in utero/lactational exposure to the non-dioxin-like polychlorinated biphenyl PCB 180. PLoS One, 2017; 12 (9), e0185241. pmid:28957439
  107. 107. Gauger K.J., Giera S., Sharlin D.S., Bansal R., Iannacone E., Zoeller R.T. Polychlorinated biphenyls 105 and 118 form thyroid hormone receptor agonists after cytochrome P4501A1 activation in rat pituitary GH3 cells. Environ Health Perspect, 2007; 115 (11): 1623–30. pmid:18007995
  108. 108. Matthews J., et al., Co-planar 3,3',4,4',5-pentachlorinated biphenyl and non-co-planar 2,2',4,6,6'-pentachlorinated biphenyl differentially induce recruitment of oestrogen receptor alpha to aryl hydrocarbon receptor target genes. Biochem J, 2007; 406(2): p. 343–53. pmid:17511620
  109. 109. Sarin H. Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells. Mol Clinical Oncol, 2016; 4: 326–368, 2016.
  110. 110. De S., Ghosh S., Chatterjee R., Chen Y.Q., Moses L., Kesari A., et al. PCB congener specific oxidative stress response by microarray analysis using human liver cell line. Environ Int, 2010; 36 (8), 907–17. pmid:20638727
  111. 111. Hellal-Levy C., Couette B., Fagart J., Souque A., Gomez-Sanchez C., Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett, 1999: 464 (1–2), 9–13. pmid:10611474
  112. 112. Loomis A. K., Thomas P. Binding Characteristics of Estrogen Receptor (ER) in Atlantic Croaker (Micropogonias undulatus) Testis: Different Affinity for Estrogens and Xenobiotics from that of Hepatic ER. Biol Reprod, 1999; 61 (1), 51–60. pmid:10377031
  113. 113. Eil C., Lippman M.E., Loriaux L.D. A dispersed-whole cell method for the determination of androgen receptors in human skin fibroblasts. Steroids, 1980; 35 (4), 389–404. pmid:7376228
  114. 114. Eil C., Gamblin G.T., Hodge J.W., Clark R.V., Sherins R.J. Whole cell and nuclear androgen uptake in skin fibroblasts from infertile men. J Androl, 1985; 6 (6), 365–71. pmid:3935634
  115. 115. Armanini D., Endres S., Kuhnle U., Weber P.C. Parallel determination of mineralocorticoid and glucocorticoid receptors in T- and B-lymphocytes of human spleen. Acta Endocrinol (Copenh), 1988; 118 (4), 479–482.
  116. 116. Eletxigerra U., Martinez-Perdiguero J., Merino S., Barderas R., Ruiz-Valdepeñas Montiel V., Villalonga R., et al. Estrogen receptor α determination in serum, cell lysates and breast cancer cells using an amperometric magnetoimmunosensing platform. Sens Biosensing Res, 2016; 7, 71–76.
  117. 117. Matsushima A., Liu X., Okada H., Shimohigashi M., Shimohigashi Y. Bisphenol AF is a full agonist for the estrogen receptor ERα but a highly specific antagonist for ERβ. Environ Health Perspect,2010; 118 (9), 1267–1272. pmid:20427257
  118. 118. Zwergel T., Kakirman H., Rohde V., Wullich B., Unteregger G. Androgen receptor expression, proliferation index and aneuploidy in tissue explant cultures derived prostate carcinoma cells co-cultivated on membranes. Eur Urol, 1998; 33 (4): 414–23. pmid:9612688
  119. 119. Dykstra K.D., Payne A.M., Abdelrahim M., Francis G.L. Insulin-like growth factor 1, but not growth hormone, has in vitro proliferative effects on neonatal foreskin fibroblasts without affecting 5-alpha-reductase or androgen receptor activity. J Androl, 1993; 14(2):73–8. pmid:8514622
  120. 120. Martinez D.A., Zuscik M.J., Ishibe M., Rosier R.N., Romano P.R., Cushing J.E., et al. Identification of functional insulin-like growth factor-II/mannose-6-phosphate receptors in isolated bone cells. J Cell Biochem, 1995; 59 (2), 246–57. pmid:8904318
  121. 121. Merrill M.J., Edwards N.A. Insulin-like growth factor-I receptors in human glial tumors. J Clin Endocrinol Metab, 1990; 71 (1), 199–209. pmid:2164527
  122. 122. Muckom R, McFarland S, Yang C, Perea B, Gentes M, Murugappan A, et al. High-throughput combinatorial screening reveals interactions between signaling molecules that regulate adult neural stem cell fate. Biotechnol Bioengin, 2019; 116 (1), 193–205.
  123. 123. Piechota M., Korostynski M., Golda S., Ficek J., Jantas D., Barbara Z., et al. Transcriptional signatures of steroid hormones in the striatal neurons and astrocytes. BMC Neurosci, 2017; 18 (1), 32. pmid:28288585
  124. 124. Murani E., Trakooljul N., Hadlich F., Ponsuksili S., Wimmers K. Transcriptome Responses to Dexamethasone Depending on Dose and Glucocorticoid Receptor Sensitivity in the Liver. Front Genet, 2019; 10 (559).
  125. 125. Reddy T.E., Pauli F., Sprouse R.O., Neff N.F., Newberry K.M., Garabedian M.J., et al. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res, 2009; 19 (12), 2163–71. pmid:19801529
  126. 126. Zennaro M.C., Le Menuet D., Lombes M. Characterization of the human mineralocorticoid receptor gene 5'-regulatory region: evidence for differential hormonal regulation of two alternative promoters via nonclassical mechanisms. Mol Endocrinol, 1996; 10 (12), 1549–60. pmid:8961265
  127. 127. Viengchareun S., Le Menuet D., Martinerie L., Munier M., Tallec L.P.-L., Lombès M. The Mineralocorticoid Receptor: Insights into its Molecular and (Patho)Physiological Biology. Nucl Recept Signal, 2007; 5, e012. pmid:18174920
  128. 128. Chuan-Dong G., Schwartz J.R., Vedeckis W.V. A Conserved Molecular Mechanism Is Responsible for the Auto-Up-Regulation of Glucocorticoid Receptor Gene Promoters. Mol Endocrinol, 2008; 22 (12), 2624–42. pmid:18945813
  129. 129. Karmakar S., Jin Y., Nagaich A.K. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and activator protein 1 (AP1) in dexamethasone-mediated interference of ERalpha activity. J of Biol Chem, 2013; 288 (33), 24020–34.
  130. 130. Rigiracciolo D.C., Scarpelli A., Lappano R., Pisano A., Santolla M.F., Avino S., et al. GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells. Oncotarget, 2016; 7 (1), 94–111. pmid:26646587
  131. 131. Caroccia B., Seccia T.M., Campos A.G., Gioco F., Kuppusamy M., Ceolotto G., et al. GPER-1 and estrogen receptor-beta ligands modulate aldosterone synthesis. Endocrinol, 2014; 155 (11): 4296–304.
  132. 132. Ye P., Kenyon C.J., Mackenzie S.M., Nichol K., Seckl J.R., Fraser R., et al. Effects of ACTH, dexamethasone, and adrenalectomy on 11beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) gene expression in the rat central nervous system. J Endocrinol, 2008; 196 (2), 305–11. pmid:18252953
  133. 133. Poulard C., Kim H.N., Fang M., Kruth K., Gagnieux C., Gerke D.S., et al. Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA, 2019; 116 (8), 3052–61. pmid:30733284
  134. 134. Altuwaijri S., Chuang K.H., Lai K.P., Lai J.J., Lin H.Y., Young F.M., et al. Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells. Mol Endocrinol, 2009; 23 (4), 444–53. pmid:19164450
  135. 135. Montesinos MM, Pellizas CG, Velez ML, Susperreguy S, Masini-Repiso AM, Coleoni AH. Thyroid hormone receptor beta1 gene expression is increased by Dexamethasone at transcriptional level in rat liver. Life Sci, 2006; 78 (22): 2584–94. pmid:16330054
  136. 136. Desdoits-Lethimonier C., Lesne L., Gaudriault P., Zalko D., Antignac J.P., Deceuninck Y., et al. Parallel assessment of the effects of bisphenol A and several of its analogs on the adult human testis. Human Reprod (Oxford, Eng), 2017; 32 (7), 1465–73.
  137. 137. Hercog K., Maisanaba S., Filipic M., Sollner-Dolenc M., Kac L., Zegura B. Genotoxic activity of bisphenol A and its analogues bisphenol S, bisphenol F and bisphenol AF and their mixtures in human hepatocellular carcinoma (HepG2) cells. Sci Total Environ, 2019; 687, 267–76. pmid:31207516
  138. 138. Wang C., Zhang J., Li Q., Zhang T., Deng Z., Lian J., et al. Low concentration of BPA induces mice spermatocytes apoptosis via GPR30. Oncotarget. 2017; 8 (30), 49005–15. pmid:28446726
  139. 139. Drobna Z., Henriksen A.D., Wolstenholme J.T., Montiel C., Lambeth P.S., Shang S., et al. Transgenerational Effects of Bisphenol A on Gene Expression and DNA Methylation of Imprinted Genes in Brain. Endocrinol, 2018; 159 (1), 132–144.
  140. 140. Moriyama K., Tagami T., Akamizu T., Usui T., Saijo M., Kanamoto N., et al. Thyroid hormone action is disrupted by bisphenol A as an antagonist. J of Clin Endocrin Metabol, 2002; 87 (11), 5185–90.
  141. 141. Sheng Z.G., Tang Y., Liu Y.X., Yuan Y., Zhao B.Q., Chao X.J., et al. Low concentrations of bisphenol a suppress thyroid hormone receptor transcription through a nongenomic mechanism. Toxicol Appl Pharmacol, 2012; 259 (1), 133–42. pmid:22227104
  142. 142. Kundakovic M., Gudsnuk K., Franks B., Madrid J., Miller R.L., Perera F.P., et al. Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol A exposure. Proc Natl Acad Sci USA, 2013; 110 (24): 9956–61. pmid:23716699
  143. 143. Ben-Jonathan N., Hugo E.R., Brandebourg T.D. Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome. Mol Cell Endocrinol, 2009; 304 (1–2), 49–54. pmid:19433247
  144. 144. Atlas E., Pope L., Wade M.G., Kawata A., Boudreau A, Boucher J.G. Bisphenol A increases aP2 expression in 3T3L1 by enhancing the transcriptional activity of nuclear receptors at the promoter. Adipocyte. 2014; 3 (3), 170–9. pmid:25068083
  145. 145. Quesada I., Fuentes E., Viso-Leon M.C., Soria B., Ripoll C., Nadal A. Low doses of the endocrine disruptor bisphenol-A and the native hormone 17beta-estradiol rapidly activate transcription factor CREB. Faseb J, 2002; 16 (12), 1671–3. pmid:12207000
  146. 146. Kazemi S., Mousavi S., Aghapour F., Rezaee B., Sadeghi F., Moghadamnia A.A. Induction Effect of Bisphenol A on Gene Expression Involving Hepatic Oxidative Stress in Rat. Oxidat Med Cellul Longev, 2016; 5.
  147. 147. Somm E., Schwitzgebel V.M., Toulotte A., Cederroth C.R., Combescure C., Nef S., et al. Perinatal exposure to bisphenol a alters early adipogenesis in the rat. Environ Health Perspect, 2009; 117 (10), 1545–55.
  148. 148. Lee J.-E., Ge K. Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis. Cell Biosci, 2014; 4, 29. pmid:24904744
  149. 149. Al-Bader M, Ford C, Al-Ayadhy B, Francis I. Analysis of estrogen receptor isoforms and variants in breast cancer cell lines. Exper Therapeut Med, 2011; 2 (3), 537–44.
  150. 150. Pupo M., Pisano A., Lappano R., Santolla M.F., De Francesco E.M., Abonante S., et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect, 2012; 120 (8), 1177–82. pmid:22552965
  151. 151. Lapensee E.W., Tuttle T.R., Fox S.R., Ben-Jonathan N. Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells. Environ Health Perspect. 2009; 117 (2):175–80. pmid:19270784
  152. 152. Alper O., Stetler-Stevenson W.G., Harris L.N., Leitner W.W., Ozdemirli M., Hartmann D., et al. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci, 2009; 100 (9): 1748–56. pmid:19594548
  153. 153. Hoover R.N., Hyer M., Pfeiffer R.M., Adam E., Bond B., Cheville A.L., et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med, 2011; 365(14), 1304–1314. pmid:21991952
  154. 154. Block K., Kardana A., Igarashi P., Taylor H.S. In utero diethylstilbesterol (DES) exposure alters Hox gene expression in the developing mullerian system. Faseb J, 2000; 14, 1101–1108. pmid:10834931
  155. 155. Couse J.F., Dixon D., Yates M., Moore A.B., Ma L., Maas R., et al. Estrogen receptor-α knockout mice exhibit resistance to the developmental effects of neonatal diethylstilbesterol exposure on the female reproductive tract. Develop Biol, 2001; 238, 224–238. pmid:11784006
  156. 156. Huang W-W., Yin Y., Bi Q., Chiang T-C., Garner N., Vuoristo J., et al. Developmental diethylstilbesterol exposure alters genetic pathways of uterine cytodifferentiation. Mol Endocrinol, 2005; 19(3), 669–682. pmid:15591538
  157. 157. Lim W., Jeong W., Kim J-H, Lee J-Y., Kim J., Bazer F.W., et al. Differential expression of alpha 2 microglobulin in response to diethylstilbesterol and in ovarian carcinomas in chickens. Reprod Biol Endocrinol, 2011; 9: 137. pmid:21978460
  158. 158. Grimm F.A., Hu D., Kania-Korwel I., Lehmler H.J., Ludewig G., Hornbuckle K.C., et al. Metabolism and metabolites of polychlorinated biphenyls. Crit Rev Toxicol, 2015; 45 (3), 245–72. pmid:25629923
  159. 159. Sugino M., Hatanaka T., Todo H., Mashimo Y., Suzuki T., Kobayashi M., et al. Safety evaluation of dermal exposure to phthalates: Metabolism-dependent percutaneous absorption. Toxicol Appl Pharmacol, 2017; 328, 10–17. pmid:28506834
  160. 160. Kirkup M.E., Murphy J., Beck M.H., Sansom J.E. Occupational contact sensitization to 1,2-diaminocyclohexane. Contact Derm, 2001; 45 (2), 121–122. pmid:11553132
  161. 161. Ondrus A.E., Lee H.-l.D, Iwanaga S., Parsons W.H., Andresen B.M., Moerner W.E., et al. Fluorescent saxitoxins for live cell imaging of single voltage-gated sodium ion channels beyond the optical diffraction limit. Chem Biol, 2012; 19 (7), 902–912. pmid:22840778
  162. 162. Fozzard H.A., Lipkind G.M. The tetrodotoxin binding site is within the outer vestibule of the sodium channel. Mar Drugs, 2010; 8 (2), 219–34. pmid:20390102
  163. 163. Dhar S.S., Johar K., Wong-Riley M.T.T. Bigenomic transcriptional regulation of all thirteen cytochrome c oxidase subunit genes by specificity protein 1. Open Biol, 2013; 3 (3), 120176. pmid:23516108
  164. 164. Orlowska K., Swigonska S., Sadowska A., Ruszkowska M., Nynca A., Molcan T., et al. Proteomic changes of aryl hydrocarbon receptor (AhR)-silenced porcine granulosa cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Plos One, 2019; 14 (10), e0223420. pmid:31584984
  165. 165. Lim Y., Traber M.G. Alpha-Tocopherol Transfer Protein (alpha-TTP): Insights from Alpha-Tocopherol Transfer Protein Knockout Mice. Nutr Res Pract, 2007; 1 (4): 247–53. pmid:20368946
  166. 166. Koh M., Takitani K., Miyazaki H., Yamaoka S., Tamai H. Liver X receptor up-regulates alpha-tocopherol transfer protein expression and alpha-tocopherol status. J Nutr Biochem, 2013; 24 (12), 2158–67. pmid:24231105
  167. 167. Johnson C.H., Bonzo J.A., Cheng J., Krausz K.W., Kang D.W., Luecke H., et al. Cytochrome P450 regulation by α-tocopherol in Pxr-null and PXR-humanized mice. Drug Metab Dispos, 2013 (eNov 2012); 41(2), 406–13. pmid:23160821
  168. 168. Kumar D., Yusuf M.A., Singh P., Sardar M., Sarin N.B. Modulation of antioxidant machinery in α-tocopherol-enriched transgenic Brassica juncea plants tolerant to abiotic stress conditions. Protoplasma, 2013; 250 (5), 1079–89. pmid:23361901
  169. 169. Park S.-K., Page G.P., Kim K., Allison D.B, Meydani, M. Weindruch, R., et al. Differential effect of α- and γ-tocopherol supplementation in age-related transcriptional alterations in heart and brain of B6/C3H F1 mice. J Nutr, 2008; 138 (6): 1010–1018. pmid:18492827
  170. 170. Haase K., Pelling A.E. Investigating cell mechanics with atomic force microscopy. J. R. Soc Interface, 2015; 12, 20140970: 1–16.
  171. 171. Kamm R.D., Bashir R., Arora N., Dar R.B., Gillette M.U., Griffith L.G., et al. Perspective: The promise of multi-cellular engineered living systems. APL Bioengineering, 2018; 2, 040901. pmid:31069321